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SUMMARY 
Lewis rats that are primed with guinea pig spinal cord 
homogenised in Complete Freund's adjuvant develop overt 
symptoms of experimental allergic encephalomyelitis (EAE). 
Treatment with the iron-chelating agent, Desferrioxamine B 
(DFO) at various times prior to the onset of EAE markedly 
reduced both the severity and duration of disease. When DFO 
was administered to rats soon after the development of neuro-
logical signs a rapid recovery occurred, though mild, 
transient symptoms were often seen about one week after 
withdrawal of the drug. Treatment with DFO was accompanied by 
a diminution of T cell responses, and, on histological 
examination, an absence of inflammatory cells from lesions. 
In vitro experiments _confirmed that DFO, at concen-
trations effective in vivo, totally inhibited the prolifer-
ation of Concanavalin A-stimulated lymphocytes. This inhibition 
was reversed by adding iron, but not other metal salts to the 
cultures. DFO was more effective at suppressing T lymphocytes 
than B lymphocytes, and had no detectable effect on macrophage 
function or production of lymphokines. 
Using alternate in vivo models, it was shown that DFO 
suppressed the expression of delayed hypersensitivity, and 
altered the "homing" of normal T lymphocytes (but not B 
lymphocytes) to their dependent areas of the spleen. 
Thus, DFO appears to suppress EAE by inhibiting the 
sensitization and proliferation of T effector cells, altering 
the migration of these cells to sites of inflammation and, as 
a result, the expression of delayed hypersensitivity. 
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CHAPTER 1. INTRODUCTION. 
1 . 1 Experimental Allergic Encephalomyelitis (EAE) . 
Experimental allergic encephalomyelitis (EAE), which 
serves as a model for multiple sclerosis (MS), originated 1n 
early investigations into the adverse effects of rabies 
v a c c-i n at ion , w h i ch often res u 1 t e d i n " par a 1 y t i c accidents " 
associated with acute disseminated sclerosis. It was thought 
at the time that the cause of the severe reactions may have 
been the brain material in which the virus was grown, rather 
than the virus itself. This was shown to be the case in 1933 
by Rivers, Sprunt and Berry who injected normal rabbit brain 
into 8 monkeys , three times a week over a period of months . 
Two of the monkeys developed ataxia and weakness, accompanied 
by demyelination and mononuclear cell infiltration into the 
brain and spinal cord. 
Induction of EAE without adjuvant required multip le 
injections of central nervous system (CNS) material, but with 
the introduction of Freund's adjuvant, supplemented with 
Mycobacteria, (Freund and McDermott , 1942) EAE became 
practical as a laboratory disease model . Rivers et al (1933) 
used as many as 94 injections to achieve symptoms in 2 out of 
8 monkeys, whereas a single injection of CS material in 
complete Freund's adjuvant produced symptoms in monkeys in 
approximately two weeks (Mo rgan, 1947; Kabat, Wolf and Bezer, 
1947). 
The possibility that MS might have an "allergic" 
origin, together with the failure to find a viral cause for 
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MS, resulted in an experimental boom for EAE in the early 
1960s. The factor responsible for producing symptoms was shown 
to reside in white matter rather than grey matter (Morgan 
1947, Alvord 1948). Furthermore, the encephalitogenic activity 
of the CNS material was shown to parallel the ontogenic 
development of myelin, which is poorly developed at birth, 
reaching sufficient quantity by 2 weeks of age to induce EAE 
in guinea pigs (Schwenkter and Rivers, 1934). In 1962, 
Laatsch et al showed by differential centrifugation of brain 
homogenate that the encephalitogenic activity was associated 
with the greatly enriched myelin fraction. The isolation by 
Kies et al in 1958 of the encephalitogenic polypeptide myelin 
basic protein (MBP), obtained by acid extraction of the water-
soluble fraction of myelin, led to the search for a similar 
"antigen" for multiple sclerosis. 
The cause of MS is still unknown; epidemiological trends 
suggested that infection during chilhood (or a chronic 
infection in the CNS, by a virus as yet unidentified) could 
result in immune sensitization to a sequestered CNS antigen, 
and that reactivation of the immune response occurred 
following a second encounter with the virus or another 
precipitating event such as pregnancy. However, despite much 
searching, neither virus nor antigen has been found, although 
the virus model still enjoys considerable support (Wege, 
Watanabe and ter Meulen, 1984; Tardieu et al, 1984). Several 
viruses have been isolated from the brains of patients with 
MS, including measles, herpes simplex, cytomegalovirus, 
rubella coronavirus and lymphocytic choriomeningitis (Bauer, 
I 
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Poser and Ritter, 1980; Boese, 1980) but no common etiology has 
emerged from these studies. 
EAE has had variable acceptance as a model for MS. The 
introduction of a chronic, relapsing form 1n strain 13 guinea 
pigs (Stone and Lerner, 1965; Wisniewski and Keith, 1977) and 
SJL/J mice (Brown and McFarlin, 1981; Lublin et al, 1981), 
which has many clinical and pathological similarities to MS 
(McKay, Carnegie and Coates, 1973), provided a valuable tool 
for investigation into the relapsing/remitting nature of MS. 
Recent research has focussed on immune regulation in EAE and 
in MS, since alterations in the ratios of T cell subsets have 
been found to occur 1n both diseases concurrent with relapses 
(Reinherz, Weiner and Hauser, 1980 ; Brinkman, Nilleson and 
Hammes, 1983; Weiner and Hause r, 1983; Antel et al, 1984). 
The CNS has always been considered an immunologically 
privileged site, because it is shielded from the immune system 
by the blood-brain barrier (BBB) , and lacks an organised 
lymphatic system. Early studies showed that it was possible to 
transplant allogeneic, and even xenogeneic grafts into the CNS 
(Murphy and Sturm, 1923). Generally, antigens introduced into 
the CNS do not induce an immune response in the periphery, 
unless the BBB is damaged (Leibowitz and Hughes, 1983). 
Furthermore, Santos (1982) has shown that introduction of T 
dependent antigens into the CNS failed to activate peripheral T 
suppressor cells. However, Scheinberg, Edelman and Levy (1964) 
found that tissue grafts in the brain are rejected 1n a similar 
fashion to those in the periphery (albeit slower), and evidence 
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is now accumulating that the cells of the CNS themselves are 
associated with immune responses which were previously 
thought to be restricted to cells of the peripheral lympho-
reticular system (Fontana et al, 1981a, 1981b, 1982, 1983; 
Merrill et al, 1983; Fontana, Fierz and Wekerle, 1984). In 
addition, the CNS undoubtedly plays a part in the regulation 
of the peripheral immune system through the action of various 
neuropeptides (Faith et al, 1984; Blalock, 1984: Renoux, 1984). 
The complex relationship between the CNS and the immune 
sy,tem is currently an area of active research (Ader, 1981; 
Leibowitz and Hughes, 1983; Behan and Spreafico, 1984), and is 
of special relevance to MS, where abberations of immune 
regulation, once thought to be causative, may prove instead to 
be a result of the disease process. EAE is an appropriate 
model in which to study such neuroimmunological relationships. 
1.2 Induction of EAE. 
EAE can be induced in a wide variety of species, 
including mice, rats, guinea pigs, rabbits, dogs, sheep, 
monkeys and chickens. Susceptibility varies among inbred 
strains; amongst the most commonly used species, EAE is most 
readily induced in the Strain 13 guinea pig, the SJL/J 
mouse, and the Lewis rat. Susceptibility in the rat is thought 
to be associated with an immune response gene closely linked 
to the major histocompatability complex (MHC), RTl.B, which is 
thought to control Class II (Ia) responses (Williams and 
Moore, 1973; Gasser et al, 1975; Wettstein, Frelinger and 
Hood, 1981). However, a resistant Lewis strain (Le-R) colony 
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has been described 1n which resistance is not linked to RTl.B; 
incubation of donor cells with lipopolysaccharide restored 
their ability to transfer EAE to naive Le-R rats (Driscoll, 
Kies and Alvord, 1985). 
The usual inoculum consists of brain and spinal cord 
white matter, whole spinal cord or purified myelin basic 
protein (0.5-l.25mg/animal), homogenized in saline and 
emulsified 1:1 in Complete Freund's Adjuvant to which 
Mycobacterium tuberculosis has been added (60ug-
2.5mg/animal). The use of adjuvant is thought to result 1n 
better antigen presentation, to boost both DTH and antibody 
responses, and to be virtually obligatory for rapid, 
reproducible disease induction for laboratory studies. 
Encephali togenicity depends upon the species of neural 
antigen used, the amount of Mycobacteria, and the 
proportions of water and oil in the adjuvant emulsion (Lee 
and Schneider , 1962; Paterson and Bell, 1962). In 
particular, the amount and type of Mycobacteria are 
important.~ butyricum is known to boost 0TH responses 
markedly, while having little effect on antibody production 
(Bomford, 1980a and 1980b). It also induces a more severe 
form of EAE in rats than M. tuberculosis H37Ra (Hempel et 
al, 1984), which is usually used for the induction of 
chronic relapsing EAE. It has been reported that EAE can be 
induced in the rat without Mycobacteria (Paterson and Bell, 
1962; Beck, Whitehouse & Pearson, 1976) and without adjuvant 
(Levine and Wenk (1965a). 
Macrophage activation and presentation of MBP 1n an 
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immunogenic form is essential for stimulation of effector 
lymphocytes. Soluble MBP is not immunogenic, but MBP bound to 
microspheres can sensitize rats, and lymph node cells taken 
from these animals can induce disease in naive recipients 
(Carbone, Ovadia and Paterson, 1983). Naive thymocytes can be 
sensitized in vitro by incubation with macrophages which have 
been pulsed with MBP (Steinman et al, 1977; Ben-Nun, Otmy and 
Cohen, 1981). 
Bordatella pertussis vaccine is necessary for induction 
of acute EAE in the mouse (Lee and Olitsky, 1955). Two 
intravenous injections, 48 hours apart, are given at the time 
of injection with CNS material. This has the effect of 
increasing blood-brain permeability in certain mouse strains 
with gene tically determined sensitivity to vasoactive amines 
(Linthicum and Frelinger, 1982; Linthicum, Munoz and Blaskett, 
1982). The active factor is the toxin pertussigen (Bergman, 
Mu noz and Portis, 1978), which has several effects, including 
lymphocytosis, the ability to increase vascular permeability, 
and increased sensitivity to vasoactive amines. Its effects 
can be blocked by serotonin antagonists (e.g. methysergide) 
(Linthicum, Munoz and Blaskett, 1982), indicating a role for 
serotonin in the induction phase. 
~ pertussis can be substituted for Freund's adjuvant in 
guinea pigs, although the dose is critical (Weiner, Tinker and 
Bradford, 1959). In rats, the addition of B. pertussis to 
guinea pig spinal cord and CFA induces a severe, fatal form of 
EAE termed hyperacute EAE (Levine and Wenk, 1965b; Levine and 
Sowinski, 1973; Levine, 1974; Lennon, Westall, Thompson and 
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Ward, 1976). EAE has been induced in genetically resistant 
strains of mice by means of pertussigen (Munoz and McKay , 
19 84) . 
1.3 Clinical course of the disease. 
The clinical course of EAE is similar for all susceptible 
species; approximately two weeks after injection of spinal 
cord or MBP in CFA, animals exhibit symptoms of ascending 
paralysis, beginning with a flaccid tail (in caudate species), 
and involving hindlimb weakness or paralysis, incontinence, 
loss of righting reflex, and sometimes forelimb paralysis and 
death . In adult guinea pigs EAE is a severe fatal disease with 
onset of signs 9-14 days after sensitization. The relapsing 
models in the guinea pig and mouse are usually of delayed 
onset with more variation in the duration and severity of 
symptoms, and with a relapsing/remitting or a chronic 
progressive disease course (Stone and Lerner, 1965; Brown and 
McFarlin , 1981). 
EAE in the Lewis rat is an acute, monophasic disease, 
(described by Paterson et al, 1970). Animals exhibit a weight 
loss of 5-10% on about day 8 after injection, followed by the 
onset of paralysis on days 10-12, lasting an average of about 
8 days, with full recovery by about day 28 (Fig. 1.1). Forelimb 
paralysis, chronic disease and death are seldom seen in the 
Lewis rat, occurring more frequently in older (more than 16 
month) animals. In about 10% of animals there is a second 
episode of paralysis, usually mild, occurring between days 
7 
- · Figure 1.1 Lewis rat, showing signs of EAE. 
Lewis rat, 16 days after injection of spinal cord 
homogenised in Complete Freund's adjuvant, showing 
typical signs of flaccid tail and hindlimb paralysis. 
19-25 (McFarlin, Blank and Kible r, 1974). 
Correlation between flaccid paralysis and the number of 
lesions in the CNS is poor (Hoffman et al, 1973; Raine et al, 
1980; Paterson, 1982; Simmons et al, 1982 and 1984). Damage 
associated with large, chronic lesions and necrotic tissue 
damage generally causes long-term spastic paralysis (Stone and 
Lerner, 1965; Lassman, Kitz and Wisniewski, 1980). The flaccid 
paralysis which occurs in acute EAE may resolve rapidly, 
occurring in the presence of severe inflammatory lesions, and 
other mechanisms have been proposed to explain loss of nerve 
transmission which leads to paralysis. Several authors have 
suggested that oedema, resulting from a decrease in effective-
ness of the blood-brain barrier, is the maJor factor responsible 
for clinical signs in acute EAE (Daniel , Lam and Pratt, 1981; 
Leibowitz and Kennedy , 1972 ; S immons et al, 1982 , 1984) . 
Considerable swelling of the spinal cor d occurs du ring EAE 
(Levine , Simon and ~e n k , 1966), and p ressure on the nerve 
fibres of the cauda equina, and oedema associated with fibrin 
deposition in EAE lesions (Paterson , 1976) have both been 
implicated as a cause of cumulative loss of conduction as 
impulses travel down nerve fibres. Paterson ( 1976) showed that 
fibrinogen-depleted rats did not develop paralysis although the 
extent of cellular infiltration was the same as in EAE controls. 
Other metabolic changes which may lead to paralysis 
include a decrease in noradrenaline and 5-hydroxytryptamine 
(5HT) in the lumbar-sacral region (Lycke and Roos, 1973; 
Honeggar and Isler, 1984). Those areas of the spinal cord 
which are rich in 5-HT terminals, i.e the lumbar and sacral 
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regions, are also sites of predilection for lesions of EAE 
(Lennon and Carnegie, 1971), and it has been suggested that 
interference with neurotransmission in this area may account 
for the localization of clinical symptoms of EAE . Synthesis 
of SHT is not reduced, but there is a greater turnover 
(Honeggar and Isler, 1984). MBP binds SHT (Weinstock et al, 1977) 
and this may be the reason for decreased levels during EAE. 
MBP itself causes a long-lasting depolarization of neurones in 
isolated frog spinal cord, leading to loss of transmission 
(Honegger et al, 1977; Gahwiler and Honegger, 1979; Isler and 
Honegger 1983). Guinea pigs with symptoms of EAE showed 
depletion of SHT receptors and ·, in severely affected animals, 
there was a total loss of receptors (Weinstock et al, 1977; 
White, 1979). An increase in monoamine oxidase activity has 
been reported in guinea pigs with EAE . (Saregea et al, 1965). 
This reflects increased metabolism of serotonin, and may 
partially account for the fall in 5-HT levels. 
Disturbances in neuro-electrical transmission have been 
demonstrated in rabbits injected with whole brain and 
adjuvant. Such animals exhibited marked disturbance in the 
electroencephalogram before onset of clinical signs (Feldman, 
Tal and Behar, 1969 ), Sera from animals with EAE, and from 
patients with MS, block the intraneuronal electrical activity 
of cultures of mammalian brain (Ross and Bornstein, 1969). 
Bieger and White (1981) reported an impairment of axoplasmic 
flow in EAE, with extensive damage to catecholamine axons, 
which are involved in regulation of the immune response by the 
9 
hypothalamus (Besedovsky et al, 1983). 
Many attempts have been made to explain the rostral 
progression of paralysis, with recovery proceeding in the 
reverse order, which occurs in all forms of EAE. It is not 
related to the injection site (which is usually the footpad), 
since the same pattern occurs when other routes of sensitiz-
ation are used, including transfer of sensitized cells 
(Oldendorf and Towner, 1974). Simmons et al (1982) found 
increased oedema and lactacidosis in the sacrococcygeal region 
compared to lumbar (less) and thoracic (least) regions, which 
correlated well with the appearance and abatement of symptoms. 
Simmons et al (1982) suggested that progressive metabolic 
disturbance of the peripheral nodes of Ranvier in nerve root 
myelinated fibres could account for the ascending nature of the 
paralysis. White, Bhatnagar and Bardo (1983) found 
norepinephrine depletion in the spinal cords of rats with EAE, 
in a rostrocaudal gradient with most severe depletion in the 
lumbar region, and suggested this as a reason for the rostral 
progression of paralysis. 
1.4 Myelin and Myelin Basic Protein. 
The myelin sheath, which encircles and insulates axons 
greater than 2 um in diameter, is formed by oligodendrocytes 
in the CNS and Schwann cells in the peripheral nervous system. 
Each oligodendrocyte sends out a number of processes, 
ensheathing up to 40 axons (Peters and Vaughn, 1970). Myelin 
is characterized by its high lipid content (Table 1.1), its 
relative stability and low enzyme activity. Its structure 
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Table 1.1 Composition of rat myelin. 
% dry weight (approx.) 
Cholesterol 
Galactolipids 
cerebrosides* 
sulfa tides* 
Phosphoglycerides 
Sphingomyelin 
Protein 
27.7 
27.5 
22.7 
3.8 
43.1 
7.9 
proteolipid protein 20.0 
myelin basic protein 10.0 J 
* not found in peripheral nerve myelin . 
70-80% 
20-30 % 
(shown in Figure 1.3) is essentially a lipid bilayer. The 
basic protein forms the major dense line, which can be seen on 
electron micrographs (Figure 1.2). In both EAE and MS, it is 
the myelin sheath which is destroyed, while axons are spared. 
For this reason, the "antigen" of EAE and of MS was thought to 
reside in myelin. 
Lumsden, Robertson and Blight (1966) were the first to 
show that a dialysable small molecular weight component of 
bovine myelin was able to induce the encephalitis of EAE. This 
was found to be a peptide with a molecular weight of 18,000 
daltons (Carnegie and Lumsden, 1966 and 1967). Subsequent 
sequencing of GPMBP by Westall et al (1971) and Carnegie 
(1971a, 1971b), revealed that a small portion only of the MBP 
molecule was responsible for encephalitogenic activity, that 
the configuration was important, and that encephalitogenicity 
resided in the tryptophan residue (115), since blocking this 
residue abolished activity. Carnegie (1974) also recognised 
the complementarity in shape between the encephalitogenic 
fragment containing the tryptophan residue (111-121) and 
serotonin (5-hydroxytryptamine). 
The complete amino acid sequences are now known for bovine 
(Eylar et al, 1971; Brostoff et al, 1974), human (Carnegie, 
1971b), rabbit (Martensen et al, 1981), rat (Dunkley and 
Carnegie, 1974), guinea pig (Diebler, Nomura and Kies, 1982), 
mouse (Zeller et al, 1984), chicken (Eylar et al, 1974) 
chimpanzee (Westall et al, 1975) and monkey (Shapira et al, 
1971) myelin basic proteins. The sequence of MBP shows marked 
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Figure 1.2 The structure of myelin. 
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homology between species, with the exception of rat MBP which 
has two encephalitogenic basic proteins, one small and one 
large molecular weight (Martenson et al, 1972). 
Although the sequence of the molecule shows little 
variation between species, the portion which induces 
encephalitis may vary, for example bovine MBP sequence 113-121 
is encephalitogenic for guinea pigs, but Lewis rats respond to 
sequence 75-84 (Hashim, Carvalho and Sharpe, 1978). 
Guinea pig MBP is the most encephalitogenic of all 
species in the Lewis rat, being 25 times more active than 
bovine, human or rabbit MBP and 10 times more active than 
rat MBP (McFarlin et al, 1973). This is due to the 
substitution of serine for threonine at position 82 (Kibler et 
al, 1977). The sequence for guinea pig MBP, shown in figure 
1.3, contains a major encephalitogenic fragment 71-85, with a 
minor determinant 44-48 (Alvord, 1984). The shortest effective 
peptide is 74-87, but additional residues (63-91) increase 
encephalitogenicity, 45-91 being equivalent to the whole 
molecule in encephalitogenic activity (Alvord, 1984) 
All T lymphocyte functions (T help, T cell induction of 
EAE and lymphoproliferative responses) in the rat are 
associated with residues 71-85 of GPMBP (Chou et al 1979a). 
Sequence 44-48, the minor encephalitogenic fragment, also 
elicits 0TH (Alvord, 1984). This does not necessarily imply 
that encephalitogenicity depends upon 0TH, since in some 
species the peptide sequences for DTH and encephalitogenicity 
are located in different regions (Spitler et al, 1972), and 
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alteration of a single peptide to abrogate encephalitogenicity 
does not alter DTH (Hashim and Sharpe, 1974). That is, 
lymphocytes can still recognise and respond to the fragment, 
but it does not cause disease. The sequence which induces 
antibody is 85-88 (Chou et al, 1979a), and Chou, et al 
(1979b) have shown that giving antiserum raised against 
residues 68-79 to rats will protect against induction of 
EAE , but antiserum to residues 79-88 will not. 
Chronic EAE has been produced in rabbits (Cambi et al, 
1983) and guinea pigs (Hashim, Wood and Moscarello, 1980) by 
proteolipid protein. Attempts to induce EAE with other 
purified myelin antigens have been unsuccessful. Galacto-
cerebroside, which has been implicated in demyelination by 
an antibody/complement dependent mechanism, not only fails 
to induce disease, but does not protect against subsequent 
challenge, as is the case with MBP (Hughes and Leibowitz, 
1975). 
1.5. The lesion of EAE. Early changes. 
One of the first measurable changes in the CNS is an 
increase in vascular permeability on day 6 in the rat 
preceding cellular infiltration by 2-3 days (Oldstone and 
Dixon, 1968; Daniel, Lam and Pratt, 1981 and 1983; Suckling et 
al, 1983; Sobel, Blanchette and Colvin, 1984). This may not be 
related to antigen sensitization alone, however, since CFA 
itself can increase vascular permeability to serum albumin 
(Suckling, 1984), a maximum level being reached on day 7, and 
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declining to day O levels by day 13. In contrast, GPSCH-CFA 
results in a long-lasting increase in permeability which peaks 
on day 14 and remains at that level for at least 50 days. 
Similar results have been obtained by Stohl and Gonatas (1978) 
who demonstrated chronic blood-brain barrier-permeability to 
specifically sensitized lymphocytes in rats lasting at least 
60 days after injection of GPSCH-CFA. This was not antigen-
specific, since MBP-immune, CFA-immune and normal cells all 
infiltrated to the same degree. Rumjanek, Leyton and Morley 
(1984) measured cellular infiltration and plasma protein 
extravasation into the brain and spinal cord of Lewis rats 
with EAE and found that cellular infiltration occurred 
earlier, was of short duration in the spinal cord, and was 
accompanied by plasma protein extravasation which correlated 
well with severity of clinical symptoms. Upon re-challenge, 
cellular infiltration occurred in the brain but not the spinal 
cord, and was not accompanied by plasma protein extravasation. 
They concluded that, in re-challenged animals, the reaction is 
more specific, and that cellular infiltration is not dependent 
upon gross vascular damage. This view is supported by Rose and 
Parrott (1977), who have shown that lymphocyte migration and 
vascular permeability are not interdependent. Vascular 
permeability is a serotonin-dependent phenomenon (Schwartz, 
Askenase and Gershon, 1977), resulting in plasma protein 
extravasation. Lymphocytes, however, can migrate indepen d ently 
of serotonin-dependent vascular permeability. Several authors 
have demonstrated a good correlation between plasma protein 
extravasation and severity of symptoms in the Lewis rat 
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(Daniel, Lam and Pratt, 1981 and 1983; Leibowitz and Kenned y , 
1972 ; Simmons et al, 1982), and have suggested that the 
resulting oedema is the major factor responsible for the 
clinical signs in acute EAE, since extravasation leads to 
leakage of fibrinogen and deposition of fibrin, which has been 
correlated with paralytic signs in EAE (Paterson, 1976; 
Kristensen and Wisniewski, 1977) . Daniel, Lam and Pratt (1983) 
found that permeability to mannitol 1n rats with EAE, began in 
the lower spinal cord where it reached its highest level 
during the acute phase of the attack. From 15 days onwards, it 
slowly returned to normal, starting from the caudal end of the 
spinal cord . 
Blood-brain barrier-permeability appears to be related to 
the amount of Mycobacteria used in the inoculum. Simon and 
Anzil (1974) found that higher doses of Mycobacteria resulted 
in increased vascular permeability to anti-MBP antibody, but 
this was not related to levels of circulating antibody to MBP. 
Some areas of the blood-brain barrier, for example the 
spinal and trigeminal ganglia, spinal roots, area postrema, 
hypothalamic structures and optic chiasm, do not exhibit the 
tight junctions found elsewhere in the CNS, having fenestrated 
junctions similar to vascular endothelium elsewhere, Juhler et 
al (1984) have postulated that permeability is effected by a 
"loosening" of these junctions rather than damage to vascular 
endothelium, suggesting that a chemical mediator is 
responsible for the initial blood-brain barrier changes. 
During the first few days after injection of antigen, 
15 
there is local proliferation in the lymph node draining the 
injection site. Removal of the draining lymph node 2-10 days 
after injection of spinal cord in rabbits, prevents 
development of disease (Condie et al, 1957). Effector cells 
then leave the lymph node and enter the blood circulation 
via the thoracic duct (Stohl and Gonatas, 1980). How they 
get into the CNS is not known at present, but has been the 
subject of much investigation. The fact that lesions of EAE 
begin around capillaries of the CNS suggests that events on 
the vascular endothelium are responsible for the cellular 
infiltrate . Lymphocytes are normally excluded from the CNS, 
however MBP-sensitized cells can enter the CNS with apparent 
ease, in the absence of gross damage to vascular endothelium 
(Stohl and Gonatas, 1978). The interesting question of what 
it is that lymphocytes "see" raises several possibilities. 
Simon and Anzil (1974) found evidence of perivascular 
locali z ation of MBP as early as 5 days after injection of 
guinea pigs with syngeneic MBP or brain material. This was 
thought to be of endogenous origin, and occurred in the 
absence of apparent inflammatory histology. Smith (1969) also 
found altered turnover of my elin components before 
histological changes became apparent. Class II maJor 
histocompatability complex ( MHC) g lycoproteins (Ia antigens) 
are also expressed on vascular endothelium in the pre-clinical 
stage of EAE (by day 7), in both resistant and susceptible 
strains (Sobel et al, 1984b). 
Ia antigen certainly appears to play a role in EAE, since 
treatment of antigen-presenting cells with anti-Ia antibody 
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blocks T cell proliferation to MBP in vitro, and prevents 
relapses in SJL/J mice in vivo (Steinman et al, 1981; Sriram 
and Steinman, 1983). Ia presented in conjunction with antigen 
(MBP) could represent the first "target" of EAE, resulting in 
the activation of T helper cells, with release of lymphokines 
and amplification of the immune response, thus facilitating 
entry into the CNS. Recently, Mccarron et al (1985) have 
reported presentation of GPMBP on vascular endotheli q\ c.e\\s .from 
SJL/J mice. 
Other pre-clinical changes include enhanced astrocyte 
reactivity, as measured by increased GFAP turnover (Linington, 
Suckling and Cuzner, 1983), fibrillary astrogliosis (Field, 
1961; Bubis and Luse, 1964; Lampert, 1967) and expression of 
fibronectin on vascular endothelium from day 5 after injection 
of Strain 13 guinea pigs with GPSCH-CFA (Sobel, Blanchette and 
Colvin, 1984). Fibronectin is a 440 kilodalton glycoprotein 
produced by endothelial cells and macrophages, and is deposited 
in inflammatory sites during DTH reactions (Clark, Dvorak and 
Colvin, 1981). It has been implicated in cell migration and 
macrophage activation, and can be produced by glial cells in 
culture (Hynes and Yamada, 1982), although its functions in 
vivo are not known . 
1.6 The nature of the cellular infiltrate. 
The first cells to enter the perivascular space in the 
CNS are lymphocytes, which have been detected as early as 5 
days after injection of neural antigen (Waksman and Adams, 
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1962; Rauch and Einstein, 1974; Traugott, Stone and Raine, 
1978; Traugott et al, 1981). The earliest infiltrating cells 
in Lewis rats with EAE were found in the spinal root entry 
zone and sub-pial area (Hickey et al, 1983). The general 
pattern of cellular distribution is similar for all models of 
EAE (Traugott et al, 1981, 1982a, 1982b; Sriram et al, 1982; 
Hickey et al, 1983; Hickey and Gonatas, 1984; Traugott, 1985). 
In early CNS lesions (5 days after injection of antigen), T 
cells of the DTH/helper subset are found in the perivascular 
space, together with albumin and (non-specific) immunoglobulin. 
By day 8, B cells and macrophages enter the lesion, and 
immunoglobulin and complement deposits are also evident at 
this stage. At the height of clinical signs, the typical 
lesion of EAE contains approximately 60-80 % T cells, of which 
40-60% are W3/25+ (DTH/helper) and 18-20% are Ox 8+ 
(cytotoxic/suppressor), 30% macrophages, and 12-15% B cells. 
Staining with the W3/13 marker for mature T cells has 
revealed that only a small proportion (18%) are positive , 
suggesting that the majority of T cells in lesions are 
recently activated (Hickey, 1983). In all forms of EAE studied 
(and interestingly, in MS) , DTH/helper T cells can be found 
scattered throughout the normal white matter paren chy ma; other 
cell types are confined to the perivascular lesion (Traugott , 
1985). Lewis rats differ from the guinea pig and SJL mouse in 
that during recovery there are fewer total infiltrating cells, 
most of these are Ox8+ cells, and they are found in the lesion 
and scattered throughout the white matter parenchyma (Hickey 
and Gonatas, 1984) . 
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Early lesions contain approximately 30 % macrophages, 
with the proportion increasing to about 50% as the lesion 
progresses . Although there is some evidence for activation 
of microglia (Field, 1961), most of the phagocytes appear to be 
blood-derived (Kosunen et al, 1963; Waksman and Adams, 1962). 
In MS this may not be the case, 
since most Ia+ cells do not stain with the monoclonal antibody 
OKMl , which stains peripheral blood monocytes, indicating 
ei t her a microglial or astroglial origin (Traugott, Reinherz 
and Raine, 1983b; Traugott, Scheinberg and Raine, 1985). 
Polymorphonuclear cells are not usually seen in lesions 
of EAE. Exceptions are the acute phase in rabbits (du Clos et 
al, 1981), where pertussis has been used in the sensitizing 
injection, e.g . in mice (Traugott, 1985), and hyperacute EAE 
in rats (Levine and Wenk, 1965b). 
It has been argued that the predominance of DTH / helper 
cells implied a major role for them in the patholog y of the 
lesion. However, Trotter and Steinman (1984a) have shown that 
both T cell subsets (Lyt-1+ and Lyt-23+) home equally well to 
CNS lesions in the SJL/J mouse, and the ratios are the same as 
those found in blood, that i s , DTH / helper:cytotoxic / suppressor 
of approximately 3-3.5:1. ( McKenzie and Potter, 197 9 ). 
Furthermore, the homing pattern was not antigen-specific. 
Werdelin and McCluskey (1971) found a similar lack of antigen-
specificity in passive transfer of 3 H-thymidine-labelled, 
senstized lymph node cells in Lewis rats. Less than 5 % of 
cells accumulating in CNS lesions were of donor origin, and 
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antigen specific. This does not necessarily negate a role for 
T cells in the pathology of the lesion, however. Normal T 
cells bind to myelin (Kuttner and Woodruff, 1979), and T cells 
with a wide range of antigen specificities may accumulate in 
lesions where they encounter previously sequestered antigens, 
thus broadening the specificity of the immune response. 
In acute EAE, there is a fall in the numbers of 
DTH/helper cells in the blood at the time of onset of symptoms 
(Hauser et al, 1984b; van Lanbalgen et al, 1984): this 
coincides with the arrival of lymphocytes in lesions. 
Dissociation of the brains of guinea pigs with chronic 
relapsing EAE yielded a population of lymphocytes sufficient 
to account for the fall in peripheral blood lymphocytes 
(Schuller-Levis et al, 1984). 
In summary, although migration of T lymphocytes to the 
CNS can be demonstrated, and the cellular distribution in CNS 
lesions is well documented, the way in which T lymphocytes 
cause CS damage in EAE has yet to be fully elucidated. 
1.7 Demyelination . 
Chronic relapsing EAE, like MS , is characterised by 
extensive demyelination in the region of inflammatory 
lesions. In contrast, MBP-induced EAE produces an 
inflamma tory disease with very little demyelination (Ho++manJ 
Ga 5;ton ond Sp'itleY"' 19 73) . Incorporation of any one of the myelin 
lipids sulfatide, galactocerebroside or ethanolamine 
phosphoglyceride in the inoculum, enhances demyelination in 
lesions of guinea pigs with EAE (Moore et al, 1984), and it 
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is generally thought that, while MBP is necessary for 
induction of the inflammatory response, an additional immune 
response against one or more of the lipid myelin surface 
antigens is essential for demyelination. 
Demyelination is preceded by axonal swelling (Condie 
and Good, 1959; Bubis and Luse, 1964; Field and Raine, 1966), 
the mechanism of which is unclear. A calcium-activated neutral 
protease which degrades axonal proteins, MBP and proteolipid 
protein has been found in the CNS (Guroff, 1964; Zimmerman and 
Schlaepfer, 1982; Banik et al, 1983). An increase in 
intracellular Ca++ could theoretically activate such an 
enzyme, initiating the degradation of myelin from within, with 
resultant widening of the intraperiod spaces between the 
myelin lamellae. Such changes are often seen prior to demyelin-
ation, both in vivo and in vitro . This is followed by 
vesicular lysis of the major dense lines by macrophages . 
Ultrastructural analysis has shown macrophages apparently 
actively "stripping" myelin lamellae from the axon, by 
insertion of processes under the sheath (Lampert and 
Carpenter, 1965; Lampert, 1967), and some authors have 
observed that damage only occurs where there is intimate 
contact between inflammatory cells and myelin (Ko sunen et al, 
1963; Bubis and Luse, 1964; Lampert, 1965). 
Activated macrophages secrete several enzymes, including 
phospholipases (Trotter et al, 1982) and proteinases (Cammer 
et al, 1978), sometimes on a continuous basis for several days 
(Werb and Dingle, 1976). Inhibitors of acid proteinases 
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(Boehme et al, 1978) and neutral proteinases (Sibley , Kiernat 
and Laguna, 1978; Brosnan et al, 1980) have been shown to 
protect animals against EAE . While proteolipid is resistant to 
proteolytic attack, MBP and the acidic proteins which make up 
about half of the protein in myelin are particularly 
susceptible to protease activity (Einstein and Czejtey, 1968; 
Brosnan, Bornstein and Bloom , 1981). Banik, Hogan and 
McAlhaney (1984) have suggested that,since the proteins MBP 
and proteolipid protein are buried in the lipid bi-layer, 
phospholipases might allow the exposure of proteins for 
proteolysis to take place , 1.e. swelling of the myelin 
membrane might not be a problem unless activated macrophages 
are also present . Banik et al (1976) have shown that suscept-
ibility of BP to the action of trypsin is enhanced by prior 
degradation of myelin lipids with phospholipase . 
Recen tl y , Trotter and Smith (1984) have demonstrated 
that opsonization of myelin liposomes with antisera to rat 
m elin increased pta e and degradation of myelin by 
macrophage monolayers . This could mean that oligoclonal and 
circulating immunoglobulin may potentiate demyelination 
by macrophages . 
Demyelination can be demonstrated 1n vitro by 
incubation of sp~nal explants or cerebellar cultures with 
sera from patients it . S, or ani mals with EE . EE sera 
ill demyelinate cerebellar c lt res only if disease 1s 
ind ced i th hole c_-s tissue ( Bornstein and .ppel, 1961 ) 
b t not if. BP is used (Seil, Falk , Kies and lvord, 1968 ) . 
Cerebellar c lt res exposed to antiserum from rabbits 
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sensitised with whole CNS tissue show demyelination by 1-3 
hours, which is complete by 6 hours (Raine and Bornstein, 
1976) . Demyelination in vitro appears to involve two separate 
processes . One is a complement-dependent myelinolysis, the 
other , observed when complement is inactivated before addition 
of the sera to the cultures, is a swelling of myelin with a 
doubling of the intraperiod space , similar to that observed in 
vivo . Raine and Bornstein (1976) showed that the factor 
r esponsible for both activities was anti-galactocrebroside 
antibody . Subequently, Brosnan et al (1977), and Brosnan, 
Traugott and Raine (1983) have used the rabbit eye model to 
elucidate the roles of cellular and humoral events in 
demyelination . Injection of anti-Ge serum into the vitreous 
has no pathologic effect. However, the addition of lymphokine 
obtained from Con A-stimulated lymphocytes, or induction of an 
inflammatory infiltrate in response to sensitization by rabbit 
spinal cord or an unrelated antigen (PPD or lecithin), 
resulted in primary demyelination in the vicinity of the 
cellular reaction. 
Thus, two mechanisms of primary demyelination in EAE 
have been demonstrated in vivo; bystander demyelination and 
antibody-dependent cell-mediated demyelination. 
Bystander demyelination occurs as the result of a cell-
mediated response to non-neural antigens in the immediate 
vicinity of myelinated nerve fibres. Wisniewski and Lassman 
(1983) have suggested that the small amount of demyelination 
which does occur in MBP-sensitized animals is a result of such 
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a response to the MBP pool present in the extracellular space 
(Simon and Anzil, 1974). In MS, however, the cellular 
infiltrate may not necessarily be in response to CNS 
antigen(s) but could possibly be directed against viral 
antigens on the surface of persistently infected cells. 
There are several reports of direct cytotoxic effects of 
lymphocytes upon myelinated cultures in vitro (Arnason, 
Winkler and Hadler, 1969; Bornstein and Iwanami, 1971). 
Recently, Lyman et al (1985) have reported that continuous T 
cell lines mediating EAE, obtained from SJL/J mice, demyel-
inated syngeneic spinal cord cultures, and that both helper 
and cytotoxic /suppressor subsets possessed demyelinating 
activity. 
1.8 Contribution of CNS cells to the patho l ogy of EAE . 
The idea that cells of the CNS can act in an immuno-
logical way is a relatively new idea. However, the increased 
activity and proliferation of astrocytes which 1s seen 1n 
lesions of MS and EAE (Field, 1961 ; Adams , 1983), and the 
presence of lymphoid cells in lesions, has suggested that 
some interaction between these cells or their products may 
contribute to demyelination. 
It is now known that astrocytes possess some macrophage-
like properties; following incubation with lipopolysaccharide 
(LPS) astrocytes release prostaglandin E and an interleukin 1 
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(IL-1)-like mediator which is capable of stimulating 
lymphocytes, as measured by increased thymidine uptake 
(Fontana et al, 1982). This has interesting implications, 
since glucocerebroside has been shown to induce both the 
formation and release of IL-1 (Gery and Lepe-Zuniga, 1984) and 
one of the effects of IL-1 is to increase the viscosity of Lyt 
l+ lymphocyte membranes, thus increasing their capacity to 
bind antigens (Puri, Schinitzky and Lonai, 1980). Astrocytes 
can also present antigen (MBP) to cloned T cell lines 
(Fontana, Fierz and Wekerle, 1984). In addition, although 
cells of the CNS do not normally express Ia antigens, 
astrocytes may be induced to do so by gamma interferon (Wong 
et al 1984a, 1984b, 1985). Astrocytes contain lysosomal 
enzymes capable of degrading myelin, which are activated in 
EAE lesions (Arstila et al, 1973; Allen, 1983), and can 
phagocytose myelin. Thus it is possible that their activation 
by immune cells, or their products, may perpetuate myelinolysis 
within the lesion. 
Astrocytes can be stimulated to proliferate by lympho-
kines released by T and B cells of human (Barna et al, 1984) 
and rat (Merrill et al, 1983; Fontana et al, 1 98 1a, 1981b) 
origin in response to mitogens. Astrocytes also bind IgG; 
Barna et al (1984) found that exposure of human astrocytoma 
cells to purified human IgG results in enhanced DNA synthesis, 
cytoplasmic process formation, and intensity of immunohisto-
chemical staining for acid phosphatase and GFAP. By immuno-
peroxidase analysis, fibronectin, which was virtually absent 
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from untreated astrocytes, appeared to be slightly enhanced by 
prior incubation with IgG (Barna et al, 1984). Further 
implication of glial cells in the pathology of EAE was 
suggested by Eigner, Pitts and Wikstrand (1981), who induced 
clinical and histological EAE in guinea pigs and monkeys by 
injection of a human glioblastoma. Thus it is possible that 
glial cells can produce factor(s) which can induce symptoms of 
EAE. 
The role of microglia, if any, in EAE is not known. The 
majority of macrophages and monocytes found in lesions of EAE 
are derived from the peripheral blood circulation (Werdelin 
and McCluskey, 1970), although Field (1961) has reported 
activation of microglia, demonstrated by Hortega's silver 
carbonate stain. 
While the CNS does not possess organized lymphatic 
tissue, Prineas (1979) has described the presence of thin-
walled channels, containing lymphocytes and macrophages, 
occurring in the perivascular space, in CNS tissue from 
patients with various neurological diseases, including 
multiple sclerosis, which may serve an immunological function. 
Large molecular weight antigens introduced into the brain 
drain into the deep cervical lymph nodes of the neck 
(Oehmichen et al, 1983), where, presumably, sensitization of 
lymphocytes could occur. Smaller molecules are probably 
transported out of the CNS via astrocytes directly into the 
blood, or diffuse into the bloodstream through the cribriform 
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plate (Bradbury, 1981). Thus, it would seem that the brain has 
an efficient system for drainage of waste molecules OUT, but 
that transport of both molecules and cells INTO the brain is 
much more selective (Oehmichen et al, 1983). 
1.9 The resolving lesion: recovery mechanisms. 
Acute EAE is a self-limiting disease, and animals 
recovering from disease are resistant to further attempts to 
induce EAE for at least 8 weeks (Willenborg, 1979). Such 
resistance can be demonstrated in both cell transfer (Ben-Nun 
and Cohen, 1981) and CFA-induced models (Welch, Holda and 
Swanborg, 1980; Swierkosz and Swanborg, 1975). Recovery 
appears to depend upon inhibition of effector cell activity; 
although antigen-reactive cells can be found in recovered 
animals, their activity is suppressed (Waxman, Fritz and 
Hinrichs, 1980). This is not due to lack of antigen 
stimulation, since MBP is found in the antigen depot for at 
least a year after injection (Tabira et al, 1984). Lewis rats 
are resistant to re-induction after about day 18 (Welch, Holda 
and Swanborg, 1980), and lymph node cells taken from rats at 
this time will transfer resistance to naive animals 
(Willenborg, 1979; Welch, Holda and Swanborg, 1980). Soluble 
factors extracted from T suppressor cells, obtained from mice 
protected against EAE by injection of mouse spinal cord in 
IFA, also transfer resistance (Arnon, 1981; Beraud et al, 
1982). The inhibition of T cell responses is not simply due to 
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repair of the blood-brain barrier, since the CNS remains 
permeable to T cells for at least 60 days after injection 
(Stohl and Gonatas, 1978). 
Thus it appears that T suppressor cells are probably 
responsible for recovery in acute EAE, and may be involved in 
remissions of chronic relapsing EAE and MS. Manipulations 
which lower the numbers of suppressor cells, such as cyclo-
phosphamide treatment (Lando, Teitelbaum and Arnon, 1979; 
Miyazaki et al, 1985) or irradiation (Willenborg, 1982) allow 
reinduction of disease in animals with EAE. Similarly, a 
lowering of the numbers of suppressor cells, as seen during 
pe,-, ?'-'era\ 
relapses of MS (Bach, 1985), may upset the immunoregulatory 
A 
balance, allowing reactivation of T helper cells. 
Complete remyelination is common in acute EAE, probably 
because of the cessation of production of the factor(s) which 
cause demyelination. It has been shown in vitro that removal of 
demyelinating sera results in remyelination of cerebellar 
'Bov-f'I ste·,V1 a,J A ppe I , I Cl ~'J Ro.w,e. O.V\o\ ~~ f'IS'teu-,, \ct 70 J 
culturesA(Seil, 1977). However if cells are left in contact with 
demyelinating sera, oligodendrocytes eventually die. This could 
presumably happen in vivo. 
1 . 10 The role of antibody. 
Antibody to MBP can be detect e d in serum by day 6 after 
antigen challenge (Gonatas et al, 1 9 7 4 ). Serum from recovered 
animals can protect if given early, from days 0-8 (Hughes, 
1974), however Richert et al (1982) found that antibody did not 
prevent cellular transfer of disease in rats. 
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There is no direct evidence that antibody plays a role in 
the pathogenesis of acute EAE. Antibody production does not 
correlate well either with time of onset, severity of 
disease or with relapses (Lisak et al, 1969; Lennon et al, 
1971; Tabira and Endoh, 1985). Attempts to transfer disease to 
normal animals with serum have been unsuccessful (Kabat et al, 
1947; Chase, 1959; Bernard et al, 1976), except by direct 
injection of serum into the brain (Jankovic, Draskoci and 
Jancic, 1965; Simon and Simon, 1975), which results in 
symptomless lesions which were, albeit, typical of EAE. 
Further evidence that antibody is not directly involved 
in the induction of EAE was provided by Bernard et al (1976), 
who showed that transfer of purified T cells into mice induced 
disease without detectable antibody production. Conversely, 
transfer of purified B cells induced antibody to MBP, without 
symptoms or CNS lesions. Similarly, Ortiz-Ortiz and Weigle 
(1976) showed that suicide of specific T cells by 125I-MBP 
inhibited induction of EAE, however suicide of B cells did not 
affect disease production, even though no antibody could be 
detected. 
Interest in antibody arose as a result of the discovery 
of oligoclonal bands of IgG in the serum and CSF of patients 
with MS. However, most of this antibody has no known antigenic 
counterpart. Oligoclonal bands have been described in both 
chronic (Olssen et al, 1984) and acute EAE (Whitacre et al, 
1981; Whittaker and Whitacre, 1984). Much of this lg appears to 
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* Furthermore, since EAE can be prevented by thymectomy, 
but not bursectomy, of chickens (Jankovic and Ivaneski, 
1963; Blaw et al, 1967), these results require further 
elucidation. 
be directed against the Mycobacteria in the inoculum (Glynn et 
al, 1982; Olssen, 1984), However, Mehta, Patrick and Wisniewski 
(1985) recently reported that oligoclonal IgG from guinea pigs 
with chronic relapsing EAE, obtained during subsequent 
relapses, was largely specific for MBP. 
About 10-12% of inflammatory cells in EAE lesions are B 
cells (Sriram et al, 1982), and cells producing antibody to 
MBP have been detected in EAE lesions (Lennon et al, 1972). 
Serum from animals injected with whole spinal cord contains 
antibody to a wide range of neural antigens (Bornstein and 
Appel, 1961; Rauch and Raffel, 1964; Bornstein and Crain, 1965). 
Treatment of rats from birth with anti mu chain antibody 
inhibits B cell differentiation and prevents antibody 
production (Bazin, 1978; Cooper et al, 1980). Gausas et al 
(1982) found that anti-mu-treated rats failed to develop 
clinical signs or antibodies to MBP when challenged with GPSCH-
CFA, but not with MBP-CFA. All rats had cellular infiltrates, 
but fibrin deposition was almost absent. Willenborg and Prowse 
(1983) showed that treatment of neonatal rats with antiserum to 
IgM inhibited both clinical and histological EAE. T cell 
responses, as measured by PHA stimulation, and allograft 
rejection, were not affected. However, there is some evidence 
that T helper function may be impaired by anti-mu treatment 
(Kim et al, 1984) .* 
Aclacinomycin A is an antibiotic which inhibits RNA (but 
not DNA) production, and is effective against B cell leukaemias 
and certain B cell-mediated autoimmune diseases. It has no 
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effect against T cell leukaemias or the generation of 
allogeneic cytotoxic effectors, but it suppresses antibody 
plaque formation and in vivo antibody production to sheep red 
blood cells. Treatment of Lewis rats with EAE suppressed 
production of anti-MBP antibody, however all T cell responses 
were normal, and the treated animals developed clinical and 
histological EAE (Dickneite et al, 1984). 
Antibody may play a role in demyelination within 
inflammatory lesions, and it may be important both during 
recovery and for resistance to re-induction of EAE (Paterson 
and Harwin, 1963; Willenborg 1979, 1980). The relevance of 
antibody in MS is less certain, mainly because the nature of 
the antigen against which the oligoclonal Ig is directed is 
unknown. 
1.11 Delayed hypersensitivity. 
The general pathology of EAE is typical of delayed-type 
hypersensitivity (DTH) reactions: the disease can be trans-
ferred with DTH/helper T cells but not with serum; the 
inflammatory lesions contain a predominance of DTH/helper 
lymphocytes in the early stages, while macrophages are at a 
higher frequency in older lesions; there are few polymorpho-
nuclear cells, (which are a feature of antigen-antibody complex 
mediated hypersensitivity reactions); there is oedema and 
fibrin deposition; DTH can be demonstrated as early as 3-4 
days after sensitization, before antibody can be detected. 
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There is little doubt that T lymphocytes are required for 
the induction of EAE . Depletion of T cell precursors in vivo by 
neonatal thymectomy (Wick, 1972; Bernard, Leydon and McKay, 
1976), thoracic duct drainage (Gonatas and Howard, 1974) or 
anti-thymocyte serum (Ortiz-Ortiz and Weigle, 1976) results in 
a failure to induce disease. Susceptibility to EAE is restored 
by injection of normal thymocytes (Ortiz-Ortiz and Weigle, 
1976). Bursectomy of chickens (Blaw et al, 1967), on the other 
hand, has no effect on disease induction. 
EAE can be transferred with lymphoid cells from animals 
with EAE to naive recipients (Paterson, 1960; Stone, 1961; 
Astrom and Waksman, 1962), the optimum time being 9 days after 
sensitization (Stone, 1961). Manipulation of the transferred 
cell population revealed that induction of disease depended 
upon the Lyt 1+23- (mouse), W3/25+ (rat) T cell subset which is 
responsible for helper and delayed hypersensitivity functions 
(Bernard and McKay, 1983; Pettinelli and Mcfarlin , 1981; Holda 
and Swanborg, 1982; Bernard and McKay , 1983 ) . BP -s pecific T 
cell lines isolated from Lewis rats with EAE all transferred 
disease to naive recipients; these were shown to be 3/25+ 
(Ben- un, Wekerle and Cohen, 1981; Hauser et al, 1984b) . 
Relapsing EAE has been induced in SJL/J mice by transfer of 
lymph node cells 
(Mokh tarian, cfarlin and Raine, 1984 ) . 
Transfer of disease requires prior activation of cells by 
incubation with BP (Holda , elch and Swanborg, 198 0 ; Hinrichs, 
Roberts and axman, 1981; Richert, Kies and Alvord, 1981 ) , Con 
A (Panitch and Mcfarlin, 1977; Killen and Swanborg, 1982a; 
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Ortiz-Ortiz and Weigle, 1982), interleukin 2 (Ortiz-Ortiz and 
Weigle, 1982) or activation by mixed lymphocyte culture 
(Hayosh, Simon and Swanborg, 1984), procedures which presumably 
expand clones of effector cells. Incubation of EAE effector 
spleen cells with monoclonal antibodies to T helper cells 
(W3/25) before transfer, abrogates their activity (Swanborg, 
1983). However, removal of B cells from transferred cell 
populations has no effect on the course of the disease 
(Richert, Kies and Alvord, 1981). 
Macrophages appear to be necessary for the successful 
transfer of EAE, since depletion of either donor or recipient 
macrophages results in failure to induce disease (Panitch and 
Ciccone, 1981; Brosnan, Bornstein and Bloom, 1981; Killen and 
Swanborg, 1982a). EAE has been transferred with peritoneal 
cells from which non-adherent cells had been removed (Driscoll, 
Kies and Alvord, 1979), with macrophages primed with MBP in 
vitro (Carbone, Ovadia and Paterson, 1983) and with small 
numbers of dendritic cells obtained from lymph nodes or spleens 
of Lewis rats with EAE (Knight et al, 1983). 
It appears, therefore, that induction of EAE requires an 
antigen-processing cell and an immune T cell. This does not 
necessarily mean that the cell that finally induces the disease 
process is the donor T cell: other recipient-derived cells may 
also be involved in mediating CNS damage. One point that is 
established is that recipient T cells are not required for 
disease expression, since transfer of spleen cells into the 
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Lewis ·nude rnu/rnu rat induced disease with similar severity to 
that found for immunocompetent Lewis rats (Hinrichs, Wegmann 
and Humphres, 1984). Similar results have been obtained using 
the nude SJL/J mouse (Bernard, 1984). 
Skin reactivity to intradermal injection of MBP has been 
detected as early as 3 days after sensitization in guinea pigs 
(Shaw et al, 1965). Peak levels are reached at approximately 
day 9-10, that is, 3-4 days before the appearance of clinical 
signs (Shaw et al, 1965; Field, 1975) and reactivity reduces to 
recovery levels by day 18, where it remains for a relatively 
long period (at least 40 days) after injection (Swanborg and 
Holda, 1980), and long after symptoms have cleared and 
remyelination has begun (Stohl and Gonatas, 1978). The 
persistence of DTH in the face of clinical recovery is in 
contrast to MS, where at least one report has suggested that 
clinical exacerbations and remissions are accompanied by a rise 
and fall in MBP-specific DTH (Colby et al, 1977). 
In EAE, early skin reactivity to MBP correlates well with 
the severity of subsequent disease (Wa k sman, 1956; Shaw et al, 
1965; Hughes and Field, 1968; Vadas et al, 1975). During the 
acute attack there is a fall in DTH s k in responses . 
,his may be due to mi g ration of sensiti z ed T cells to the CNS 
(Traugott, Stone and Raine, 1978) or to t h e initiation of a 
suppressor T cell res ponse to MB P ( Ben- Nun, Eisenstein and 
Cohen, 1982 ) . Skin reacti v ity has been demonstrated to peptides 
containing the encephalitog enic fragment; the response 
parallels that induced by MBP (Hashim et al, 1973; Hashim and 
Sharpe, 1974 and 1975). 
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The presence of sensitized T cells in the peripheral 
blood, lymph nodes, spleen and peritoneal exudates has been 
demontrated in vitro by macrophage migration inhibition (David 
and Paterson, 1965; Hughes and Field, 1968; Vandenbark and 
Hinrichs, 1974) and by lymphocyte proliferation in response to 
MBP (Brockman et al, 1968; Dau and Peterson, 1969; Bartfield 
and Atoynatan, 1970; Lisak and Zweiman, 1974) and to whole 
spinal cord (David and Paterson, 1965). Cellular hypersens-
itivity to whole spinal cord was found to be directed against 
the MBP component (David and Paterson, 1965). However, 
subsequent investigators failed to show the presence of 
cellular hypersensitivity to the highly encephalitogenic 
peptide 112-126, indicating a dissociation between encephal-
itogenicity and cellular immunity to MB P (Eylar et al, 19 7 0 ; 
Bergstrand, 1972; Bailey, 1972; Spitler et al, 1 9 72 ) . 
Proliferation has been observed i n vi vo in bl o od 
lymphocytes of rabbits with EA E . Dowling and Coo k (1 96 8), 
using incorporation of radiolabel in peripheral blood 
leukocytes, observed an increased percentage of leukocytes 
actively synthesizing DNA between 6 and 11 days after 
sensitization with neural antigen. 
The expression of DTH requires the T-dependent release of 
vasoactive amines such as histamine and serotonin from mast 
cells, which results in an increase in vascular permeability 
(Gershon, Askenase and Gershon, 1975). Susceptibility to EAE in 
the mouse has been associated with VAA sensitivity (Linthicum 
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and Frelinger, 1982; Linthicum, Munoz and Blaskett, 1982). Mast 
cells are found in the meninges and post-capillary venules of 
the CNS, occurring in greater numbers in the guinea pig and man 
than in rats or mice. Depletion of serotonin by the drug 
Reserpine inhibits DTH responses, and has been shown to 
abrogate the T-cell-mediated inflammatory resonse induced in 
mice by Sindbis virus (Mokhtarian and Griffin, 1984). This may 
be of relevance in relapses of EAE and MS, which are associated 
with severe meningeal inflammation and macrophage activation 
(Suckling et al, 1984a). 
Fibrin is deposited in lesions of EAE (Oldstone and 
Dixon, 1968; Rauch, Einstein and Csejtey, 1978), being first 
detected 2-3 days before cellular infiltration (Paterson, 
1976). Activation of the clotting system and deposition of 
fibrin in sites of inflammation is a feature of DTH reactions 
(reviewed by Dvorak, Galli and Dvorak, 1980). It is presumed to 
occur as a consequence of increased vascular permeability 
(Colvin and Dvorak, 1975), which allows extravasation of plasma 
proteins into the perivascular space where fibrinogen is 
converted to fibrin. Two additional sources of fibrin are 
worthy of consideration. Firstly, neural cells are a rich 
source of thromboplastin; an y dama g e within the CN S may thus 
result in release of thrombo p lastin, leading to additional 
fibrin formation. This can be me asured q uantiti v ely in vitro 
as procoagulant activity, and is a sensitive indicator of CN S 
trauma (Graebar and Stuart, 1978). Secondly, fibrin deposition 
could result from infiltrating monocytes, which produce cell-
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bound procoagulant factor in response to immune stimulants such 
as interleukin 2 (Geczy and Hopper, 1981) or endotoxin (Farram, 
Geczy, Moon and Hopper, 1983). Geczy et al, (1984) showed that 
guinea pig peritoneal cells produced procoagulant on incubation 
with MBP, and that activity was maximum at the height of 
disease, i.e. 12-14 days after sensitization. 
Ackerman Ulrich and Heitz (1981) have observed that 
fibrinogen was restricted to vessels containing cellular 
infiltrates, and was not found elsewhere in histological 
sections of spinal cord from Lewis rats with acute EAE. 
This would suggest that fibrin deposition does not occur as 
a result of a general increase in vascular permeability, 
leading to plasma protein extravasation, but is produced by 
infiltrating cells. Fibrinogen is a much larger molecule 
than albumin (340,000 : 66,000 daltons), and it may be that 
fibrinogen can only enter lesions where vascular damage has 
occurred. 
A large proportion of the cells in sites of DTH 
inflammation are blood-derived monocytes (Gershon, Askenase and 
Gershon, 1975). In EAE, these cells comprise about 50 % of the 
cellular infiltrate at the time of clinical symptoms (Traugott 
et al, 1982b; Sriram et al, 1982), and are thought to play a 
prominent role i n the pathology of the lesion. A monocyte 
chemotactic factor has been described in the CSF of guinea pigs 
with chronic relapsing EAE (Kirby, Suckling and Rumsby, 1983), 
and macrophage chemotactic and activating factors have been 
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demonstrated in vitro by stimulation of sensitized T 
l ymphocytes with MBP (Hughes and Newman, 1968; Vandenbark and 
Hinrichs, 1974). Activated macrophages are theoretically 
capable of causing considerable damage and demyelination within 
CNS lesions; apart from directly binding to (Epstein, Prineas 
and Raine, 1983) and phagocytosing (Lampert, 1978} 
the myelin sheath, they secrete several 
factors which have been shown to damage myelin, including 
neutral proteases (Cammer et al, 1978; Brosnan et al, 1980), 
superoxide (Chia, Thompson and Moscarello, 1983) and hydrogen 
peroxide (Freund and Pick, 1985; Willmore et al, 1983). In 
addition, rat IL-1 has been shown to possess protease activity 
(Dessaint et al, 1979, Katz et al, 1980), and secretion of IL-1 
by activated macrophages could contribute to myelin damage as 
well as activating T lymphocytes. 
As discussed previously, the primary targets of neutral 
proteases, myelin basic protein and proteolipid protein, are 
not readily accessible to proteolytic attack; the former is 
buried deep in the lipid layer, while the latter is resistant 
to proteolysis. However, disruption of the lipid layer by the 
products of superoxide or hydrogen peroxide, could expose these 
proteins. Thus, the process of demyelination might reflect a 
combination of oxidative dama g e by macrophages, and a protein-
generated immune response. 
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1.12 Lipid peroxidation and CNS damage. 
The toxicity of oxygen and the reactive intermediates 
which are produced during its reduction to water are now 
well documented (Fridovich, 1983; Di Guiseppi and Fridovich, 
19 8 4 ; Ha 11 i we 11 and Gutteridge , 19 8 4 and 198 5 b ) . The 
action of oxygen radicals on the nervous system has been 
reviewed recently by Halliwell and Gutteridge (1985a). The 
complete reduction of one molecule of oxygen to water 
requires four electrons, and during this sequential process, 
several intermediates are produced: 
e-
02 
e-+ 2 H+ e+H+ e-+H+ 
02 H202 \. HO· \ 
H20 H 2 0 
These intermediates, particularly the hydroxyl radical 
(·OH), are highly reactive. Protective mechanisms which 
exist for scavenging radicals (usually before ·OH can be 
formed) are listed below. 
superoxide dismutase 
catalases 
p ero x idases 
Activated macrophages produce both superoxide (o:) and 2 
hydrogen peroxide (H 2 0 2 ). These products by themselves are 
poorly reactive, however in the presence of small amounts of 
catalytic iron (Fe II), the highly toxic hydroxyl radical 
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may be formed by the reaction described by Haber and Weiss 
(1934): 
Fe 3 + + 02 Fe
2 + + 02 (reduction of iron) 
Fe 2+ + H202 Fe
3 + + OH. + OH (Fenton reaction) 
H~0 2 
Fe-salt + OH· + OH (Haber-Weiss reaction) 02 + 02 catalyst 
The hydroxyl radical is an unstable and highly reactive 
chemical species which oxidizes virtually any organic compound 
it encounters. Although its life span is measured in 
microseconds, and its concentration may be extremely small, it 
is capable of a great amount of damage, particularly in lipid-
rich environments, where damage to fatty acid side chains may 
start a chain-reaction of lipid peroxidation. Furthermore, the 
toxic effects may be perpetuated due to altered lipids, lipid 
peroxides, altered proteins and peptides, some recirculating, 
long-lived and potentially harmful (Esterbauer, 1982). The 
products of lipid peroxidation are also chemotactic for 
macrophages (Petrone et al, 1980) and cytotoxic (Slater, 
1984). 
Myelin, the main component of white matter, is 
approximately 70% lipid. In addition the brain is rich in iron 
(Stocks et al, 1974; Floyd and Zaleska, 1984) and ascorbic 
acid (Spector, 1977). Iron (II) salts are involved in several 
neurotransmitter functions, including degradation of 
catecholamines (Dillman, Johnson and Martin, 1979), and the 
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binding of serotonin to its receptors (Tamir and Lin, 1982). 
Nearly all non-haem iron is bound to the transport proteins 
transferrin and ferritin and reacts very slowly, if at all; 
however, in the presence of a reducing agent such as ascorbate, 
ferric iron may be reduced to the catalytic ferrous form. In 
healthy tissue these reactants are insulated from each other, 
however in sites of cellular damage they can interact, thus 
greatly increasing the potential for free radical generation 
and oxidative damage (Dormandy 1983). In EAE, initial damage to 
myelin appears to be as a result of macrophage contact (Lampert, 
1968), and macrophages activated by lymphokine are known to 
release H2 0 2 (Freund and Pick, 1985). Lesions of EAE also 
contain additional iron from extravasation and breakdown of 
red blood cells, and catalytic iron is present in CSF 
(Gutteridge et al, 1982; Halliwell and Gutteridge, 1984). 
Several enzymes (e.g. monoamine oxidase) release H2 0 2 directly, 
and production of H2 0 2 by rat brain in vivo has been 
demonstrated (Sinet, Heikkila and Cohen, 1980). 
The two main scavengers of H2 0 2 in blood are catalase and 
glutathione peroxidase. Levels of catalase are low in the CNS 
(Hartz et al, 1973), being l / 75th that of other lipidic 
(adipose) tissue, and the small amount that is present in the 
brain is concentrated 1n the hypothalamus and substantia 
n1gra, two areas of high iron content. Therefore, the most 
likely radical scavengers present in the brain are probably 
glutathione peroxidase, ceruloplasmin, and ~-tocopherol 
(vitamin E). Glutathione peroxidase removes H2 0 2 by using it to 
oxidize the tripeptide glutathione (glutamyl-cysteinyl-
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glycine), a process requiring selenium for its action 
(Wickstrom, Westermarck and Palo, 1976). Ceruloplasmin is found 
in appreciable quantities in the CNS (Al-Timini and Dormandy, 
1977), and acts by transporting ferric iron out of tissue, 
where it combines with transferrin in the blood. Free radicals 
are also scavenged by 5-hydroxytryptamine (SHT or serotonin); 
this may be another reason for the loss of this transmitter 
in EAE. 
Lipid peroxidation causes loss of membrane potential 
and integrity, increases permeability to ions (e.g. Ca++) 
and inactivates membrane-bound enzymes and receptors. The 
binding of serotonin to its receptors in rat cortical 
membranes is decreased by lipid peroxidation (Muakkassah-
Kelly et al, 1983). Free radicals can also affect proteins 
as well as lipids, for example by rearrangement of immuno-
globulin molecules, with resultant alteration of immunological 
properties (Wickens et al, 1983). In addition, free radicals 
cause an increase in vascular permeability, an effect which 
can be inhibited by superoxide dismutase and catalase (Del 
Maestro et al, 1980). 
Thus, it is possible that lymphoid cells liberating 02, 
or H2 0 2 , could cause the initial damage to
 the myelin 
membrane in EAE, exposing previously sequestered proteins. 
Both normal lymphocytes (Kuttner and Woodruff, 1979) and 
macrophages (Epstein, Prineas and Raine, 1983) have been 
shown to bind to myelin. It may be that activation by any 
means may be sufficient to cause 
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"bystander" demyelination, once the appropriate cells are 
attracted into the CNS. Lipid damage could result in 
chemotaxis, further damage, and activation of macrophages, 
while exposure of the myelin proteins may perpetuate the 
specific immune response. 
1.13 Aim of the present investigation. 
The macrophage procoagulant assay, developed by Geczy 
and Meyer (1982) afforded a new sensitive technique for 
the quantitation of delayed hypersensitivity (DTH) in vitro. 
It was hoped to establish whether the procoagulant assay was a 
reliable measure of 0TH in EAE, and whether 0TH responses 
contributed to the pathology of EAE. 
In addition, Lewis rats were treated with the iron-
chelating agent desferrioxamine, to determine the effect of 
depletion of catalytic iron on the clinical course of EAE, 
on the immune response in EAE, and on 0TH responses in 
general. 
Finally, the role of other protective mechanisms, in 
particular, the acute phase response, was examined in EAE. 
43 
* Unless otherwise stated, rats were used at 5 per group. 
CHAPTER 2 MATERIALS AND METHODS 
2.1 Animals. 
All animals were bred at the Animal Breeding 
Establishment at the John Curtin School of Medical Research, 
A.N.U. Female Lewis/JC rats were bred from pairs obtained 
from CSIRO, Brisbane in 1972. Due to contamination in 
Brisbane, the Lewis strain rats bred at the JCSMR carry the 
AA allele; most other Lewis rats are aa. This strain, now 
known as Lewis/JC, is fully susceptible to EAE. However the 
disease is not as severe as in the original strain, and 
deaths are rare. They were used at 8-10 weeks of age and 
;k 
weighed approximately 120-1509. 
CBA/H and BALB/c xSJL/J mice were used at 6-8 weeks of 
age, and weighed approximately 25g. 
Adult female Belgian lop-eared rabbits weighed between 
1.6 and 2.8 kg. 
An iron-deficient diet,and a control diet which had 
been replenished with iron,were obtained from ICN 
Nutritional biochemicals (Cleveland, Ohio). All other 
animals were fed "Barastoc" animal pellets (Barastoc 
Products, Sth Yarra, Vic) and water ad libitum. 
2.2 Statistics. 
Statistical significance of data was evaluated by means 
of the student's t-test. Unless otherwise shown, standard 
deviations were less than 10%. 
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Purified protein derivative (PPD) was obtained from the 
State Serum Institute, Copenhagen, Denmark. 
The 5E9 monoclonal antibody against the human 
transferrin receptor was a generous gift from Dr. D. 
Fayle, Dept. Medicine and Clinical Science, JCSMR. 
1 
I 
Gro...de. ", ) 
2.3 Chemicals and media. 
Concanavalin A (Con A) was obtained from Pharmacia; 
phytohaemagglutitin (PHA) from DIFCO (Detroit, Michigan, 
USA). Lipopolysaccharide (LPS), pokeweed mitogen (PWM), o\/a\'ovm·,n (oA) 
ra. t ~ po+l'"o..rl5+ e,,,-r, n , 
Carrageenan (type IV lambda) 'A human transferrin and human 
ceruloplasmin (Type X, 3,200 units/ml) were obtained from 
Sigma Chemical Co. (St. Louis, USA). 
Fluorescein-conjugated Concanavalin A (FLK-2100 
Fluorescein lectin kit) was obtained from Vector 
Laboratories Inc. (Burlingame, Ca., USA). Thy 1.2 antibody, 
Clone F7D5, was obtained from OLAC, (Blackthorn, U.K.) 
All other chemicals were of Analar grade from BDH 
Chemicals (Aust). 
Media for use 1n tissue culture were obtained from 
Grand Island Biological Company, Grand Island, New York. 
Dulbecco's Modified Eagle Medium was supplemented with 10% 
heat-inactivated foetal calf serum (HIFCS), 10- 4 ML-
asparagine and antibiotics (penicillin lOOU/ml, streptomycin 
lOOU/ml, neomycin lOOug/ml) for culture of PU5-l.8 cells. 
RPMI-1640 medium, supplemented with HIFCS and antibiotics as 
above, was used for all in vitro assays. 
Bacto fluid thioglycollate medium (DIFCO, Michigan, 
USA) was made up at 59.6 g / L in distilled water and 
sterilized by autoclaving. To induce peritoneal macrophages, 
2 ml of this solution was injected intra peritoneally into 
rats. 
T cell growth factor (TCGF) was prepared by pulsing rat 
spleen cells (2xl0 6/ml in RPMI + 10 % HIFCS) with 4 ug/ml Con 
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A for 4 hr. The medium was replaced and the cells inc u bated 
for a further 18 hr. The supernatant was harveste d and 
concentrated lOX in an ultrafiltration unit (Amicon Corp. 
Mass. USA). 
Desferrioxamine B mesylate (Desferal) was kindl y 
donated by Ciba-Geigy Aust. Ltd. Its properties are outlined 
in detail in section 4.2. MW 656.8. The LDSO 
. . in mice is 
1240 mg/kg i.p. and lOg/kg p.o. For in vitro studies, 
saturated DFOM was prepared by mixing equimolar amounts of 
DFOM with FeC1 3 , since DFOM binds Fe (III) in a 1:1 ratio. 
d . HY.roxyurea (Hydrea) was obtained from the Royal 
" Canberra Hospital. MW 76.06. Hydroxyurea is readily 
absorbed from the gastrointestinal tract. Peak blood levels 
are reached in 2 hr, and the drug is not detectable at 12 hr 
after ingestion. 
Butylated hydroxyanisole (BHA) was kindl y mad e b y Dr. 
W. Cowden. BHA is a commercial food antioxidant. LD SO in 
mice: 2000, 2200 mg/kg. MW 180.24 
Butylated hydroxyanisole (BHA) 
OH 
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HBED (N,N'-di(2-hydroxybenzyl)ethylenediamin-N,N'-
diacetic acid dihydrochloride (MW 496.0) was kindly made by 
ANU. 
N,N'-di(2-hydroxybenzyl)ethylenediamin-N,N'-diacetic acid dihydrochloride (HBED) 
Pyridine-2 carboxaldehyde thiosemicarbazone (PATS) and 
the equivalent compound bound to FeCl 
made by Dr. W.B. Cowden. 
(FePATS) were 
Pyridine-2 carboxaldehyde thiosemicarbazone (PATS) 
Fe PATS 
°'CH=N I 
/ 
HN-C 
2 II 
s 
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NH 
FeCl 2 
Pyridoxal isonicotinoyl hydrazone (PIH) was also made 
by Dr. W.B. Cowden. It is readily absorbed from the 
gastrointestinal tract, and diffuses readily into the CSF. 
It is stable for 48 hr in water. 
Pyridoxal isonicotinoyl hydrazone (PIH) 
0~ 
~C-NH-NH=CH 
I 
~ HO~ 
~ 
N 
Dihydroergotoxine mesylate (Hydergine) was obtained 
from Sandoz. Hydergine is composed of the ergot alkaloids 
ergocornine, ergocristine, oc-ergokryptine and ~-ergokryptine 
in the ratio 3:3:3:1. MW 696.5. LD50 in mice 33 mg/kg, in 
rats 40 mg/kg. 
Dihydroergotoxine mesylate (Hydergine) 
0 ' I\ CH(CH3)2 
c-NH ........ C 
.. 
'cH o ~o 3 H ... R 
dihydroergocomine R= -CH(CH3)2 
dihydroergocristine R= -CH2-c6H5 
dihydro-~ergocryptine R= -CH CH(CH3) 2 
dihydro-- -ergocryptine R= -CH(CH3)CH2CH 3 
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2 .4 Preparation of cell suspensions. 
Peritoneal exudate cells (PEC) were induced by i.p. 
i nject ion of thioglycollate medium three days prior to 
sampling. The cells were obtained from anaesthetised 
animals by washing out the peritoneal cavity with 20 ml cold 
Hanks Balanced Salt Solution. The cells were centrifuged at 
200g for 10 min at 4°c, and resuspended in RPMI-1640 medium. 
This procedure allowed repeated sampling of individual rats. 
For use in the procoagulant assay, erythrocytes were removed 
by layering the cell suspension on Isopaque FICOLL 
(Pharmacia, Uppsala, Sweden), and centrifuging at 1,250g for 
~~ ~ oc . 
20 min~ Less than 1% red cells remained after separation. 
Spleen and lymph node cell (LNC) suspensions were 
prepared by gently pressing organs through a 60 gauge wire 
mesh into RPMI-1640 medium. Aggregates were removed by 
passing the suspensions through nylon gauze (20u mesh, 
Simons Ltd, Sydney). Cells were washed and resuspended in 
RPMI-1640 medium containing 5 % heat-inactivated fetal calf 
serum and antibiotics. 
2.5 Preparation of Myelin Basic Protein. 
Myelin basic protein was p repared from guinea pi g 
spinal cord by the method of Diebler, Martensen and Ki e s 
(1972). Briefly, spinal cords were defatted by 
homogenization in chloroform/methanol, 2:1 (v / v), and the 
residue extracted with O.OlN HCl. Purified MBP was then 
obtained by ion-exchange chromatography on CM-52 resin. The 
yield of MBP from 50g of original spinal cord material was 
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50mg. The purified MBP was lyophilized and stored at -70°c. 
2.6 Induction of EAE. 
Spinal cords were excised from adul-t Hartley guinea 
pigs, meninges and vasculature removed, and a 20% w/w 
suspension prepared by homogenization in 0.9% saline, using 
a MulsiJet syringe (MulsiJet, Elmhurst, Ill. USA), and 
0 
aliquots were stored at -70 C. For use, the homogenate was 
emulsified in an equal volume of Freund's Incomplete 
Adjuvant (CSL, Melbourne, Aust.) to which had been added 4 
mg/ml Mycobacterium butyricum (Difeo, Detroit, USA). This 
inoculum is designated GPSCH-FCA. Rats were injected with 
0.2 ml, divided between the footpads of all four feet. 
2.7 Clinical assessment of EAE. 
Rats were weighed daily, and assessed for clinical 
symptoms using a scale of 0-5, as follows: 
0 = asymptomatic 
1 = weight loss, flaccid tail 
2 = ataxia, slow righting reflex 
3 = paraparesis, incontinence 
4 = paraplegia or quadriplegia, 
limb movement 
5 = moribund or death. 
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no voluntary 
2.8 Histology. 
Animals were anaesthetised with Avertin, and perfused 
via the left ventricle with saline, followed by fixation/ 
perfusion with form 1 saline. The brain and spinal cord 
were then removed into formal saline and embedded in 
paraffin. Mid-sagittal sections were cut at 6u thickness, 
and stained with haemato xylin and eosin to demonstrate 
cellular infiltrates in lesions or with toluidine blue for 
areas of demyelination. Sections were scored as follows: 
(based on the system described by Levine and Wenk, 1963) 
0 = no lesions 
1 = 1-5 lesions in an entire section (mild) 
2 = 1-5 lesions in 10 fields 
3 = more than 5 lesions in 10 fields 
4 = many lesions in almost all fields (severe) 
Cell suspensions and pieces of tissue for electron 
microscopy were fixed in 2% paraformaldehyde, 
2% glutaraldehyde in 0.2M sodium cacodylate buffer, pH7.3. 
After 3 hr, the tissues were postfixed in osmium tetroxide 
and embedded in Spurr's resin. 
2.9 Administration of Desferrioxamine. 
Desferrioxamine is excreted rapidly in vivo, with a 
half-life of approximately 30 min (Keberle, 1964). For this 
reason, it was administered via an osmotic pump (type 2ML1 
for rats and type 2001 for mice, from ALZA Corp ., Palo Alto, 
USA) which was implanted subcutaneously on the back. The 
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The dosage of 70 mg/rat/day (584mg/kg) was chosen as 
the maximum soluble amount with which pumps could be 
filled, and was well below the lethal limit of 
1240mg/kg. 
drug was reconstituted 1n water at 250 mg/ml, and the pumps, 
which operated for a period of seven days, delivered 70mg 
* DFOM/rat/day or 9 mg DFOM/mouse/day at a constant rate. In 
all experiments, EAE controls inoculated with GPSCH-FCA were 
sham operated. At the end of the treatment, the pumps were 
removed and checked to make sure they had emptied completely. 
2.10 Measurement of Desferrioxamine 1n plasma. 
The method used was that of Summers et al (1979). To a 
10 ml sample of heparinized blood was added lOOul of lOmM 
ferric nitriloacetate. The plasma was separated by 
centrifugation, and 50ul of lM MgS04 was added. The plasma 
was then filtered through a Centriflo ultrafiltration unit 
(Amicon, Sydney) to remove proteins larger than 25,000 
Daltons, and the optical density was measured in a 
Hitachi model 101 spectrophotometer at 440 nm, using the 
same subject's ultrafiltrate obtained before injection of 
DFOM as a blank. Ferrioxamine standards were prepared in 
0.9% NaCl. The recovery of ferrioxamine and desferrioxamine 
added to serum is 97-100 %. A scaled-down version of this 
method was used for CSF determinations, which were read in a 
Dynatech MR 600 plate reader. 
2.11 Measurement of CNS permeability to 12 5 I- BSA. 
Iodination of Bovine Serum Albumin (BSA) was performed 
according to the method of Fraker and Speck (1978). The 
inside of a tube was coated with 25 ul of Iodogen, which was 
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The dissociation rate of t'2.S I from BSA has not been 
determined. As discussed in Nossal and Ada (1971), 
nearly all (greater than 99.9%) of IL~ forms a stable 
complex _with tyrosine. The breakdown products of iodo-
labelled proteins are thought to result from 
proteolysis rather than deiodination of the protein. 
Furthermore, there is no reutilization of radioactive 
i o di de . Thus , any II l ea k age II of unbound I lS' I w o u l d be 
negligible, as indicated by CNS levels of 12~ I found 1n 
uninjected control s . 
~ 
dried by aspiration with N2 gas; lOOug of BSA in lOOul was 
added to Sul of 125 I (Specific activity 5 mCi/mg, Amersham, 
England), and reacted for 5 min on ice, with gentle shaking. 
The mixture was diluted to 1 ml in PBS, and dialysed for 
~ 
24hr in 3 changes of PBS, at 4°c, to remove unbound
125 I. At 
various times after sensitization, rats were injected with 5 
uCi/lOOg body weight intraperitoneally. After 16hr, the 
animals were perfused with saline via the left ventricle for 
5 min, the brain and spinal cord were removed and counted in 
a Beckman Gamma 4000 counter. 
2.12 Measurement of mononuclear infiltrate by [ 125 I]UdR 
labelling. 
This procedure, based upon that described by Vadas et 
al, (1975) depends upon the incorporation of the DNA 
precursor deoxyuridine into rapidly dividing mononuclear 
cells which localise in inflammatory lesions. Rats were 
injected i.p. with 1 ml of 10- 4 M 5-fluorodeoxyuridine 
(Sigma, St. Louis, USA) in saline; 30 min later, 15 uci 
(0.6 ml) of [ 125 I]5-iodo-2'-deoxyuridine ([ 12 5 I]UdR) (specific 
activity 5 Ci/mg, Radiochemical Centre, Amersham) was given 
by i.p. injection. The animals were perfused with saline 18-
24 hr later, and the brain and spinal cord was counted as 
for 125 I-BSA. 
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2.13 Measurement of DTH by footpad swelling . 
Mice and rats were primed as described for individual 
8 
experiments . An eliciting dose of 10 sheep red blood cells, 
Con A (0 . 5 mg/ml) or Carrageenan (Type I , Sigma C- 1013) was 
administered in 50 ul using a 30 - gauge needle . The degree of 
a 
swelling was measured at 4 hr , 24 hr and 48 hr usingAdial-
gauge caliper ("Schnelltaster", H. C . Kroplin, Hessen, 
Ge r many) . Each " unit " r epresents an increase in thickness of 
0 . 1mm (+ 0 . 05mm) . 
2 . 14 Macrophage procoagulant assay (MPCA) . 
The MPCA assay is based upon the fact that specifically 
sensitised T cells recognise antigen presented on 
appropriate stimulator cells, and react by producing 
lymphokine(s) which, in turn, cause the production of 
procoagulant on the surface of macrophages . It is this 
procoagulant which is measured by the capacity to reduce the 
clotting time of normal plasma . All media used in this 
a ssay are first filtered through a Zetapor filter (AMP, 
Chatswood, Australia) to remove endotoxin . Peritoneal cells 
(2xl0 6 ) were incubated with or without My elin Basic Protein 
(MBP) at 5 , 10, or 20 ug/ml, in 0.5ml RPMI containing 5% 
heat - inactivated foetal calf serum . After 16 hr incubation 
at 37°c, 5% co 2 , the cells were washed twice and resuspended 
1n 200ul of Hanks Balanced Salt Solution . lOOul of cell 
suspension was mixed with an equal volume of rat plasma 
(prepared as described by Geczy and Meyer (1982)), and, upon 
54 
addition of lOOul of CaC1 2 (0.03M), the clotting time was 
determined using a BBL Fibrinometer (Becton Dic k inson, 
Sunnyvale, Ca. USA). The percent reduction in clotting time 
(RCT) was extimated as follows: 
% RCT = (CT without antigen) - (CT with antigen) 
X 100 
(CT without antigen) 
Lymph node cells were incubated with Myelin Basic 
Protein (lOug/ml) at 2xl0 6 /ml in RPMI + 5% heat-inactivated 
foetal calf serum+ 10- 4 M 2-mercaptoethanol. After 72 hr, 
the lymphokine-rich supernatant was removed and diluted 1/2, 
1/4 and 1/8. A 0.3ml aliquot was then incubated for 16 hr 
with 4 x 10 5 PU5 cells, a continuous macrophage line derived 
from BALB/c mice, which produces procoagulant upon 
stimulation with lymphokine (Geczy et al, 1 9 83), and the 
·\ r\ T't""ip\, ccx-te 
cells were assayed as above. 
" 
55 
sensitized peritoneal exudate cells + antigen 
(2xl0 6 cells/0.Sml) ( MBP, lOug/ml) 
OR 
lymphokine from sensitized LNC or 
spleen cells incubated with MBP 
(final dilution 1/2, 1/4, 1/8) 
+ normal macrophages 
or PUS cell line 
(2xl0 5 cells/0.Sml) 
12 hr, 
Wash cell pellet three times 
l 
Resuspend 1n 0.5ml 
0.1ml cell suspension 
0.1ml rat plasma 
0.1ml 0.03M CaC1 2 
Record recalcification time 
Fig 2.1 The macrophage procoagulant assay. 
method. 
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Outline of the 
2.15 Depletion of Thy l+ cells. 
Thy l+ cells were eliminated from meuse spleen cell 
suspensions by treatment with antibody and complement. Anti-
thy.1.2 antibody (Clone F7D5, OLAC, Blackthorn, UK) was 
diluted 1:10 in PBS, and 25 ul was added to 5xl0
6
cells in 1 
ml PBS. After 30 min at room temperature, the cells were 
9 •. ,.t'\8Cl pi9 
washed by centrifugation at 400g, and complement (CSL 
" 
Laboratories, Melbourne, Aust.) was added to give a final 
concentration of 1:20. The cells were incubated at 37°c for 
30 min, and washed again. Approximately 30% of spleen cells 
were depleted by this method. 
2 . 16 Rosetting of Ig+ cells. 
Coupling immunoglobulin to sheep red blood cells (SRBC) . 
SRBC were washed four times in 0 . 9% NaCl and 
resuspended at 0 . 25 ml packed cells to 4 ml saline in a 15 
ml tube . To this tube was added 30ul sheep anti-mouse Ig 
(120 mg/ml), followed by 0 . 4 ml CrC1 3 (0 .1 %), with mixing. 
After 5 min at room temperature, The cells were centrifuged 
gently, resuspended in 5 ml PBS, centrifuged again, and 
finally resuspended in 2 . 25 ml RPMI containing 5% HIFCS. 
Rosetting of Ig+ cells. 
A suspension of CBA spleen cells was prepared as in 
section 2 . 4, and suspended at 4xl0 7 /ml; 2.5 ml was added to 
2.5 ml lg-coupled SRBC at 4°c, 20ul 25% NaN 3 was added, and 
the cells were centrifuged gently . The pellet was 
resuspended and layered onto Isopaque FICOLL to remove 
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* Human PBL were obtained from normal blood donors at the 
Royal Canberra Hospital. Whole blood was centrifuged at 
l,OOOg for 10 min. The buffy coat was removed, layered 
onto Isopaque-FICOLL · and centrifuged at 1,250g for 20 
. 40 min at C. 
/ 
I 
/ 
rosetted cells, which go to the bottom of the tube. Non-
rosetted (Ig-) cells, which form a band on top of the 
FICOLL, were recovered, washed, and resuspended in RPMI+l0% 
HIFCS. 
2.17 Measurement of T cell proliferation by thymidine uptake. 
Spleen cells, lymph node cells, or human peripheral 
~ 
blood lymphocytes (obtained as a buffy coat of blood taken 
from normal individuals) were suspended in RPMI-1640 medium 
containing 5% heat-inactivated foetal calf serum and 
antibiotics, and incubated at 37°c in 5% CO 2 in air for 48 
hr, in 96-well Linbro plates at 2xl0 5 cells/0.2ml/well. 
Reagents were added at the following concentrations: Con A, 
lug/ml; A23187, luM; PHA, PWM and LPS, all at 50ug/ml; PPD1 
oA ond \~9/ml MBP , Sug/ml; A DFOM, lOug/ml. During the last 4 hr of 
culture, 3 H-thymidine (0.2uCi in 25ul, Specific activity 102 
mCi/ml, Radiochemical centre, Amersham, U.K.) was added to 
each well. Cells were harvested onto filter paper using a 
Titertek cell harvester, transferred to vials containing 5ml 
scintillation fluid (Xylene/PPO) and counted in a Packard 
Tri-carb liquid scintillation spectrometer. 
2.18 Labelling of spleen cells with H33342 dye. 
Hoechst 33342 is a bisbenzimide derivative which binds 
to DNA, and once bound becomes strongly fluorescent. It is 
taken up by viable cells, and remains intracellular, being 
diluted only by division. The method used was that of Brenan 
and Parish (1984). A stock solution of H33342, 600ug/ml 
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ditilled water, was stored at 4°C. For use, 6 ug/ml was 
added to 5 10 7 spleen cells in 1 ml PBS. The cells were 
incubated for 15 min at 37 °c. Labelling was stopped by 
adding cold PBS. Cells were washed twice and resuspended in 
PBS for 1:v. injection (10 7 cells in 0.2 ml). After one 
hour, mice were killed, the spleens removed into cold 
sucrose and snap frozen in liquid nitrogen. A longitudinal 
face was cut using two razor blades mounted in a perspex 
holder, and the whole spleen placed in ape tri dish 
containing 0.9% NaCl. A coverslip was placed over the cut 
face of the section, and the whole spleen was examined on an 
Olympus (BH series) microscope with an HBO 100W mercury 
vapour lamp and 365 nm excitation and >435 emission filters. 
2.19 Interleukin 1 (IL-l)assay. 
Augmentation of PHA-stimulated C3H/HeJ mouse thymocytes 
was used as a measure of IL-1 activity (Mizel, Oppenheim and 
Rosenstreich, 1978). The macrophage cell line PU5-l.8 
produces IL-1 on stimulation with lipopolysaccharide (LPS). 
Cells were seeded at 1 x 10 6 /ml in RPMI-1640 medium contai-
ning 10% HIFCS and 20ug/ml LPS, and incubated for 48 hr at 
37 ~' 10% CO 2 in air. Both supernatants and cells were 
assayed for IL-1 activity. Cells were gently resuspended in 
the supernatants, transferred to centrifuge tubes and spun 
at 100g for 5 min. Supernatants were removed and the cell 
pellet was resuspended in a equal volume of RPMI-1640 
medium, and frozen and thawed three times to release intra-
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cellular 11-1 . Cell debris was removed by centrifug ation. 
Twofold dilutions of material to be assayed were added to 
cultures of mouse thymocytes obtained from 5-7 week-old 
C3H/HeJ mice , at 10 6 cells/well in a 96 - well microtitre 
plate , in RPMI - 1640 medium containing 10 % heat - inactivated 
foetal calf serum , 2xl0 - 5 M 2- mercaptoethanol and 1 ug/ml 
PHA . Tritiated thymidine (luCi/well) was added at 48 hr, 
the cells were harvested at 72 hr onto filter paper 
using a Titertek cell harvester and counted in a Packard 
Tri - carb scintillation counter . 
2 . 20 Interleukin 2 (IL - 2) Assay . 
The IL-2 assay depends upon the ability of IL-2-
containing supernatants to support growth of Con A blasts 
(Lafferty et al, 1980 ) . Con A blast cells were prepared by 
6 
stimulating spleen cells (lxlO / ml) with Con A at 1 ug/ml, 
0 in RP MI + 10 % HIFCS, for 3 da y s at 37 C . Doubling dilutions 
of supernatants containing IL-2 were placed in a 96-well 
tray, and Con A blasts ( 2 x 10 4 / well) were added in 200 ul. 
Trays were incubated for 16 hr at 37°c and then 3 H-thymidine 
was added for 5 hr (2 uci / well in 25 ul ) . Cells were 
harvested and counted as above. 
2 . 21 Mixed l y mp hoc y te culture. 
Mixed lymphocyte cultures were prepar ed b y mixing 1 ml 
of stimulator cells (CBA spleen cells irrad iated with l OOOR 
from 60 co source) at 2xl06 cells / ml with an equal number of F1 
responder cells (BALB / c x SJL / J lymp h node cells ) in 24-well 
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Linbro plates . The culture trays were placed at 37°c in a 
gassed (5% CO 2 - air) incubator . Cultures were harvested 
either at 3 days for cell proliferation assay or 5 days for 
cytotoxic T cell assay . For measurement of proliferation, 
cultures were dispensed in 0 . 2 ml volumes in Linbro 96-well 
trays , 2 uCi of 3 H- thymidine was added and the cells 
harvested 6 hours later . 
Cytotoxic T cell activity was measured using an 
automated colorimetric assay described by Parish and 
Mullbacher (1983) . Briefly, L929 (H - 2k) target cells were 
seeded in flat-bottomed 96 - well Linbro plates at 5xl0 4 
cells/well in 0 . 1ml of RP I 1640 medium plus 1 0% foetal calf 
serum . The Linbro plates were first coated with Poly-L-
lysine (SOug/ml) for 1 hr and then washed in PBS to enhance 
cell attachment . Target cells were allowed to adhere to the 
plates for 1 hr before the addition of effector cells. 
Effector and target cells were inc bated together for 4 hr, 
the medium was then discarded and viable target cells 
stained for 20 min at 37°C wi th O.lml /well of war m 0 . 035% 
neutral red in Hanks Balanced Salt Sol tion. The stain was 
discarded and the target cells ashed t ice by submerging 
the plates in PBS and tipping off the excess buffe r. 
eutral red was released by adding lOOul of 50 acetic 
Acid / ethanol mixt re and the optical density of each ~ell 
was then measured by a Titertek R600 plate reader. Per 
cent lysis of target cells at each K/T ratio as calc lated 
using the following for mula : 
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Culture of astrocytes and oligodendrocytes. 
Primary astrocyte and oigodendrocyte cultures were 
established by the method of McCarthy and de Vellis 
(1980) .Brains were removed from 3-4 newborn rats, cut 
into small pieces and placed in 10 ml DME containing 
0.1% trypsin and 10 ug/ml deoxyribonuclease 1 
(Calbiochem, La Jolla, CA) at 37°c, with occasional 
shaking. After 20 min, the suspension was filtered 
through nylon gauze (20p, Simons, Sydney). The cells 
were deposited by centrifugation at 100g, resuspended 
in 30 ml DME containing DNase, 10% HIFCS, antibiotics, 
and supplemented with Eagles NEAA (CSL, Melbourne). 
After 7 days culture in 75cm flasks (Nunc, Roskilde, 
Denmark) monolayers of astrocytes could be seen, with 
rounded, refractile oligodendrocytes resting on top of 
the monolayer. At this stage, the flasks were placed on 
an orbital shaker at 250 rpm for 12 hr, after which 
the oligodendrocyte-rich supernatant was removed to a 
fresh flask and astrocyte monolayers were subcultured 
by trypsinization. This procedure was repeated three 
times. The resulting astrocyte- and oligodendrocyte-
rich cultures were more than 90% pure as determined by 
anti-GFAP and anti-galactoce~ebroside staining 
respectively, and by electron microscopy. 
% lysis = C-T xlOO where C = mean OD of control wells 
C 
T = mean OD of wells 
containing effector cells 
2.22 Assay for anti-MBP antibody. 
Guinea pig MBP was added to a 96-well microtitre plate 
(Dynatech) at 2ug/well in 200ul. Plates were incubated 
overnight at 4°c, and then washed three times with 
phosphate-buffered saline (PBS). To reduce the amount of 
non-specific binding, 200ul of 2% BSA in PBS was added to 
each well for 30 min at room temperature, and the plates 
were washed three times with 0.2 % gelatin, 0.5% Tween 20 in 
PBS (G/T). Serum dilutions were made in 2 % BSA, 0.5% Tween 
20 in PBS, and added at 200ul/well. After 90 min at room 
temperature, plates were washed 5 times with G/T and 
200ul/well of peroxidase-labelled ra bb it anti-rat 
immunoglobulin (DAKO, Denmark) diluted 1:2,000 in G/T was 
added. After 1 hr at room temperature, plates were washed 5 
times with G/T. The substrate (0.3 % w/v o-phenylene diamine, 
0.04% H2 0 2 1n 10 ml citrate phosphate buffer [15mM Na 
citrate, SOmM NaHP04 , pH 5.4]) was added at 200 ul/well, for 
15-30 min at room temperature, and the reaction was stopped 
by adding SOul 2N HCl to each well. Plates were then read in 
a Dynatech plate reader at 540nm. 
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The profiles obtained from FACS analysis represent 
light scatter, which essentially measures cell 
size (horizontal axis) and intensity of fluorescence 
(vertical axis). In this way, it is possible to 
quantitate the numbers of brightly fluorescent 
(positively stained) cells. The results are expressed 
as a percentage of the total cell population. 
2.23 Flow cytometry. 
Cell sorting. The lymphocytes that respond in the 
procoagulant assay were characterised using monoclonal 
antibodies specific for rat T cell subsets. The W3/25 
(helper/DTH) and OX8 (cytotoxic) monoclones were kindly 
supplied by Dr. Alan Williams, Sir William Dunn School of 
Pathology, Oxford. Lymph node cells were incubated (30 min 
at 4°c) with these monoclonal antibodies, washed 3 times in 
PBS, incubated with fluorescein-conjugated goat anti-mouse 
IgG (CSL, Melbourne) and washed again 3 times in PBS. They 
were then separated on a fluorescence-activated cell sorter 
(FACS IV, Becton Dickinson) using a 488u excitation 
wavelength. 
DNA analysis. Mouse spleen cells were suspended 1n 
RPMI 1640 medium with 5% heat-inactivated foetal calf serum 
and plated at 4xl0 6 cells/well in Linbro 24-well trays. Con 
A was added at 2 ug/ml, and DFOM at concentrations ranging 
from l.SuM to lSOuM. After 48 hr incubation, the cells were 
centrifuged at 1,000 rpm, and the pellet resuspended in 1 ml 
of phosphate-buffered saline, pH 7.0. The DNA was stained 
by the method of Taylor (1980). To each sample, 80ul of 
Mithramycin solution (125 ug/ml in 75mM MgC1 2 , 1% Triton X-
100; Pfizer, Inc.) was added, followed 1 min later by 40ul 
of ethidium bromide (250ug/ml in 1 % Triton X-100; Sigma 
Chemical Co.). The sample was immediately filtered through 
20um nylon gauze and analysed in the fluorescence-activated 
cell sorter using a 457nm excitation band and a 520nm long-
pass emission filter. 
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The spectrometric assay for aldehydes (Jacobsen and 
Dickinson, 1974) is based on the formation of intense 
magenta and violet coloured 6-mercapto-3-substituted-s-
triazolo(4,3- b)-s-tetrazine derivatives from 4-amino-
3-hydrazino-5-mercapto- 1,2,4-triazole. 
The bleomycin assay for catalytic ("free") iron was as 
described by Gutteridge, Rowley and Halliwell (1981) 
and modified by Buffinton et al (1986). Briefly, 
bleomycin in the presence of iron (II) degrades DNA to 
form a thiobarbituric acid-reactive product. This 
provides a sensitive assay for "free" iron which would 
be available to participate in the formation of 
hydroxyl radical in vivo. The bleomycin assay does not 
detect iron bound to transport proteins or to enzymes. 
Although other metal ions can bind to bleomycin, they 
do not result in DNA degradation. Thus, the assay is 
highly specific for iron (II). 
. 
I 
2.24 Estmation of fibrinogen in plasma. 
Fibrinogen levels in plasma were determined by the 
method of Wycoff (1970). An aliquot of plasma (50 ul) was 
diluted in 3 ml Mcilvaine's buffer (0.2M Na 2 HP0 4 , O.lM 
citric acid, pH 5.2). After incubation at 55°c for 20 min, 
the turbidity was measured at 400 nm in a Hitachi 101 
\ 
spectrophotometer. 
2.25 Measurement of serum caeruloplasmin. 
Caeruloplasmin can function in vitro as an oxidase, 
converting the substrate p-phenylenediamine hydrochloride 
into a purple oxidation product (Wurster's Red). The assay, 
which is based on that of Ravin (1961) is essentially the 
same for rat and human serum, except that the optimum pH for 
rat is 5.6 and for human 5.4 (Smith and Wright, 1974). 
Serum was diluted 1:80 in acetate buffer (pH 5.5), and 160ul 
was added to each of 8 wells in a 96-well Linbro round-
bottomed plate. The substrate p-phenylenediamine 
hydrochloride, had been recrystallized, stored dessicated 
and made up immediately before use (0.5 % in distilled 
water). 20ul was added to each well, and the plate was 
incubated for 15 min at 37°c. Sodium Azide (20ul of a 10 0 
mM solution) was added to 4 of the 8 wells to act as a 
control. At the end of the incubation, 20 ul was added to 
the rest of the wells to inhibit further oxidation, and the 
plate was read at 540nM on a Dynatech MR600 plate reader. A 
standard sampl~ at 32 units/ml was prepared from Sigma human 
caeruloplasmin Type 1 (3200 units/mg/ ml). 
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Purification of ~ 1 M. 
Briefly, an acute phase response was produced in male 
Sprague Dawley rats aged between 21 and 28 weeks by 
subcutaneous injection with commercial grade mineral 
turpentine. Protease was removed by treatment with 
aprotinin (Sigma) and the a-globulin fraction extracted 
on CM Affigel Blue followed by separation on a 
Sepharose CL6B (Pharmacia) column. The ~,M was eluted 
using a gradient of 0-0.25 M NaCl in 0.05 M Tris HCl 
buffer, pH 8.0. The purity of the preparation was 
determined by immunoelectrophoresis and by isoelectric 
focusing, and was shown to consist of a single band in 
0 the free (unbound) form. The protein was stored at 4 C 
in Dulbecco's phosphate-buffered saline (PBS). 
2.26 Measurement of ~ 2 macroglobulin. (~ 2M) 
Purification and measurement of serum ~ 2 M was performed 
by N. Hunter and K. Weston, as described in Hunter et al 
(1985). Briefly, serum ~ 2 M was meaured by rocket electro-
phoresis against goat anti-human ~ 2 M (Cappel), at a concen-
tration of 150ul per 12 ml 1% agarose M per glass plate. 
Electrophoresis was carried out for 16 hr at 6 V cm-1 in 0.025M 
sodium barbitone, pH 8.6. The plates were dried and stained 
with 0.5% Coomassie blue G 250. 
2.26 Measurement of Ca++ uptake by quin2 acetoxymethyl ester. 
The method of Tsien, Pozzan and Rink (1982) was used to 
detect Ca++ uptake by the fluorescent indicator quin2. Quin2 
acetoxymethyl ester (50 uM) was added to a suspension of 
CBA/H thymocytes at 108 cells/ml and incubated at 37°c for 20 
min. The suspension was then diluted tenfold and incubated 
for a further 40-60 min. The cells were then centrifuged at 
l,OOOg for 3-4 min, resuspended in fresh RPMI-1640 medium at 
10 7/ml and kept at room temperature. For measurement of 
fluorescence, l-2ml of cells were centrifuged at 14,000g for 
a few seconds, and the cells were resuspended in HEPES-
buffered balanced salt solution without phenol red. Quin2 
fluorescence was read on a Perkin-Elmer LS-5 Luminescence 
spectrometer in cuvettes kept at 37 °c. Excitation and 
emission wavelengths were 339 and 4 92 nm with 4 and 10 nm 
bandwidths. Recordings were made from cells containing 1 uM 
A23187 with or without the addition of 10 uM DFO. 
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CHAPTER 3 
3.1 Introduction. 
PROCOAGULANT AS A MEASURE OF DELAYED 
HYPERSENSITIVITY IN EAE. 
The production of procoagulant factor on the surface of 
cells of the macrophage lineage is thought to be responsible 
for their immobilization, adherence to endothelium and the 
deposition of fibrin which are the hallmarks of DTH reactions 
(recently reviewed by Geczy, 1983). As such it has been used as 
the basis of a sensitive in vitro test for delayed hyper-
sensitivity in the mouse (Geczy et al, 1983; Farram et al, 
1983) and in man (Geczy and Meyer, 1982) termed the macrophage 
procoagulant assay (MPCA). Sources of macrophages used in the 
MPCA include blood monocytes, peritoneal macrophages, and 
several cell lines, including PUS-1.8 (obtained from BALB/c 
mice) which was used in this study. 
The nature of the procoagulant factor is unknown. It is 
similar to thromboplastin in that it can activate the extrinsic 
clotting pathway (Geczy and Hopper, 1981). However the 
mechanism may depend on the type of inducer used. 
Lipopolysaccharide-induced PCF appears, for example, to be 
different from lymphokine induced PCF, since activation of 
the clotting cascade occurs at two separate points, possibly 
by two different factors; one acting on factor VII and the 
other on factor X (see figure 3.1), (Geczy, 1983). 
PCF can be induced directly on the surface of macrophages 
by several agents, including endotoxin, or indirectly by the 
action of a lymphokine, procoagulant inducing factor (PCIF), 
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which is liberated by T cells of the W3/25 (helper/DTH) type 
following contact with mitogens such as Con A, or an antigen 
to which they have been sensitized. Release of PCIF requires 
the presence of one or more accessory cells, which have yet to 
be fully characterised (Geczy et al, 1983). The PCIF appears 
to be very similar to migration inhibition factor (MIF) 
(Geczy , 1983) , however , its exact nature is also unknown . 
Intrinsic 
pathway 
'\!I' 
IX IXa 
(L) Tissue factor+ VII 
+ phospholipid l 
Tissue factor ~ VII complex 
+ phospholipid 
X Xa 
l 
(E) Prothrombin ( II ) ~~~~7 Thrombin ( Ila ) 
Fibrinogen 
(L -e nhanced binding 
by macrophages) 
1 Fibrin 
Factor XIII 
(? L) 
Fibronectin 
(? L ) 
Stabilized cross -l inked fibrin 
Fig . 3 . 1 . Proposed activation of the clotting cascade, 
by macrophages activated with either lymphokine (L) or 
endotoxin (E) . From Geczy, (1983) . 
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3 . 2 Clinical course of EAE. 
Lewis rats injected with whole guinea pig spinal cord 
invariably showed a sudden weight loss of some 8-10% on day 
8 or 9 (see fig 3 . 3). This was followed in 2-4 days by 
neurological signs which ranged from a flaccid tail to 
severe paralysis. Clinical signs (assessed as described in 
section 2 . 7) showed a peak on day 14, and animals usually 
recovered by day 21-23 . However a second, milder incidence 
of disease during the next 7 days occurred in approximately 
10% of animals . Both mortality (2%) and the occurrence of 
chronic disease (less than 1%) were rare . 
Histological sections of medulla and spinal cord taken 
from groups of 5 rats, on days 4, 7, 10, 14, 18, 22 and 28 
after sensitization, showed perivascular infiltrates of 
mononuclear cells, which were first evident on day 10 after 
injection , and were fully developed by day 14 (Figu re 3 . 2) . By 
day 28 , lesions were still evident, (containing predominantly 
macrophages), although all animals had recovered by this ti me . 
EXT PAGE : 
Figure 3 . 2 Histological sections from rat spinal cord 
showing, a) normal, 
b) moderately severe lesions, 14d after injection with GPSCH-CFA 
c) severe, confluent lesions, 22d after injection with GPSCH-CFA 
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3.3. Kinetics of the procoagulant assay. 
Spleen cells, lymph node cells (LNC) and peritoneal 
exudate cells (PEC), taken from rats 10 days after injection 
of GPSCH-CFA, all reacted to myelin basic protein in a 
similar manner (figure 3.4). The clotting time of normal rat 
plasma was reduced by approximately 50% at the optimum 
incubation time of 12 hr. In initial experiments, 50 rats 
were tested for non-specific PCA reactivity one week before 
use, and all were found to be negative. 
The concentrations of guinea pig MBP routinely used to 
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stimulate these cultures were 5, 10 and 20 ug/ml. The 
optimum concentration was found to be 10 ug/ml, and all 
results shown are at that concentration. 
All cell suspensions obtained from animals for use in 
the procoagulant assay were routinely purified on Isopaque-
FICOLL to remove erythrocytes, since it was found that as 
few as 10 5 per 2xl06 incubated cells were sufficient to 
reduce the clotting time of normal rat plasma by 80%. 
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Figure 3.4 Kinetics of the procoagulant assay. 
Spleen ( • • ) and lymph node cells ( o- -o ) , incubated 
with PUS-1.8 cells, and peritoneal exudate cells (a--a) were 
incubated in the presence of 10 ug/ml GPMBP. Results are shown 
as the% reduction in clotting time compared with normal 
p 1 as ma . ( 0, ••• -0 ) norm a 1 L NC i n cub a t e d w i t h 1 0 u g / m 1 MB P • 
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3 . 4 Correlation of PCA activity with lymphoproliferation. 
One of the most widely used in vitro tests for cell-
mediated immunity is the proliferative response of 
lymphocytes to specific antigen, which results in the 
release of interleukin-2 (IL-2). A comparison was made 
between the lymphoproliferative and procoagulant response to 
GPMBP . Popliteal lymph node cells, taken from rats 10 days 
after injection of GPSCH-CFA, were incubated with 5, 10 and 20 
ug/ml GPMBP for 48hr . The supernatants were removed, and 
tested for induction of procoagulant on PUS-1.8 cells, and the 
remaining cells were pulsed for a further 4 hr with 
3 H- thymidine . The results, (figure 3.4), show that the 
correlation between procoagulant activity and lymphoprolif-
eration as in vitro indicators of delayed hypersensitivity was 
close , as indicated by the line of best fit. 
The PCA has been reported to be more sensitive than the 
lymphoproliferative assay for the demonstration of DTH to 
some antigens, notably PPD in man (Geczy and Meyer, 1982). 
s 
However it was found that the reponse of rat LNC to MBP was 
A 
n egative below 5 ug/ml MBP when measured by both lymphoprolif-
eration and PCA (figure 3 . 4), indicating that in EAE, at least, 
both methods appear to be of equal sensitivity. 
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Fig. 3.4 Correlation of procoagulant activity with 
lymphoproliferation. 
LNC taken from rats injected with GPSCH-CFA 10 days previously, 
were incubated with GPMBP at A Sug/ml, • lOug/ml, 20ug/ml. 
Open and closed symbols represent 2 separate experiments. 
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72 
3.5 Specificity of the procoagulant assay. 
LNC from animals sensitized to GPSCH-CFA responded to 
GPMBP but not to ovalbumin in the MPCA (Table 3.1). 
Conversely, animals sensitized to ovalbumin in CFA, or to CFA 
alone, did not react to MBP in vitro. All rats which had 
received CFA in the inoculum responded to Purified Protein 
Derivative (PPD), since CFA contains Mycobacterium 
tuberculosis, from which PPD is derived. 
Table 3 .1 Specificity of the MPCA assay for myelin basic protein. 
· Sensitization in vivo 
Antigen 
GPSCH-CFA 
GPSCH-CFA 
GP SCH-CF A 
NIL 
CFA 
Day 
7 
14 
21 
14 
73 
MPCA response 
(% reduction in clotting time) 
on in vitro challenge with: 
MBP 
23.4 
45.9 
25.2 
3.4 
4.8 
OA 
2.5 
3.0 
3.5 
3.8 
NIL 
3.7 
2.5 
3.6 
2.3 
3.3 
PPD 
27.8 
54.6 
46.4 
5.5 
49.5 
* These results clearly show t0at the cells which produce 
the lymphokine, now termed procoagulant-inducing factor 
(PCIF), are W3/25+, OXB-. This table represents a 
single experiment. 
3.6 Characterization of effectors in procoagulant assay. 
The cells which produce lymphokine in response to MBP are 
W3/25+ (helper/DTH) cells (Table 3.2). LNC taken from rats 
which had been sensitized with GPSCH-FCA 10 days previously 
were stained with the monoclonal antibody W3/25 or Ox 8, and 
separated on a Fluorescence-activated cell sorter (as 
described in section 2.23) into stained and unstained 
populations. These were then incubated with normal rat 
peritoneal cells at a ratio of LNC:PEC 1:10, for 72 hr, in the 
presence of MBP, and supernatants were assayed for 
procoagulant activity using the PU5-l.8 cell line.~ 
Table 3.2 FACS separation of T cells responding in the 
procoagulant assay. 
Lymph node cells 
(LNC) sorted for: 
W3/25 (helper/DTH) 
Unstained 
% of cells 
stained 
25 . 3 
0 
Ox 8 (cytotoxic/suppressor) 
Unstained 
7.2 
0 
Unseparated 0 
74 
% reduction in 
clotting time 
35 . 4±2 .1 
5.0 
5 . 0 
38.2±3 .5 
48.0±4.4 
3.7 Time course of MPCA in vivo. 
Delayed hypersensitivity was measured by reactivity to 
MBP in the MPCA, over a period of 60 days. Cells taken from 
the draining (popliteal) lymph nodes, spleen and peritoneal 
cavity showed earliest activity at 4-6 days (figure 3.5), with 
a peak at 8 days, and a decline to normal levels by day 20, 
with the exception of LNC, which continued to show reactivity 
until day 60. 
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Figure 3.5 Time course of MPCA in vivo, showing the response 
to GPMBP of --- spleen cells, • • lymph node cells and o--oPEC, 
taken from rats sensitized with GPMBP. 
A····• LNC from rats sensitized with ovalbumin 1n CFA. 
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3.8 Correlation of MPCA with clinical signs. 
The procoagulant activity of PEC taken on day 10 was 
compared with the subsequent clinical picture. Generally, rats 
which had high PCA on day 10 also developed high clinical 
scores, (Table 3.3). However there were exceptions to this, 
for example rat #4 had high PCA but mild symptoms, and rat#9 
had low PCA on day 10, but developed severe symptoms by day 
14, which lasted for 7 days. It was concluded that the MPCA 
activity of PE cells did not correlate well with either length 
or severity of disease. 
Table 3.3. Correlation of MPCA activity with clinical signs. 
Rat No. PCA day 10 Clinical score** 
( % RCT)* 12 14 16 18 
1 44.4 4 4 3 0 
2 42.5 0 4 3 1 
3 33.0 2 4 3 0 
4 33.0 0 1 0 0 
5 22.8 2 4 3 0 
6 16.7 1 1 0 0 
7 11.4 1 2 1 0 
8 10.6 0 0 0 0 
9 9.3 2 4 2 2 
10 7.3 0 1 2 3 
* Procoagulant activity was measured from PEC. 
then observed daily until fully recovered. 
Animals were 
** Clinical score is given from day 12-18 after injection with 
GPSCH-CFA. No symptoms were present before day 12. 
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3.9 Correlation of MPA with cellular infiltrate into the CNS. 
Twenty rats were injected with GPSCH-CFA on day O, and 
PEC were tested for PCA in response to GPMBP on days 7 and 14. 
On day 14, they were killed, and sections of medulla and 
spinal cord were graded according to severity of histological 
lesions (section 2.8). Table 3.4 shows that the severity of 
lesions in the CNS and procoagulant activity of PEC correlated 
well; rats with low histological scores had reduced 
procoagulant activity compared with those with severe 
infiltration. 
Table 3.4 Correlation of PCA with cellular infiltration. 
Histological 
score 
(no. animals) 
day 14 
1 ( 3) 
2 ( 6) 
3 (8) 
4 ( 3) 
Procoagulant activity of PEC 
(% reduction in clotting time) 
day 7 
10.3±1.7 
26.2±2.4 
30.5±2.8 
34.7±5.6 
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day 14 
34.5+3.2 
56.1±4 .7 
61.4±5.9 
65.9±6.0 
clinical 
score. 
day 14 
l, 2, 3 
1,2,2,3,3,4 
2,2,3,3,3,3,4,4 
3,4,4 
,"'I 
' 
~ 
This e x periment consists of 2 parts: 
1 ) To determine the cellular source of coagulant 
activity found in CNS damage, thought to be 
thromboplastin. 
2) To determine whether CNS cells could be induced to 
form a procoagulant factor, using LPS or IL-2 as the 
stimulus, which could contribute ~o the high coagulant 
activity found in CNS damage. 
~ 3.10 Attempted induction of PCA in glial cells. 
It is well known that the brain is a rich source of 
thromboplastin. Indeed, brain homogenates are commonly used 
in commercial thromboplastin preparations. In addition, the 
CSF of patients with CNS trauma contains significant levels of 
thromboplastin and as such is a sensitive indicator of damage 
(Graebar and Stuart, 1978). 
Although the fibrin deposition 1n EAE has been attributed 
to vascular leakage, the possibility exists that neural cells 
themselves are a source of inducible procoagulant activity, and 
may contribute to the fibrin deposition in EAE lesions. 
Astrocyte- and oligodendrocyte-enriched cell populations 
were obtained from newborn rats by the method of McCarthy and 
de Vellis (1980). Cells were incubated at 2xl06/ml with LPS 
(0.1, 1, 10, 100 ug/ml) or with twofold dilutions of TCGF in a 
volume of 0.5ml. Cells were harvested at 12 and 24 hr, and 
tested for procoagulant activity. In addition, aliquots of 
cells were washed, frozen and thawed 3 times to test for 
intracellular thromboplastin. Procoagulant activity was not 
induced in any of the cultures by either TCGF or by LPS, nor 
was intracellular procoagulant activity increased. The 
thromboplastin was found to reside mainly in the astrocyte 
fraction, oligodendrocytes having little procoagulant 
activity (Table 3.5). 
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Table 3.5 Procoagulant activity of glial cells. 
Treatment Clotting time of rat plasma (secs.)* 
TCGF (l/4) 
LPS (lOug/ml) 
Frozen/thawed 3X 
(diluted 1/4) 
Astrocytes 
149.4 
147.3 
146.8 
41.4 
Oligodendrocytes 
145.6 
154.l 
141.7 
106.2 
* Cell cultures were established in triplicate, 10 cells/0.Sml, 
and harvested at 12 hr. 
Standard deviations were all less than 10 %. 
3.11 Discussion. 
EAE in the Lewis rat is an acute inflammatory disease, 
accompanied by strong DTH responses. The macrophage 
procoagulant assay (MPCA) is a reliable indicator of DTH in 
rats with EAE. 
MPCA activity of lymphoid cells was optimum at an antigen 
concentration of 10 ug/ml, and little activity was detected 
below 5 ug/ml, suggesting that the sensitivity of the MPCA for 
EAE is similar to other in vitro tests for DTH, such as 
macrophage migration inhibition and lymphoproliferation. By 
contrast, reactivity to PPD in man has been reported to be 
highly sensitive, results being obtained with as little as 1 ng 
antigen (Geczy and Meyer, 1982; Geczy, personal communication). 
Tests of LNC and PEC from rats with EAE showed 
that reactivity to MBP as measured by the MPCA could be 
detected as early as 6 days after sensitization with whole 
spinal cord homogenate; peak levels were reached by days 8-1 0 , 
and declined thereafter, although LNC still responded 60 days 
after initial sensitization. Procoagulant activity correlated 
well with lymphoproliferative responses to GPMBP, and with 
cellular infiltration into the CNS. However, neither histology 
nor MPCA status correlated well with clinical signs, or duration 
of disease; nor were MPCA responses on day 10 a good indication 
of future severity of disease. Poor correlation of DTH with 
clinical signs does not necessarily negate a role for DTH in 
the pathology of EAE; drugs which suppress cell-mediated 
responses have been used successfully to treat affected animals 
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and it may be that other factors, associated with the DTH 
response, are involved in the generation of clinical symptoms. 
Fibrin deposition, as occurs in sites of DTH inflammation 
has been suggested as a cause of paralysis in EAE (Paterson, 
1976). The main source of fibrin is thought to be via 
extravasation of plasma proteins; whether macrophages 
producing PCF within lesions of EAE contribute to fibrin 
deposition is not known. Indirect evidence for such a role is 
suggested by Geczy et al (1984) who found that peritoneal 
macrophages, taken from guinea pigs with EAE, produced 
procoagulant factor on stimulation with MBP, but that during 
recovery such PEC produced an anti-coagulant factor, the 
nature of which is unknown. 
Astrocytes were shown to contain high levels of 
thromboplastin, and damage to astrocytes is presumably a source 
of procoagulant factor found in the CSF as a result of trauma 
(Graebar and Stuart, 1978). However, procoagulant could not be 
induced on the surface of intact astrocytes by stimulation with 
LPS or TCGF in vitro. CSF taken from rabbits with severe 
chronic EAE (section 4.19) contained significant amounts of 
PCA. Whether this is blood-derived, or resulted from cellular 
damage within the CNS, is not known. 
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CHAPTER 4. SUPPRESSION OF EAE BY DESFERRIO XAMI NE. 
4 .1 Introduction. 
Although strong DTH responses can be demonstrated in 
EAE, the contribution of the hypersensitivity response to 
the pathology of the lesion, and to the clinical expression 
of disease, is not clear. Iron-deficiency anaemia is 
associated with poor cell-mediated, but normal antibody 
responses (Joynson et al, 1972; Fletcher et al, 1975; 
Kuvibilida, Baliga and Suskind, 
Suskind, 1982; Kuvibilida et al, 
1981; Baliga, Kuvibilida and 
1983); conversely, 
incorporation of iron in the adjuvant used to induce EAE 
results in severe symptoms and prolongation of disease 
(Levine and Sowinski, 1970). In addition, iron has been 
shown to participate in free radical-generated lipid 
peroxidation, as outlined in section 1.12. If such a process 
is involved in the pathology of the EAE lesion, depletion of 
catalytic iron might be expected to reduce oxidative damage 
within the lesion, resulting in amelioration of disease. 
The choice of Desferrioxamine (DFO), therefore, to 
deplete animals of iron was based on two properties. One was 
its high specificity for non-haem, ferric iron, which effec-
tively depletes tissues of traces of iron which would 
normally be available to generate the dela y ed 
hypersensitivity response, and participate in iron-catalysed 
free-radical formation. The second property is the abilit y 
of DFO to act as a radical scavenger in its own right, (Hoe, 
Rowley and Halliwell, 1984). DFO was administered to rats 
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with EAE, to examine the effect, if any, on the disease 
process, and the pathology of CNS lesions. 
4 . 2 Properties of desferrioxamine. 
Desferrioxamine is a fungal metabolite obtained from 
Streptomyces pilosis. It was first isolated by Bickel 
(1960) , and has proved a valuable drug in the treatment of 
iron overload caused by multiple transfusions (e.g. in 
thalassemia and haemodialysis) and in iron poisoning 
(Modell and Beck, 1974) . Its high affinity for ferric iron 
(Table 4 . 1) means that it can be used to great advantage 
both in vitro and in vivo, without significantly affecting 
levels of other essential ions, such as calcium and 
magnesium . As it is not absorbed from the gastrointestinal 
tract , it is usually given parenterally. DFO binds iron in a 
1:1 ratio, forming a tight complex (Figure 4.1), which is 
then excreted via the kidneys, turning the urine a reddish-
brown colour. The colour of the iron-bound ferrioxamine 
complex forms the basis of its assay in plasma (Section 
2 . 10), since it can be measured spectrophotometricall y . 
The half-life of DFO in blood is approximately 30 min, 
with complete excretion by 4 hr. Although some metabolism 
occurs in vivo by an~ globulin en zyme found in plasma, 
degradation accounts for less than 3 0% of available DFO in 3 
hr (Keberle, 1964), and is therefore p robably insignificant 
in the overall in vivo metabolism of DFO. 
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Table 4.1 Binding constants for various metal ions of 
desferrioxamine and transferrin. 
Metallic ion Desferrioxamine Transferrin 
Fe 3 + 1031 1028,29 
ca 2+ 10 2 
Mg2+ 104 
zn 2+ 1011 
cu 2+ 1014 
Fe 2 + 1010 
From Keberle (1964). 
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Desferrioxamine B 
Ferrioxamine B 
Figure 4.1 The structure of desferrioxamine Band 
ferrioxamine B. 
(from: Keller-Schierlein, 1975; Pitt and Gupta, 1975). 
DFO removes iron from the iron-storage proteins ferritin and 
hemosid~rin very effectively without affecting haem iron 
(Propper, Shurin and Nathan 1975). In vitro studies have 
shown that DFO will bind up to 14% of transferrin-bound ·iron 
(Keberle, 1964), but this could not be demonstrated in vivo 
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(Hallberg and Hedenbe~g, 1965). In general, the amount of 
iron chelatable by DFO in vivo is related to the amount of 
storage iron, particularly to the concentration of ferritin 
(Jacobs, Kaye and Trevett, 1969; Balcerzak, Jensen and 
Pollack, 1966). Propper, Shurin and Nathan (1975) have 
concluded that DFO appears to act upon an intermediate 
compound in the pathway of iron transfer from storage 
(haemosiderin, ferritin) to plasma (transferrin) pools (See 
Fig. 4.2). Since DFO binds trivalent iron only, and storage 
iron is in the 2+ state, an oxidation step is necessary. 
Ceruloplasmin is the most likely source of ferroxidase in 
vivo, although ascorbate can also act in this way. Frieden 
(1971) has shown that the rate of Fe++oxidation in the 
presence of 2 uM ceruloplasmin is 10-100 times faster than 
non-enzymatic oxidation under physiological conditions. 
PARENCHYMAL 
CELLS 
HEMOSIDERIN 
FERRITIN 
TRANSFERRIN 419~-----tl R.E. CELLS I 
ERYTHRON 
Figure 4.2 Major iron pools of the body. 
(from: Propper, Shurin and Nathan, 1975) 
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4.3 Estimation of plasma and CSF levels of Desferrioxamine. 
Initial experiments showed that intramuscular 
injections of DFO into rats with EAE did not alter the 
disease process. Since DFO is excreted rapidly, with a half-
life in plasma of about 30 minutes, a continuous infusion 
was effected by means of an Alzet osmotic pump which could be 
implanted subcutaneously, delivering 3 mg DFO/hr for 7 days. 
Five normal rats were bled at various times after 
implantation of Alzet osmotic pumps containing 500mg DFO. 
Maximum levels of DFO in plasma were reached within 24hr of 
starting infusion, and were maintained at a steady rate of 
approximately 10-20ug/ml throughout (Fig 4.3). 
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2 4 6 8 
Days after pump implanted 
Fig 4.3 Plasma levels obtained after implantation of osmotic 
pumps containing 500mg Desferrioxamine. 
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The maximum amount of DFO that can be loaded into an 
osmotic pump is 500 mg and,since levels of 10 ug/ml were 
subsequently shown to be necessary for suppression of 
lymphoproliferation in vitro, the amounts used here would be 
marginal for effective immunosuppression. Animals which are 
much larger than those used in these experiments (more than 
150 g) would theoretically need larger doses of DFO. In 
addition, storage iron levels may vary between individual 
animals, and certainly does vary according to age, since the 
iron concentration in spleen is about 10 times lower in 
young (20 day) animals than in adult rats (Kochanowski and 
Sherman, 1983). Investigations are currently in progress to 
evaluate other continuous drug delivery systems, so that 
dose responses can be assessed. 
Because EAE is a disease that affects the CNS, it was 
important to determine whether DFO was able to cross the 
blood-brain barrier. Levels were determined in rabbits, 
since it is difficult to obtain CSF from rats without blood 
contamination. Blood and CSF were taken at various times 
after a single injection of lg of DFO. Maximum levels 
of 150ug/ml were reached in the plasma l hour after injection, 
and in the CSF 3 hours later (Figure 4.4). This showed 
clearly that DFO was able to cross the blood-brain barrier, 
and the delay of two hours indicates that it has probably 
diffused through the CNS into the CSF. It is therefore 
likely that the drug would be available to act within 
lesions of EAE. 
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Fig. 4.4 Levels of DFO in plasma and CSF of rabbits given a 
single injection of 500mg DFO. 
4.4 Effect of desferrioxamine on clinical EAE. 
Treatment of GPSCH-FCA-sensitized rats with DFO prior 
to the onset of symptoms either completely prevented the 
weight loss that is associated with clinical EAE (days 0-7, 
Fig 4.Sa), or greatly reduced the magnitude of such weight 
loss (day 8-15, Fig 4.Sb). The same general effect is seen 
in rats given the drug from day 11-18 (Fig 4.Sc). Also, 
clinically affected rats that were treated from day 14-21 
regained weight more rapidly than untreated controls (Fig 
4. Sd) • Administration of DFO to normal rats caused no 
change in normal weight gain. 
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Figure 4.5 Effect of DFO on clinical course of EAE. 
Rats were given DFO on: days 0-7 (a), days 8-15 (b), da ys 
11-18 (c) and days 14-21 (d). The groups were: 
A AGPSCG-CFA-primed and treated with DFO. 
• • GPSCH-CFA-primed and untreated. 
• a ·Unprimed and given DFO. 
s ro1s pel'" ~foup. 
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These patterns were repeated in both the incidence 
(number of animals affected), the severity of clinic a l 
impairment and the duration of disease (Table 4.2). Some 
neurological 
withdrawal 
signs were seen in a few animals subsequent to 
of the drug (Groups A,D and H), but these were 
generally mild and of reduced duration. In addition, the 
clinically affected rats that were given DFO showed rapid 
improvement during the course of treatment (compare G and H, 
Table 4 . 2) . 
Rats from group C (which showed no evidence of primary 
disease) and its control group D, were challenged at day 35 
with GPSCH-CFA. No symptoms were seen in any animals, 
indicating that these animals had become protected against 
re-induction of disease, even though initial symptoms were 
absent . 
4.5 Histological studies. 
The impression gained from histological analysis of 
sections of medulla and spinal cord from rats treated early 
with DFO was that the severity of the inflammatory process 
was minimal when compared with that recognised in the EA E-
primed controls (Fig 4.6). Relatively few lesions were 
observed, and the extent of the cellular . . invasion was 
slight . Also, it was noted that sections from those animals 
that had already developed symptoms at the commencement of 
treatment showed evidence of numerous old lesions, with 
fibrin depostion but little cellular infiltration. The few 
cells that were present had the general appearance of 
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Table 4.2 Effect of DFO on the duration and severity of symptoms of EAE. 
Number Treatment Days after sensitization 
in 
Group group DFO Days 12 14 16 18 20 22 24 28 
A 5 + 0-7 0 0 1.0(5)* 0 0 0 0 0 
B 5 - 0 3.0(5) 3.5(5) 2.0(5) 0.5(2) 0 0 0 
C 5 + 8-15 0 0 0 0 0 1.5(1) 0 0 
D 5 - 3.3(3) 4.0(3) 3.0(4) 1.0(2) 2.0(2) 3.0(1) 0 1.0(1) 
E 5 + 11-18 0 0 0 0 0 0 0.5(1) 0 
F 5 - 1.0(3) 2.0(4) 1.7(3) 1.0(3) 1.0(2) 2.0(2) 0 0 
G 10 + 14-21 0 1.5(2) 1.4(8) 1.0(3) 0 0 1.0(1) 0 
H 10 - 0 1.5(2) 2.0(7) 2.7(6) 1.5(2) 2.3(3) 0.8(2) 0 
Osmotic pumps delivering 70 mg of DFO per day were implanted into rats (5 per group). Controls 
were sham-operated. The results for days 14-21 are cumulated data for 2 groups of 5 animals: the 
two animals that relapsed on day 24 were from the same group. 
* The results are given as: mean clinical score for those with neurological 
clinically affected animals). 
signs (number of 
b 
• 
• 
C 
Xl50 
Figure 4 . Histological sections from desferrioxamine 
(DFO)-treated rats. 
Haematoxylin and eosin-stained sections from medulla of rats, 
10 days (a,b) and 16 days (c,d) after injection of GPSCH-CFA. 
a) and c) : from untreated rats, showing typical lesions. 
b) and d): from rats given DFO on days 0-7 (b) and 7-14 (d) 
showing absence of small mononuclear cells in lesions. 
Examination of histological sections from rats given DFO 
from day 14 onwards (i . e . after the appearance of symptoms) 
indicated that fewer cells could be found in lesions by 48 hr 
after DFO treatment was started . This was confirmed by 125 IUdR 
labelling (see section 4 . 13) . 
4 . 6· Patterns of lymphocyte responsiveness . 
The initial hypothesis was that DFO may limit the 
severity of EAE by removing free iron necessary for 
generating hydroxyl radicals . However the apparent loss of 
mononuclear cells from lesions (Section 4.5) raised the 
possibility that the drug might be either directly affecting 
lymphocyte function, or affecting lymphocyte migratory 
patterns . The first possibility was examined by assaying 
PEC for their procoagulant activity to MBP. 
Peritoneal exudate cells were taken at intervals from 
the rats that had been examined clinically (Fig 4.5, Table 
4 . 2) and were tested for procoagulant activity. The level 
of response was depressed for PEC sampled from 1-3 days 
after the cessation of DFO treatment (Groups A and B dlO, C 
and D dl6 , E and F d21, Table 4.3). This diminution in 
activity was least apparent for the rats that were 
clinically affected when drug treatment was started on day 
14, though evidence of suppressed lymphoc y te function was 
still apparent in these animals (Groups G and H d21, Table 
4 . 3) . However, by day 32 (Table 4.3), PEC from all groups of 
rats given DFO showed levels of PCA that were comparable to 
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Table 4.3 Levels of T cell responsiveness in peritoneal exudates. 
Treatment I Procoagulant activity on daysb Groupa I 
I DFO Days 7 10 14 16 21 32 
A I - 0-7 - 12.0±1.7 - - 23.4±1.0 23.4±2.0 0-7 C 23.0±1.8 18.6±2.4 B + - 3.3±1.4 - -
C I - 8-15 5.5±1.3 - - 21.6±1.9 - 52.2±2.1 D + 8-15 5.5±1.1 - - 3.1+1.l - 54.4±6.2 
E I - 11-18 - 9.5±2.6 - - 23.7±2.3 45.5±2.9 F + 11-18 - 9.5 ± 2.8 -
- 1.0 49.8±2.7 
G I - 14-21 - - 18.7±1.5 - 24.1±1.8 24.4±2.7 H + 14-21 - - 19.2±1.7 - 16.7±3.5 20.8±3.3 
aThese are the same groups as those shown in Table 4.2 and Figure 4.5. 
bMean + SD for 5 animals; rats were injected i.p. with thioglycollate 3 days before sampling. 
cstatistically significant P<0.05. 
those seen in the EAE controls. Thus, the ca pacit y of 
lymphocytes to respond to MBP was completely restored within 
11 days of stopping the drug treatment (Table 4.3). This 
may be due to persistance of the antigen in the injection 
site (Tabira, Itoyama and Kuroiwa, 1984). Even so, recovery 
of lymphocyte responsiveness did not usually lead to the 
development of symptoms, and 12 of the 15 animals that were 
given DFO from day 8 onwards remained completely free of the 
disease subsequent to treatment (Groups D, F and H, Table 
4.3) 
Popliteal lymph node cells were also tested from other 
rats that were subjected to the same treatment schedules 
used for the clinical evaluation (Groups A to F, Table 4.3). 
These animals were killed at various times after removal of 
the osmotic pumps. The patterns of response seen (Table 
4.4) were generally similar to those observed for the PEC 
populations (Table 4.3). Lymph node cells taken up to 6 days 
after cessation of DFO-treatment showed reduced MPCA 
activity, however they had returned to normal levels by 16 
days after treatment was stopped. These results suggested 
that the reduced severity of disease in DFO-treated animals 
might be due to a reduction in the cellular immune response. 
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The rebound effect could be due to 1) a delay in the 
" 
normal immune response, so that the peak occurs later 
in treated animals; 2) rapid mobilization of storage 
iron after depletion by desferrioxamine, or 3) may 
reflect the fact that lymphocytes are not killed, but 
remain synchronised in Gl, resulting in an accelerated 
response once DFO is withdrawn. 
Table 4.4. MPCA-promoting activity of lymph node cells. 
Days DFOM given Day of sampling 
0-7 13 
Nil 13 
8-15 31 
Nil 31 
11-18 18 
Nil 18 
11-18 35 
Nil 35 
% reduction in 
clotting time* 
9.7±0.9 
39.0±3.3 
51.1±2.5 
33.7±2.0 
14.0+1.l 
28.7+2.3 
49.8±2.4 
35.8±1.9 
* Supernates from cultures with MBP were assayed using the 
PU5-l.8 cell line. 
4.7 Suppression of T cell function. 
In order to determine whether DFOM was inhibiting 
macrophage or T cell function, PEC from DFOM-treated rats were 
incubated with lipopylysaccharide B (LPS) which is known to 
directly stimulate procoagulant activity in macrophages 
(Farram et al, 1983). The PEC from DFO-treated rats responded 
to LPS at least as well as normal PEC (Table 4.5) . Also, the 
addition of lymph node cells from rats primed with GPSCH-CFA 
18 days previously, restored the capacity of PEC from the DFO-
treated animals to produce procoagulant factor when stimulated 
with MBP. In contrast, l ymp h node cells from EAE/DFO rats were 
unable to - stimulate normal macrophages in the presence of MBP . 
This suggested that the defect resulting from DFO treatment 
was in the lymphocyte rather than the macrophage population . 
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Table 4.5 Restoration of PEC reactivity by addition of 
lymph node cells from GPSCH-sensitized rats. 
%reduction 1n clotting time 
PEC* LNC MBP LPS 
Normal None 4.1 39.3 
EAE/DFOM (dll-18) None 1.0 42.3 
EAE/DFOM (dll-18) EAE LNC 36.5 
EAE/DFOM (dll-18) Normal LNC 4.5 
EAE (dl8) None 36.0 
Normal EAE LNC 38.0 
None EAE LNC 3.9 
Normal DFOM/EAE LNC 2.4 
None DFOM/EAE LNC 1.5 
* PEC were tested for procoagulant activity by incubation 
with antigen (MBP, 5 ug/ml or LPS, lug/ml) for 16 hr. LNC 
from EAE (day 18 PI), DFOM/EAE (DFOM d 11-18) or normal rats 
were added at 3xl0 5 /10 6 PEC, 
stimulation. 
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the optimum ratio for 
Plasma levels of DFO achieved in vivo were 
approximately 15 uM (10 ug/ml) (see page 86). The 
concentration routinely used in vitro to suppress 
proliferation was the same, 15 uM. 
4.8 Effect of DFO on production of procoagulant factor by 
PU5-l.8 cell stimulated by lymphokine. 
DFO appeared to inhibit lymphocyte reactivity, but had 
little effect on macrophages when sensitized lymphocytes were 
present (and therefore, a source of lymphokine). In order to 
determine whether production of procoagulant factor could be 
inhibited by DFO, PU5-l.8 cells were incubated in the presence 
of T cell growth factor (TCGF) and various dilutions of DFO, 
as shown in Table 4.6. DFO did not inhibit the production of 
PCF, at concentrations routinely used in vitro. This suggested 
that DFO had no effect on the ability of lymphokine to 
stimulate the production of procoagulant factor on PU5-l.8 
cells. 
Table 4.6 Effect of DFO on procoagulant activity of PU5-l.8 
cells stimulated with lymphokine. 
DFO (uM) 
2.4 
12 
60 
300 
1500 
clotting time (secs) 
+TCGF -TCGF 
79.9 126.9 
68.9 125.9 
63.6 110.4 
63.9 120.9 
56.9 112.9 
40 .2 66.4 
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%RCT 
37.0 
46.8 
47.4 
43.4 
47.3 
39.4 
4 . 9 Suppression of lymphocyte proliferation in vitro. 
A further experiment was done in vitro to establish 
whether the effect of DFO was indeed mediated via the 
removal of loosely-bound iron. Lymph node cells from EAE-
primed rats were incubated in vitro with MBP. The resultant 
proliferative response was completely inhibited by the 
addition of DFO to the medium (Table 4 . 7). However the 
inhibitory effect of DFO was substantially reversed when the 
drug was saturated w i th Fe+++ be fore add i n g it to the 
culture , indicating that DFO suppresses lymphocyte responses 
by chelating loosely-bound iron. 
Table 4.7 Effect of DFO and FeC13 on T cell proliferation. 
LNC 
EAE dlO 
Normal 
Con A 
4.0 
6.4 
MBP 
2.9 
1.0 
Stimulation index* 
MBP+DFO 
1.0 
1.0 
MBP+SDFO MBP+Fe+++ 
2.3 2.3 
1.0 1.1 
* Results are expressed as stimulation inde x relative to 
counts for unstimulated control cultures. 
96 
4.10 Phagocytosis of carbon particles by macro phag es. 
An additional experiment was carried out to rule out any 
effect of DFO on macrophage function. Macrophages were 
tested for their ability to phagocytose carbon particles in 
the presence of DFO. 
PEC were obtained from the peritoneal cavities of 
rats injected with thioglycollate broth 3 days previously. 
The cells were allowed to adhere to plastic petri dishes 
overnight; non-adherent cells were removed and the medium 
was replaced with RPMI + 10 % HIFCS and 1:10,000 "Pelikan" 
brand Indian ink, which contains a suspension of carbon 
particles in a non-toxic base. Dilutions of DFO ranging from 
1 uM to 100 uM were added to the cultures simultaneously, 
and the cells were incubated for 1 hr at 37°c. Electron 
microscopy revealed that phagocytosis of carbon particles 
was undiminished at dilutions of DFO up to 50 uM (Figure 
4.7). Some inhibition occurred at 100 uM DFO, although 
occasional cells could still be seen containing carbon 
particles within lysosomes. 
4.11 Production of antibod y to Myelin Basic Protein. 
Production of antibody to MBP is generally considered 
to be dependent on T help (Bernard, Leydon and Mackay, 1976; 
Ortiz-Ortiz and Weigle, 1976). Since DFO appeared to inhibit 
sensitization of T lymphoc ytes to MBP , and symptoms of EAE, 
it was important to determine whether the drug had any 
effect on antibody production. 
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Figure 4.7 Phagocytosis of carbon particles by 
macrophages. 
Rat PEC were incubated for 1 hr in the presence of various 
concentrations of DFO. 
l) · carbon uptake by PEC in the absence of DFO. 
2) In the presence of 50 uM DFO , carbon uptake was 
undiminished. 
3) At a concentration of 100 uM DFO, occasional sparse 
lysosomes containing carbon could be found. 
4) PEC incubated without addition of carbon or DFO . 
.. 
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Groups of 5 rats were bled at various times after DFO 
treatment, as shown in Table 4.8, and the sera were tested 
for antibody to MBP . In addition, 2 groups of animals were 
tested which had been treated with the antioxidants 
c(-tocopherol and BHA (see section 4.12). 
Antibody production in the DFO treated groups followed 
the same pattern as in EAE controls (Table 4.8). This means 
that antibody production proceeds normally in the face of a 
marked reduction in T cell responses, as measured by the 
MPCA assay and severity of clinical disease. 
Table 4.8 Anti-MBP antibody titres of rats with EAE. 
Treatment Days after sensitization 
7 14 21 28 
None ND* 128 2048 8192 
DFO day 0-7 ND 256 4096 8192 
DFO day 7-14 ND 256 8192 2048 
DFO day 11-18 ND 128 1024 8192 
DFO+FeCl3 day 7-14 ND 512 1024 8192 
cJ...-tocopherol ND 64 4096 2048 
BHA ND 16 1024 4096 
Antibody titres are expressed as the reciprocal of the 
serum dilution. ND= not detected . 
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4.12 Other iron-chelators and antioxidants in vivo. 
It was still unclear whether DFO was acting in the 
suppression of EAE by chelating iron, thereby inhibiting 
lymphocyte proliferation, or by scavenging free radicals, and 
preventing lipid peroxidation in the CNS. Several anti-
oxidants, iron-chelators and inhibitors of the enzyme 
ribonucleotide reductase (RR) were tested for their ability to 
suppress EAE. Butylated hydroxyanisole (BHA), a-tocopherol, 
dimethyl sulphoxide (DMSO), and hydergine have been shown to 
inhibit lipid peroxidation in vitro (Gutteridge, 1978; Koreh 
Seligman and Demopoulos, 1982). The iron chelators HBED 
and PIH (described in 2.2) can be given orally, and therefore 
have the advantage of being easier to administer. Hydroxyur e a 
is an antineoplastic drug which acts by inactivating RR, 
thereby preventing DNA synthesis. Another compound which 
inhibi~s RR activity, PATS (described in Section 2.2), and its 
iron-containing counterpart Fe-PATS, were also tested to 
determine whether inactivation of RR could be reversed by the 
addition of iron. 
Of all the compounds tested, the most effective were 
DFO and hydroxyurea (Table 4.9). PIH, PATS and FePATS 
appeared to be toxic, in that soon after starting treatment 
the animals exhibited ruffled fur and loss of activity and 
eating, not associated with EAE. In addition, 8 of the 10 
animals receiving PATS died on days 12-13 from causes other 
than EAE. Some reduction in both the length and severity of 
,n 
disease was seen all groups of rats which received A 
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Table 4.9 Effects of various iron-chelators and antioxidants on the clinical course of EAE. 
Expt. Treatment Dose Route Days after sensitization 
No. (d7-14) (mg/kg/day) 12 14 16 18 20 22 24 28 
1 . BHA 150 food 1.5(2)* 1.6(5) 1.8(8) 1.9(6) 2.0(6) 1.5(5) 1.4(5) 0 
Vitamin E 150 l.p. 4.0(2) 3 . 0(6) 2.2(10) 1.6(6) 1.0(4) 1.0(2) 0 0 
DMSO 1300 water 1.8(6) 1.5(7) 1.2(8) 1.2(6) 1.0(6) 0.7(3) 0 0 
Hydergine 80ug water 2.3(3) 2.3(4) 2.2(5) 1.7(4) 1.3(3) 1.0(2) 0 0 
Nil - 2.2(6) 2.6(6) 2.9(7) 2.7(7) 2.5(7) 2.5(7) 2.5(6) 2.2(4) 
2. DFO 400 pump 0 2 . 0(1) 2.0(2) 1.0(2) 0 0 0 0 
Hydroxyurea 25 pump 0 1.0(2) 2.2(4) 1.7(3) 1.5(2) 0 0 0 
FePATS 10 pump 1.8(10) 1.8(9) 2 . 0(8) 1.8(8) 1.6(6) 1.3(6) 1.0(5) 1.0(1) 
PATS** 5 pump 
Nil - 1.5(3) 1.7(7) 2.0(8) 1.8(7) 1.5(6) 1.5(5) 1.0(4) 0 
3 . SDFO 400 pump 2.3(6) 2.8(8) 3.2(10) 3.5(10) 3.0(10) 3.0(10) 2.9(10) 3.0(2) 
Feel 30 pump 1.0(6) 1.5(6) 1.7(6) 1.8(10) 2.0(10) 3.0(7) 3.0(3) 3.0(2) 
PIH 50 pump 2.0(6) 2 .0(8) 2.1(9) 1.8(8) 1.4(7) 1.8(5) 2.0(2) 0 
HBED 50 pump 2 . 3(4) 2.1(7) 2 . 2 ( 8 ) 1.8(6) 1.6(5) 1.5(5) 1.0(3) 0 
Nil - 2 .2( 6) 2.2(7) 2.1(8) 1.9(7) 1.5(6) 1.3(6) 1.0(2) 1.0(1) 
* The results are given as: mean clinical score for those with neurological signs (no. of animals sick). 
for groups of 10 rats. 
** All but 2 of this group died from days 12-13. The remaining 2 showed no signs of disease. 
antioxidants (Experiment 1, Table 4.9), however, the effect 
was not as great as in those receiving DFO or Hydroxyurea. 
Supplementation with saturated DFO (DFO:FeC13 in a 1:1 molar 
ratio) greatly enhanced the severity of disease; this 
group did not recover normal weight until 3-4 weeks after 
other symptoms had resolved (days 51-58), compared with the 
EAE controls which recovered normal weight by day 36. 
Therefore, it appears that other iron-chelators do not 
significantly alter the clinical couse of EAE. Antioxidants 
are partially effective in reducing the severity of disease. 
However the greatest effect is seen with DFO and 
hydroxyurea, both of which may act by reducing lymphocyte 
proliferation. 
4.13 125IUdR labelling of infiltrating cells. 
Histological studies (Section 4.5) suggested that small 
mononuclear cells which accumulate in lesions of EAE were 
absent from animals which had been treated with DFO. 
Scavengers of free-radicals have been shown to inhibit the 
increase in vascular permeability caused by free-radical 
generating systems (del Maestro, Bjork and Arfors, 1981). 
It was possible that DFO was acting by decreasing blood-
brain barrier permeability, and preventing entry of sensitized 
lymphocytes into lesions of EAE. To test this possibility, BBB 
permeability to specifically sensitized lymphocytes, and to a 
non-specific protein, bovine serum albumin (BSA) was measured 
in rats with EAE. 5-iodo-2'-deoxyuridine ( 125 IUdR) 1s 
incorporated into rapidly dividing cells, and 1s a 
100 
sensitive measure of the accumulation of such cells in 
inflammatory lesions. (Stohl, Kaplan and Gonatas, 1979; 
Linthicum, Horvath and Carnegie, 1979). Groups were matched 
according to day of onset and clinical score on day tested. 
On days 14, 17 and 20 after injection of GPSCH-CFA, levels 
in EAE controls were similar, at about 4,000 counts per 
minute (Fig 4.8). Rats given DFO from day 14 onwards showed 
a marked drop in 125 IUdR label on day 17, which reached 
almost normal levels by day 20. There was no significant 
difference in BBB permeability to 125 I-BSA between DFO-
treated groups and EAE controls on days 14 and 17; however 
counts on day 20 in the DFO-treated group were almost half 
that of EAE controls. This may reflect the repair of the 
blood-brain barrier as lesions resolved in the treated 
groups. However the finding for day 14 and day 17 indicates 
that· there is direct inhibition of the inflammatory process 
that is not a consequence of repair to the blood-brain 
barrier. 
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Fig 4.8 Permeability of the CNS to I-BSA and to IUdR-
labelled cells. 
Permeability to a) 12 5I-BSA and b) 125 IUdR in rats with EAE 
( D ), rats with EAE given DFO from days 14-21 ( [] ), 
and normal controls ( §§ ) . 
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4.16 Alteration of normal migration patterns by DFO. 
From the previous results it appeared that the 
migration of specifically sensitized lymphocytes into the 
CNS may have been reduced by DFO treatment. This could be 
due to suppression of proliferation of these cells, as was 
indicated by in vitro results (Sections 4.7, 5.3). Another 
possibility is that DFO may alter, in some way, the 
migration of normal lymphocytes, since it has been suggested 
that iron may influence lymphocyte migratory patterns (de 
Sousa, 1978). This was examined by labelling normal spleen 
cells with the irreversible DNA stain, Hoechst 33342 
(H33342) dye, and following their migration in normal or 
DFO-treated recipients. DFO-treated CBA mice received 
osmotic pumps containing 50mg DFO, which delivered 7mg over 
a 24 hr period. Pumps were implanted subcutaneously 16 hr 
before injection of cells. Normal CBA mouse spleen cells 
were treated by rosetting to remove Ig+ cells ("T" cell 
fraction), or by anti-Thy 1 serum to remove Thy l+ cells 
( "B" cell fraction). Each mouse received 2x 10 7 cells 1.v. 
After 1 hr, spleens were removed and examined by UV 
microscopy. There was no difference in the pattern of B 
cell migration between the DFO-treated and untreated animals 
(Figure 4.9a,b). In both groups B cells migrated to outer 
follicular areas of white pulp. In contrast, T cell 
migration in DFO-treated animals was markedly abnormal;the 
cells were found in the marginal zone between red and white 
pulp, and in a "doughnut-shaped" area around the peri-
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Fig . 4 . 9 Migration of normal spleen cells to spleen. 
a) B cells into normal mice. 
b) B cells into DFO-treated mice. 
c) T cells into normal mice . 
a) T cells into DFO-treated mice. 
Magnification X60. 
arteriolar sheath (Fig 4.9d). T cells in untreated mice were 
found 1n close proximity to the periarteriolar sheath, as is 
normally seen. 
Thus, DFO was found to alter the migration of normal T 
cells to T-dependent areas of the spleen. The migration of B 
cells was not affected, however. 
4.15 Suppression of DTH to sheep red blood cells. 
In the previous section it was shown that DFO altered 
the homing of normal T cells to T-dependent areas of the 
spleen. Another way of examining this question is by 
placing both antigen and sensitized cells into a suitable 
site, such as the footpad. This procedure normally results 
in swelling of the footpad to approximately twice the normal 
thickness, and overcomes the necessity for specifically 
sensitised effector cells to migrate into sites of 
inflammation. 
The footpad swelling response to sheep red blood cells 
(SRBC) 1s a standard procedure which is widely accepted as a 
classical model for delayed hypersensitivity, which can 
be readily measured. An outline of the experimental protocol 
1s given in Fig 4.10. CBA/H mice were sensitized to SRBC by 
an intravenous injection of 10 8 cells. Five days later, 108 
spleen cells from these mice were transferred into naive 
recipients by intravenous injection. At the same time, an 
eliciting dose of 10 8 SRBC in 50 ul PBS was injected in the 
dorsum of the hind footpad. 50 ul saline was injected in the 
opposite foot to serve as a control. The swelling was 
104 
* Direct injection of sensitized lymphocytes together 
with antigen into the footpad, failed to induce an 
inflammatory response in mice treated with DFO. This 
suggests that the alteration of migration of sensitized 
effectors is not the only means by which expression of 
DTH is inhibited. DFO may also inhibit cell 
proliferation or the migration of recipient cells 
(which form the majority of cells in DTH inflammatory 
sites). 
measured 4, 24 and 48 hr later, as described in Section 
2.13. A variation of this method was to combine the spleen 
cells with the SRBC in 50 ul, which was then injected into 
the footpad. As mentioned previously, the injection of both 
antigen and sensitized lymphocytes into a local site 
obviates the need for specific effector cell migration. 
Mice which were treated with DFO by implantation of 
osmotic pumps 3 days before challenge with SRBC did not 
express DTH to SRBC, either when sensitized spleen cells 
were given intravenously or with SRBC into the footpad 
(Figure 4.10). However, the same mice developed normal 
antibody responses to SRBC (results not shown). 
Haematoxylin and eosin-stained sections of the footpads 
of these mice showed that in place of the massive infiltrate 
of mononuclear cells characteristic of DTH responses (Fig. 
4.llb), the footpads appeared essentially normal, with a thin 
layer of cells beneath the dermis consisting of the injected 
erythrocytes and mononuclear cells (Fig. 4.llc). 
These results suggest that the lack of oedema and 
failure to recruit non-specific inflammatory cells such as 
macrophages into the inflammatory site which was seen 1n the 
DFO-treated animals is not due solely to the absence of 
~ 
sensitized lymphocytes. 
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Figure 4.10 Footpad swelling response to SRBC. 
a) Spleen cells i.v., SRBC in footpad. 
b) spleen cells+ SRBC in footpad. 
Imm: sensitized spleen cells into normal mice. 
DFO: sensitized spleen cells into DFO-treated mice. 
Nor: normal spleen cells into normal mice. 
Figure 4.11 (next page) Histological sections of mouse 
footpad, showing 
a) normal spleen cells and SRBC injected together into a 
normal mouse footpad. 
b) Sensitized spleen cells and SRBC injected together into a 
normal mouse footpad, showing the massive mononuclear 
infiltrate. 
c) sensitized spleen cells and SRBC injected together into 
footpad of a mouse given DFO from -2 days. 
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4.16 Suppression of generation of T suppressor cells. 
Animals which were injected with GPSCH-CFA, treated 
with DFO, and did not develop symptoms, were nevertheless 
resistant to reinduction when challenged on day 35 (Section 
4.4). It is thought that resistance to re-induction of EAE 
is primarily due to T suppressor cells (reviewed in Section 
1.9). It was important, therefore, to determine whether T 
suppressor cells were generated during DFO treatment. 
Spleen cells from mice given SRBC 4 days previously were 
injected into recipients at the time of sensitization, a 
procedure which has been shown to suppress the DTH response 1n 
the recipients (Ramshaw, Bretscher and Parish, 1976). In this 
experiment, the footpad swelling was reduced by approximately 
60% (Figure 4.12). However, treatment of donors by 
implantation of osmotic pumps containing DFO at the time of 
sensitization abrogated the suppression, suggesting that these 
animals did not generate T suppressor cells (Figure 4.12). 
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Figure 4.12 
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Effect of DFO on the generation of suppressor 
cells. 
Mice were sensitized with SRBC, 4 days later 1 spleen 
equivalent (containing the putative T suppressor cell 
population) was transferred to naive recipients, and mice were 
challenged with SRBC in the footpad. 
• sensitised, untreated donors. 
D sensitised, donors treated with DFO. 
~ unsensitised donors. 
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4.17 Effect of DFO on non-specific inflammation. 
Desferrioxamine appeared to be a potent suppressor of 
the expression of delayed hypersensitivity, whether or not 
the sensitized effector cells were present in the 
inflammatory site, since it inhibited the footpad swelling 
induced by injection of sensitized spleen cells both 
intravenously and directly into the footpad (Section 4.15). 
Much of the expression of DTH, i.e. oedema and erythema, is 
mediated by macrophages. . It has been suggested that 
superoxide, produced by macrophages, is one of the principal 
mediators in sites of inflammation. McCord and Wong (1979) 
have shown that superoxide dismutase (SOD), which scavenges 
superoxide, prevents the inflammatory oedema generated by 
macrophages. If DFO were able to scavenge free radicals in 
vivo, then some inhibition of inflammation could be 
expected. Carrageenan-induced footpad swelling is ideally 
suited for this purpose, since it is mediated principally by 
macrophages (di Rosa et al, 1971; Oyanagui, 1976), and is 
inhibited by SOD but not by catalase (McCord and Wong, 
1979), indicating the operation of an o2-dependent process. 
The injection of 25 mg Carrageenan into the footpad result e d 
in an acute swelling of 50-60%, reaching peak levels 4 hr 
after injection (Fig 4.13). Five rats received osmotic pumps 
(delivering 70 mg DFO per day) 24 hr before injection with 
carrageenan. In this group there was a small but significant 
reduction in footpad swelling of about 8% at each hourly 
timepoint tested. However, the reduction was not sufficient 
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to invoke superoxide ~nhibition as a maJor mechanism for the 
inhibition of inflammatory processes in EAE. 
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Figure 4.13 Eff e ct of DFO on c a rrageenan-induced foot p ad 
swelling. 
· carrageenan (25mg) was injected into the footpads of 
( ••--• ) normal rats, and ( 0-------0 ) rats which had 
received DFO in osmotic pumps 24 hr previously. 
(:ff? shows footpad th i ck n es s o f norm a 1 cont r o 1 s . 
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The injection of Con A into the footpad induces an 
infiltrate of small mononuclear cells 22 hr later. This type 
of inflammation has not been well documented, but is useful 
here in that the mononuclear infiltrate is similar to that 
found in DTH reactions (Oyanagui, 1982), appearing 22-24 hr 
after injection of 50ug Con A, and being composed of small 
lymphocytes, with few macrophages at 22 hr (Fig. 4.14a). This 
response was totally inhibited by prior treatment with DFO 
(Fig. 4.14b). Since Con A is a potent lymphocyte mitogen, this 
again indicates an effect of DFO on rapidly dividing 
lymphocytes. 
Thus, DFO effectively suppressed the non-specific 
inflammation induced by Con A, which is mediated by small 
lymphocytes, but had little effect on the macrophage-mediated 
footpad swelling produced by carrageenan . 
4.18 Products of lipid peroxidation in rabbit CSF. 
Rabbits were used in this experiment, since it is 
difficult to obtain cerebrospinal fluid from rats without some 
blood contamination. A total of 7 rabbits were injected with 
GPSCH-CFA; all developed paralysis on the days shown in 
Table 4.10. Rabbits #3 and #4 developed severe chronic 
paralysis, and were killed on day 80. At various times after 
injection, rabbits were anaesthetized with nembutal, and 0.5-
10 ml of CSF was withdrawn from the cisterna magna, cells were 
removed by centrifugation, and nitrogen was bubbled through 
0 the sample to prevent autoxidation. Samples were frozen at -70C 
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Figure 4.14 Suppression of Con A response in mouse 
footpad. 
a) Inflammatory response, accompanied by massive cellular 
infiltration, 22 hr after injection of 50 ug Con A. 
b) Mouse footpad, 22 hr after injection of Con A and 
46 hr after implantation of osmotic pumps containing DFO. 
c) Normal mouse footpad, after injection of 50 ul saline. 
b 
until tests could be carried out. CSF samples were tested 
for products of lipid peroxidation by a sensitive test for 
aliphatic and aromatic aldehydes (Jacobsen, 1974), which is 
sensitive to 0.2 ppm. None was detected in any of the samples. 
A second test to measure small amounts of catalytic iron, 
the bleomycin assay, was also negative for all samples. This 
indicates that the amount of "free" iron which could derive 
from damage to erythrocytes in lesions of EAE, is not 
sufficient to be detected in CSF, although it could 
theoretically act within the local environment of the lesion. 
Thirdly, samples were tested for procoagulant activity. 
Brain cells contain large amounts of thromboplastin, and 
damage within the CNS is easily measured by the ability of CSF 
to reduce the clotting time of normal plasma. This method has 
been used as a sensitive indicator of trauma due, for example, 
to stroke and spinal injury in humans (Graebar and Stuart, 
1978). CSF (0.1ml) was added to normal rabbit plasma (0.1ml), 
CaCl (0.1ml of 0.3M) was added, and the clotting time 
estimated as for the MPCA (section 2.14). All of the rabbits 
tested had high levels of procoagulant activity compared with 
uninjected controls (Table 4.10), indicating that damage 
within the CNS had occurred. 
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Table 4 . 10 Procoagulant activity of CSF from rabbits with 
EAE. 
Rabbit No. 
1 
2 
3 
4 
5 
6 
7 
Day symptoms day tested 
first appeared 
19 28 
20 29 
17 80 
25 80 
20 29 
23 29 
18 29 
% RCT* 
60.3 
57.6 
78.7 
76.3 
76.4 
83.1 
75.5 
*%reduction 1n clotting time 1s CT normal CSF-CT test CSFxlOO 
CT normal CSF 
4.19 Discussion. 
The severity of EAE was greatly diminished in rats 
given the iron-chelating agent desferrioxamine (section 4.3). 
The effects ranged from complete prevention of the development 
of neurological symptoms, to more rapid recovery in rats that 
were already clinically affected. The clinical pattern was 
broadly reflected in the extent of histopathological changes 
(section 4 . 4). Recovery of lymphocyte responsiveness after the 
cessation of therapy, however, did not lead to the development 
of severe disease. 
The protective effect of DFO in EAE was shown to be 
directly related to the level of responsiveness for 
lymphocytes of the DTH/helper subset, taken from both the 
lymph nodes and the peritoneal cavity (section 4 .5 ) . 125 IUdR-
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labelling of rapidly dividing mononuclear cells in lesions 
also suggested that effector cells were diminished in number 
(section 4.12), however, antibody production was not reduced. 
Thus, the most likely reason for the reduction in severity of 
disease is that DFO is a potent immunosuppressive agent for 
DTH effector T cells. The finding that DFO suppresses 
lymphocyte proliferation in vitro and the fact that this is 
reversed by the addition of FeC1 3 (Section 4.9), indicates 
that the depressive effect may operate via the removal of 
iron, most of which is bound to transferrin in the serum. The 
increase in severity of symptoms of rats given an iron 
supplement (Section 4.12,) further supports the concept that 
serum iron levels influence the magnitude of DTH responses. 
Dietary iron deficiency is associated (in various antigen 
systems) with reduced delayed hypersensitivity (Joynson et al, 
1972), failure of lymphocytes to bind to target cells (Baliga, 
Kuvibidila and Suskind, 1981), and decreased DNA synthesis 
(Robbins and Pederson, 1970) ~ Iron is also thought to be 
necessary for other aspects of lymphocyte function, including 
recirculation and homing (de Sousa, 1978). The alteration of 
normal T cell migration patterns by DFO (Section 4.14) 
supports this idea. 
Incubation with DFO appeared to have little effect on 
macrophages in vitro, in that it did not inhibit the 
production of procoagulant in response to endotoxin 
stimulation or lymphokine (section 4 . 9), nor did it inhibit 
the phagocytosis of carbon particles at concentrations which 
depress lymphocyte proliferation (4.10). The macrophage-
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mediated inflammation produced by carrageenan was not as 
greatly modified by DFO, compared with the marked effects of 
the drug on both the footpad swelling induced by Con A and the 
DTH response to SRBC (Sections 4.15 and 4.17). Since there is 
an absolute requirement for clonal expansion on contact with 
antigen (or mitogen) in DTH reactions (Oppenheim, 1968), these 
results favour the interpretation that DFO acts directly on T 
lymphocytes, preventing their proliferation and homing. 
Two observations indicate that the reduction of 
lymphocyte proliferation may lead to a decrease in 
inflammation within : firstly, a more 
rapid resolution of the disease was seen in rats that were 
treated after the development of symptoms. Secondly, the 
number of rapidly dividing mononuclear cells which were 
11.S" 
labelled with IUdR was greatly reduced within 2 days after 
beginning DFO treatment. Decreased production of procoagulant 
in inflammatory lesions might be expected to reduce the 
deposition of fibrin in white matter in EAE (Paterson, 1 976) . 
Chelation and removal of "free" iron from sites of 
inflammation may also prevent free radical-induced lipid 
peroxidation and production of chemotactic factors resulting 
from tissue damage. An excess of free iron (produced by direct 
injection of FeC1 3 ) in the CS is known to contribute directly 
to such processes, and to the development of oedema and 
gliosis (Willmore and Rubin, 1978 and 1982; Hiramatsu, Mori 
and Kono, 1984). So far, efforts to detect products of lipid 
peroxidation in EAE have failed. No malonaldehyde could be 
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detected in the CSF of rabbits with severe chronic EAE (4.19), 
using a sensitive method which is able to detect nanomolar 
amounts in serum. Nevertheless, future experiments are planned 
which aim to detect H2 0 2 and long-lived products of lipid 
peroxidation in brain slices containing EAE lesions. 
It is of interest that iron deposits in the form of 
hemosiderin, which could be readily mobilised by DFO (Shoden 
and Sturgeon, 1962) have been found in multiple sclerosis 
plaques (Craelius et al, 1982). In fact, in one study, iron 
levels in such plaques were found to be approximately 5 times 
the level found in normal nervous tissue (Craelius, Jacobs and 
Lee-Jones, 1980). Therefore, DFO could possibly be of value in 
multiple sclerosis by removing iron from plaques (thus 
reducing the potential for iron-catalysed lipid peroxidation), 
and by acting as a mild, but reversible T cell 
immunosuppressant. 
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CHAPTER 5. SUPPRESSION OFT CELL RESPONSES BY DESFERRIOXAMINE. 
5.1 Introduction. 
The principal effects of DFO in vivo appeared to be the 
inhibition of sensitization to MBP, and alteration of T cell 
migration. Since both of these functions may be dependent upon 
proliferation, (Oppenheim, 1968; van Loveren and Askenase, 
1984b), and it appeared that T cells were selectively 
affected, there was a possibility that DFO was acting to 
suppress EAE solely by preventing T cell proliferation . 
The effects appeared to be reversible in that LNC taken 
from rats treated with DFO responded poorly to MBP 
(indicating a lack of sensitization in vivo), although the 
same cells were stimulated normally by Con A in vitro . 
Mainou-Fowler and Brock (1985) showed that T cell mitogenic 
responses were inhibited if carried out in serum from iron-
deficient rats, but T cells taken from iron-deficient 
animals responded normally in normal serum. It has frequently 
been shown that people suffering dietary iron deficiency 
show poor responses to T cell mitogens and delayed skin 
reactivity (Joynson et al, 1972), although antibody 
production and B cell numbers appear to be normal. 
Similarly, DFO suppressed the in vivo expression of DTH, 
although antibody responses were normal. Iron may 
be needed for DNA synthesis, since tumour cells cultured in 
the presence of DFO showed selective inhibition of DNA but 
not RNA or protein synthesis (Robbins and Pedersen, 1970). 
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In order to analyse further the mechanism of action, 
the effect of DFO on a variety of in vitro T cell 
proliferative responses was assessed. 
5.2 Toxicity of DFO in vitro. 
Desferrioxamine was not directly toxic to cells 1n vitro, 
as shown by trypan blue exclusion (Table 5.1). Primary 
ra't 
cultures of~LNC and the continuous macrophage cell line PUS-
1.8, were grown in RPMI-1640 medium containing DFO 1n concen-
trations ranging from 1 uM to 1 mM. Although no loss of 
viability occurred during the 3 days incubation at 10 uM DFO, 
PUS-18 cells gradually lost adherence to the culture flask 
(Table 5.1). Desferrioxamine was toxic at concentrations 
greater than 100 uM. 
Table 5.1 Viability and adherence of cells cultured with 
desferrioxamine. 
days DFO % live cells* % cells adherent 
1n culture (uM) 
LNC PUS PUS 
1 10 95 99 98 
2 10 92 94 56 
3 10 87 91 22 
3 100 38 25 11.5 
* Figures given are no. of live cells/100 cells counted 
Absolute cell numbers in cultures did not vary significantly 
over 3 days. 
Standard deviations are less than 10%. 
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5.3 Effect of desferrioxamine on the proliferative response 
of lymphocytes to Con A and LPS. 
The proliferative response of mouse spleen cells to Con A 
and LPS in the presence of various concentrations of DFO 1s 
shown in Table 5.2. Spleen cells were stimulated with Con A (1 
µg/ml) or LPS (50 µg/ml) in the presence of various 
concentrations of DFO for 48 hr. 3 H-thymidine was added during 
the final 6 hr of incubation. DFO at concentrations of 15uM 
completely suppressed the Con A-induced T cell proliferation . 
Higher concentrations of the drug (60µM) were needed to obtain 
the same degree of suppression in B cells responding to LPS 
(Table 5.2). 
Table 5 . 2 The effect of desferrioxamine on the proliferative 
response of lymphocytes to Con A and LPS. 
3 H-thymidine uptake (cpm xl0 3 ± SE) 
DFO (µM) Con A LPS 
0 258 . 0 + 8.4 169.6 ± 6.5 
1 239 . 0 ± 7 .3 177.1 + 4.1 
15 5.5 ± 2.3 52.6 + 2.3 
30 3. 2 ± 1.4 21.4 + 3.0 
60 1 . 4 ± 0 . 2 2.0 + 0.1 
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5.4 Effect of desferrioxamine on the proliferative response 
of human peripheral blood lymphocytes to mitogens. 
The possibility that DFO may be of value in suppressing 
lymphocyte proliferation in humans, and the fact that DFO is 
beginning to be used to treat conditions other than iron 
overload (where iron depletion does not exceed normal levels) 
e.g. rheumatoid disease (Blake et al, 1981) raised the 
question of whether human lymphocyte responses are similarly 
suppressed in the presence of DFO. 
Peripheral blood lymphocytes from normal subjects were 
stimulated with PHA, Con A, PWM or LPS in the presence or 
absence of various concentrations of DFO. Proliferation was 
assessed after 3 days, 
final 24 hr incubation. 
3H-thymidine being added during the 
DFO inhibited the proliferation of PHA-, Con A- and PWM-
stimulated lymphocytes (Fig 5.1), and this was prevented by 
saturating levels of iron. DFO was less effective at 
suppressing LPS-induced proliferation in human PBL (Fig. 5.1) 
and mouse spleen cells (Table 5.2). PHA and Con A activate T 
cells almost exclusively (Greaves, Owen and Raff, 1974). 
Human T cells, in contrast to those from mice, are not only 
activated by PWM but are also required for B-cell 
differentiation induced by that mitogen (Keightly, Cooper and 
Lawton, 1976; Dimitriu and Fauer, 1978). LPS, in the mouse at 
least, is a known B cell mitogen (Andersson et al, 1972). 
Thus, it appears that T cells are more susceptible to 
suppression by DFO than B cells. 
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Figure 5.1 Effect of DFO on the proliferative response of 
human peripheral blood cells to a variety of mitogens. 
a) mitogen alone, b) mitogen + DFO (15µM), 
c) mitogen + DFO (15µM) + FeC1 3 (100µM) d) unstimulated cells. 
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5.5 Binding of Con A to lymphocytes. 
The suppression of mitogen reJonsiveness was not due to 
/\ 
failure of Con A to bind to the cell membrane, since 
incubation of mouse spleen cells with fluorescein-conjugated 
Con A (FITC-Con A) in the presence of DFO in concentrations 
ranging from 1 µM to 1 mM, did not result in any reduction of 
fluorescent staining, e as assessed visually by fluorscence 
~ 
microscopy (Fig 5.2). In addition, DFO did not prevent Con A-
agglutination of sheep red blood cells, at concentrations of 
Con A (1-5 µg/ml) and DFO (1-50 µM) used in the 
lymphoproliferative assay (results not shown). These results 
indicate that DFO does not interfere with the binding of 
mitogen to the cell surface. 
Figure 5.2 Binding of FITC -Con A to spleen cells. 
DFO was added to 10 6 LNC in 1 ml PBS, 50 µl FITC-Con A was 
added immediately, and the cells were incubated at 4°c for 30 
min. After 3 washes in PBS , cells were resuspended in buffered 
glycerol saline and examined under the UV microscope. 
a) Mouse spleen cells stained with FITC-Con A. 
b) As for a), in the presence of 50 µM DFO . 
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5.6 Reversal of DFO-induced inhibition with free iron. 
To determine whether the iron-chelating capacity of DFO 
was responsible for the observed inhibition of lymphocyte 
CSA mouse 
proliferation, Con A-stimulated spleen cells were cultured 
A 
with DFO (15µM) and varying concentrations of ferric chloride 
(FeC1 3 ) for 48 hr, and pulsed with 3 H-thymidine for a further 6 
hr. Table 5.3 shows that the inhibitory effect of 15uM DFO 
could be completely reversed by adding lOOuM ferric chloride. 
Higher concentrations (lmM) of ferric chloride were toxic to 
lymphocytes in that control cultures without desferrioxamine 
failed to respond to Con A. 
Table 5.3 Ability of ferric chloride to reverse the 
inhibitory activity of desferrioxamine. 
Treatment 
Con A DFO (15pM) 
+ 
+ + 
+ + luM 
+ + lOuM 
+ + lOOuM 
+ + lmM 
+ luM 
+ lOuM 
+ lOOuM 
+ lmM 
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3 H-thymidine uptake 
(cpm xl0 3 ±SE) 
230 .2 ± 18.5 
5.5 ± 0 .2 
3.9 ± 1. 2 
9.8 ± 2. 5 
286.5 ± 10.4 
8.3 ± 2.4 
224.6 ± 7.8 
223.8 ± 9.6 
260.4 ± 14.6 
3.6 ± 0.2 
The ability of iron to reverse the DFO-induced inhibition 
of cell proliferation is also demonstrated in Figure 5.3, in 
which Con A-stimulated spleen cells were cultured with 15µM 
DFO and a saturating dose of FeC1 3 (lOOµM) was added at 24 hr 
intervals. The cultures were pulsed with 3 H-thymidine 24 and 
48 hours later. FeC1 3 completely reversed the DFO-induced 
inhibition when added 24 or 48 hours later. There was some 
loss in proliferative capacity when iron was added 72 hours 
after the establishment of the cultures. 
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Fig 5.3 Ability of FeC1 3 to reverse the activity of DFO 
Spleen cells were cultured with Con A (lµg/ml) and DFO (15µM). 
At 24 hr intervals FeC1 3 (lOOµM) was added and cell 
proliferation measured 24 and 48 hr later. 
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These experiments indicate that DFO is not directly toxic 
to lymphocytes, since iron could reverse the observed 
inhibition of cell proliferation even after prolonged exposure 
to the drug. To test for the toxic effects of higher 
concentrations of the drug, spleen cells were cultured with 
DFO for 48 hours, washed and stimulated with various 
concentrations of Con A. Table 5.4 shows that DFO at 10 
times (150µM) the inhibitory concentration had only marginal 
effects upon the subsequent proliferative capacity of spleen 
cells. DFO at l.5mM was regarded as toxic in that the 
subsequent proliferative capacity of spleen cells was impaired 
at some concentrations of Con A tested. These results 
suggest, therefore, that there were no irreversible direct 
toxic effects of DFO on lymphocytes at concentrations that 
inhibited cell proliferation. 
5.7 Effect of other metal salts on the inhibitor y activit y 
of desferrioxamine. 
Although desferrioxamine has a particularly high affinity 
for Fe 3+ ions the drug does bind other metal salts 
at a much lower affinity (Table 5.5). Con A-stimulated 
spleen cultures were established with DFO (15µM) and different 
molar ratios of zinc, copper and calcium metal salts, to 
determine whether such salts would also reverse the DFO-
induced inhibition. Various concentrations of metal salts were 
added as shown in Table 5.5, and the effect on cell 
proliferation was measured 48 hr later by pulsing with 3 H-
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DFO 
concentration 
0 
15uM 
150uM 
l.5mM 
Table 5.4 The effect of culturing lymphocytes with desferrioxamine 
on subsequent proliferative responses to Con A. 
3H-thymidine uptake (cpm ± SE) 
Con A concentration (pg/ml) 
0 0.5 1.0 2.0 4.0 8.0 
5440 72482 169594 276018 230414 253923 
±1548 ±13824 ±18781 ±26026 ±68983 ±51553 
16360 79898 93369 288973 178570 116471 
±1978 ±9646 ±16759 ±23203 ±16774 ±17954 
18212 66593 78165 190438 75400 47550 
±4265 ± 13157 :t-28545 ±4965 ±7236 ±8052 
12771 36228 72978 10898 4685 8927 
±727 ±8204 .+.25408 ±288 7 ±1490 ±1851 
16.0 
28710 
±4361 
46075 
±3877 
20005 
±9642 
6880 
±1253 
Spleen cells were cultured with various amounts of desferrioxamine for 48 hr, washed three 
times in medium and stimulated with Con A. The cells were then pulsed 48 hr later with 3H-
thymidine. 
thymidine. Calcium, zinc and copper ions had little or no 
effect on the inhibitory activity of DFO (Table 5.5) at 
concentrations that were not directly toxic to lymphocytes. 
Table 5.5 The ability of various metal salts to reverse the 
inhibition of lymphocyte proliferation. 
Metal salt 
Ferric chloride 
Zinc sulphate 
Copper chloride 
Calcium chloride 
Concentration 
(uM) 
0 
10 
100 
0 
25 
50 
100 
0 
30 
60 
120 
250 
500 
0 
8.5 
17.0 
% inhibition of H-thymidine 
incorporation 
Con A Con A+ DFO 
98 
0 97 
0 0 
97 
0 88 
16 87 
9 8 99 
97 
53 96 
78 98 
85 97 
83 93 
85 87 
98 
0 98 
0 98 
Spleen cells were cultured with Con A (1 ug/ml) with or 
without the addition of DFO (15 uM). Various concentrations of 
metal salts were added and the effect on cell proliferation 
measured 48 hr later by pulsing with 3 H-thymidine. 
129 
5.8 The effect of desferrioxamine on mixed lymphocyte 
culture responses. 
To test whether DFO could also prevent other 
proliferative responses, mixed lymphocyte cultures were 
established in which Fl (BALB/c xSJL/J) lymph node cells were 
stimulated with irradiated CBA/H spleen cells. Cell 
proliferation was measured at 72 hours by pulsing with 3 H-
thymidine. The cytotoxic T cell response generated was 
measured after 5 days by incubating effector cells with L929 
target cells at various ratios. The level of cytotoxicity was 
measured after 4 hr by determining the amount of neutral red 
taken up by residual target cells. Table 5.6 shows that 15uM 
of DFO could completely suppress both cell proliferation and 
the generation of cytotoxic T cell effectors. This inhibition 
could be reversed if saturating (equimolar) levels of FeC1 3 
were added to the cultures. However, DFO had no effect on the 
ability of cytotoxic T lymphocytes to kill target cells (Table 
5. 6) ·• 
5.9 Effect of adding desferrioxamine at different times 
after initiation of proliferation. 
Spleen cell cultures were stimulated with Con A and DFO 
was subsequently added at various times between O and 48 hr. 
Forty-eight hours after the initiation of the cultures, the 
lymphocytes were pulsed with 3 H-thymidi ne and the level of 
uptake measured. Table 5.7 shows that DFO added even as late 
as 22 hr after the initiation of the culture still suppressed 
the proliferative response of the lymphocytes. There was no 
effect of the drug when added at 48 hrs, that is just prior to 
130 
Table 5.6 The effect of desferrioxamine on cell proliferation and the generation of cytotoxic 
T cells in a mixed lymphocyte culture. 
% cytotoxicity ± SE 
effector/target cell ratio 
Treatment 
3 H-thymidine 
incorporation 
(cpm ± SE) 36:1 18:1 9:1 4 :1 
Nil 
DFO 1.5 uM 
DFO 15 uM 
DFO (15uM)+FeC1 3 (100uM) 
DFO 15 uM* 
67484±3824 
39275±2497 
719±206 
41245±1838 
94±8 .1 
81±10 
0 
87±5 
95±14 
88±7.0 
53±10 
0 
69+5.2 
91+6.l 
88±7.5 
53±7.2 
0 
40±1.7 
81±10 
55±12.5 
ND 
ND 
ND 
ND 
Fl (BALB/c x SJL) lymph node cells were stimulated with irradiated CBA/H spleen cells and 72 hr 
later cell proliferation was measured by a 6 hr pulse with 3 H-thymidine. The activity of cytotoxic T 
cells was measured at 120 hrs against L929 target cells. 
* Desferrioxamine was added at the cytotoxic assay stage. 
ND Not determined. 
pulsing with 3 H-thymidine. These results indicate that DFO can 
inhibit an on-going proliferative response, but if added after 
22 hr, has no sup~essive effect. This is of interest since 
I\ 
Tormey and Mueller (1972) found that, in the proliferative 
response to Con A, there is a transferrin-sensitive period 
about 28 hr after stimulation. 
Table 5.7 The effect of adding DFO, at various times after 
stimulation with Con A, on cell proliferation. 
Time between 
addition of 
Con A and DFO 
0 
6 
22 
48 
Unstimulated 
3 H-thymidine uptake (cpmxl0 3 ±SE)* 
Desferrioxamine concentration (µM) 
0 15 30 60 
278.2 3.0 1.5 0 . 5 
+4.7 ±0.7 +0.7 ±0.l 
2.7 2.0 l. 2 
±0.l +0 . 7 ±0 . 3 
27.5 8 .7 2.4 
±4 .l +0 .5 ±0.3 
310 . 3 298.l 254.6 
±16 . 7 +6.8 ±6 .5 
12.9±0.5 
* Cells were incubated for 48 hr and pulsed with 3 H-thymidine 
for a further 4 hr before harvesting. 
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5.10 Effect of desferrioxamine on the tri ggering signal for 
cell proliferation. 
Within 24 hours Con A stimulated lymphocytes become fully 
committed to DNA replication (Stenzell, Rubin and Novogrodsky, 
1978). Removal of Con A at this time has no effect on 
subsequent blastogenesis. This can be demonstrated by adding 
~-methyl-mannoside (~-MM), a saccharide that competes with 
sites on the lymphocyte cell surface which bind the lectin: ~-
MM (0.lM) can competitively inhibit blastogenesis when added 
up to 5 hr after Con A (Stenzell, Rubin and Novogrodsky, 
1978). To test whether DFO interfered with a proliferative 
signal to the lymphocytes, spleen cells were cultured for 24 
hr with Con A (1 µg/ml) and DFO (15 µM). The activity of both 
Con A and DFO was then reversed by adding FeC1 3 (lOOuM) and Q-
MM (0.lM) and the subsequent proliferative capacity of the 
cells was measured 24 hr later. If DFO interferes with a 
cellular signal for proliferation, then the addition of ferric 
chloride and ~-MM should prevent subsequent blastogenesis. 
Table 5.8 shows that ~-MM completely inhibited cell 
proliferation when added at Ohr, but not at 24 hr after th e 
establishment of Con A-stimulated spleen cell cultures. DFO 
also inhibited lymphocyte proliferation, but this was rever sed 
when FeC1 3 was subsequently added. Adding both ~-MM and FeC1 3 
at 24 hr had little effect on the proliferative response of 
the cells, suggesting that DFO did not interfere with the 
proliferative signal to the cells. 
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Table 5.8 Effect of DFO on the triggering signal for cell 
proliferation. 
Treatment 
0 hr 24 hr 
Con A 
Con A + OC-MM 
Con A ~-MM 
Con A + DFO 
Con A + DFO FeC1 3 
Con A + DFO CC-MM+FeC1 3 
3 H-thymidine uptake 
cpm xl0 3 +SE 
355.3 ± 14.6 
7.8 ± 0.4 
376.3 ± 7.9 
3.2 ± 0.1 
187.0 ± 4.9 
171.4 ± 2.3 
Spleen cells were cultured with Con A (lµg/ml) with or 
without the addition of Q-MM (0.lM), desferrioxamine (15uM) 
I 
or FeC13 (lOOµM) for 48 hr and pulsed with 3 H-thymidine for 
6 hr before harvesting. 
5.11 Flow cytometric analysis of desferrioxamine-treated 
lymphocytes. 
Desferrioxamine seems to inhibit cell division as 
measured by thymidine uptake. Flow cytometric analysis was 
used to determine whether cells are blocked at a particular 
phase of the cell cycle. Figure 5.4 shows that lymphocytes 
stimulated for 48 hr with Con A developed the characteristic 
G2M phase peak associated with cell division. However, this 
peak did not occur in lymphocytes exposed to DFO and the DNA 
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distribution was similar to that of an unstimulated lymphocyte 
population. This result suggests that DFO blocks lym p hocy t e 
cell division in the Gl phase. 
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Figure 5.4 FACS analysis of DNA content of mouse spleen 
cells. Cells were stained with mithramycin, 
after 72 hr in culture. 
a) Con A stimlated spleen cells showing peak in G2M phase. 
b) Unstimulated cells. 
c) Spleen cells incubated with Con A in the presence of 15uM DFO. 
d) Spleen cells incubated with Con A, DFO (15uM) and FeCl (lOOuM) 
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5.12 Interleukin production. 
Supernatants from cultures of Con A-stimulated spleen 
cells incubated with or without DFO were assayed for 
interleukin production by 1) the ability to promote growth of 
Con A blasts (IL-2), 2) the induction of procoagulant factor 
on the surface of macrophages, and 3) production of IL-1 by 
PU5-l.8 cells. 
CBA mouse spleen cells were incubated with Con A (2 
ug/ml) in the presence of varying concentrations of DFO, as 
shown below . After 48 hr incubation, cells were removed by 
centrifugation, and equimolar concentrations of FeC13 were 
added to the supernatant to saturate the DFO. Twofold 
dilutions of the supernatants were added to Con A blasts to 
measure IL-2, or to PU5-l.8 cells to measure PCIF, and assayed 
as in sections 2.14 and 2.20. DFO + FeC 13 was not 
stimulatory for Con A blasts. 
Neither IL-2 nor PCF induction were suppressed by 
concentrations of DFO up to 100 uM, levels which completely 
suppresses proliferation 1n vitro (Table 5.9). 
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Table 5.9 Failure of DFO to suppress lymphokine production. 
DFO (pM) 
l 
10 
50 
100 
Unstimulated 
IL-2 
3 H-thymidine uptake 
(cpm x 103 +SE) 
25 . 8 ± 2.1 
34.6 ± 1.7 
29.4 ± 1.3 
33.3 + 1.5 
29 . l + 1.4 
1.6 ± 0.1 
PCIF 
% reduction in 
clotting time 
45.7 ± 2.2 
49.6 ± 2.1 
49.6 ± 1.7 
55.l + 2.4 
37.0 + 1.3 
0.0 
LNC were incubated with Con A (2µg/ml), and concentrations of 
DFO as shown. The supernatants were tested for their ability to 
support proliferation of Con A blasts (IL-2) and for induction 
of PCF on PUS-1 . 8 cells (PCIF) 
Interleukin l (IL-1) is produced by PU5-l.8 cells upon 
stimulation by LPS, and assayed by augmentation of proliferation 
of C3H/HeJ thymocytes incubated with sub-optimal concentrations 
of PHA . C3H thymocytes do not react to LPS, so the assay is 
specific for IL-1. Thymidine uptake by C3H thymocytes in 
response to IL-1 is less than that obtained with other mitogens, 
nevertheless, the stimulation index is usually about tenfold 
higher than unstimulated cells. PU5 -l. 8 cells were incubated 
with various concentrations of DFO, and 20 µg/ml LPS. Both cells 
and supernatant were assayed, since up to 90% of the IL-1 
produced by LPS stimulation remains intracellular (Gery and 
Lepe-Zuniga, 1984). There was some reduction in IL-1 at 
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concentrations of DFO greater than 50 ug/ml, but no 
significant difference at 10 µg/ml (Table 5 . 10) . 
Table 5.10 Production of IL-1 by PU5-l.8 cells. 
3 H-Thymidine uptake (cpm xl0 3 ) 
DFO (uM) FeCl3(uM)* 
Cells Supernatant Total 
1 2235 2393 4628 ± 254 
10 1873 1191 3264 ± 221 
50 1605 924 2529 ± 142 
100 400 658 1058 ± 54 
1 1 1838 1695 3533 ± 239 
10 10 1377 1882 3259 ± 232 
50 50 1792 1654 3446 ± 268 
100 100 2230 1292 3522 ± 125 
1538 2020 3558 ± 245 
Unstimulated 256 172 428 ± 39 
* FeC1 3 added at the same time as DFO . 
5.13 FACS analysis of transferrin receptors . 
The appearance of transferrin receptors on the surface of 
stimulated lymphocytes occurs soon after the induction of IL-2 
receptors, and appears to be dependent upon the latter. 
Neckers and Cassman (1983) have shown that blocking of IL-2 
receptors by the monoclonal antibody anti-TAC prevented both 
137 
the appearance of transferrin receptors and subsequent DNA 
synthesis. Inhibition of DNA synthesis occurred only if anti-
TAC was administered before the appearance of transferrin 
receptors. Conversely, Neckers and Cassman (1983) found that 
blockade of transferrin receptors abrogated the mitogenic 
capacity of IL-2. Although DFO was found not to inhibit IL-2 
production (section 5.12) there was a possibility that the 
appearance of transferrin receptors might be altered, either 
by inhibition of induction or by blocking of receptors. This 
was determined by FACS analysis on PHA-stimulated human 
lymphocytes, using the monoclonal antibody to human 
transferrin receptors, 5E9 (Haynes et al, 1981). 
DFO was added to 2xl0 6 /ml normal human lymphocytes to 
give a final concentration of 15 µM. Immediately, 50 ug PHA 
was added, and the cells were incubated at 37°c for up to 3 
days. At various times, aliquots were removed and stained 
with 5E9 antibody. FACS analysis showed that cells incubated 
with PHA developed transferrin receptors after 8 hr, reaching 
peak levels at 48 hr, and diminishing by 72 hr. In the 
presence of DFO, receptors appeared at the same rate, but 
accumulated on the surface, and were still evident after 3 
days incubation (Fig. 5.5). This result is in accord with 
Mattia et al (1984) who demonstrated a threefold increase in 
the number of transferrin receptors when K562 (human leukaemic) 
cells were incubated in 50 µM DFO. The increased number of 
receptors was due to a specific increase in the rate of 
receptor synthesis, which reached 3-4 times that of untreated 
cells within 6 hr after addition of DFO (Mattia et al, 1984). 
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Thus DFO not only fails to inhibit, but appears to enhance the 
synthesis of transferrin receptors. 
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Figure 5.5 FACS analysis of transferrin receptors. 
Spleen cells were incubated with mitogens in the presence or 
absence of DFO for 72 hr, then stained with the MAb 5E 9 , 
followed by FITC-conjugated goat anti-mouse antiserum. 
a) PHA-stimulated cells, b) PHA-stimulated + DFO, 1 0 ug/ml, 
c) unstimulated cells. 
Arrows indicate transferrin-positive peaks. 
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5.14 Depletion of transferrin-bound iron by desferrioxamine. 
It is generally thought that iron chelators are unable to 
remove iron from transferrin (Rubin, Houlihan and Princiotta, 
1960; Cleton, Turnbull and Finch, 1963; Brown, Hwang and 
Allgood, 1967). However, there is ample evidence that iron can 
be removed by dialysis of transferrin against EDTA, 
nitriloacetic acid (NTA) or citrate (Charley et al, 1960; 
Bates, Billups and Saltman, 1967) and this can be reversed by 
adding back iron, but not other metal ions (Aasa et al, 1963; 
Feeney and Komatsu, 1966). Indeed, dialysis of iron was one of 
the methods used to determine metal binding constants for 
transferrin (Aasa et al, 1963). 
Removal of iron from transferrin depends upon both the 
association constant (see Table 4 .1), and a kinetic factor, 
for example, NTA and citrate are able to chelate 50% of the 
iron in transferrin in 3 hours, while EDTA takes more than 4 
days~ The amount of transferrin in serum varies , the average 
for bovine serum being 2.6 mg/ml (Brock and Mainou - Fowler, 
1983), and is 30% saturated with ferric iron. Saturation of 
transferrin below 24% or above 70 % has been shown to inhibit 
lymphocyte proliferation in vitro, (Brock and Mainou-Fowler, 
1983). Thus, it is possible that DFO could remove sufficient 
iron from transferrin to render it inhibitory. 
The following experiment was done to determine whether 
DFO was capable of removing iron from transferrin, (see Fig. 
5.6). DFO was added to 10 ml of HIFCS to give a final 
concentration of 100 µg/ml. This mixture was left at 4°c for 
140 
16 hr, then spun through a Centrilfo ultrafiltration cone to 
remove molecules less than 10,000 daltons. Iron bound to DFO 
has a molecular weight of 657 and should pass through the 
filter, while transferrin (MW 76,500) should be retained. A 
solution of 2.6 mg/ml transferrin in RPMI (30 % saturated with 
iron), and an aliquot of FCS without DFO was treated in the 
same way. After centrifugation at 3,000 rpm for 20 min, the 
volume remaining in the cone was 1/lOth of the original 10 ml. 
This was then made up to the original volume with RPMI medium, 
and used as the source of transferrin in Con A-stimulated 
cultures of rat lymph node cells. The assay medium contained a 
final concentration of 1 ug/ml DFO, well below the level which 
inhibits proliferation in vitro (see section 5.3). When used 
at a concentration of 5%, FCS treated in this way did not 
support Con A stimulation of spleen cells (Table 5.11). 
Filtered FCS without DFO was not altered by the treatment. 
Addition of 10 uM DFO to FCS also inhibited proliferation, 
as expected (Table 5.11). Approximately 90% of the DFO was 
recovered in the serum filtrate, and 97% in the transferrin 
filtrate (not shown). DFO may bind to another large protein in 
serum, or may have been catabolised by a serum enzyme; however 
the treated transferrin failed to support proliferation to a 
similar extent, indicating that retention of DFO, if it 
occurred, was not sufficient to account for the suppressive 
effect. 
It was more likely that DFO had removed iron from 
transferrin, rendering it "undersaturated", and unable to 
support lymphocyte proliferation. 
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Fig. 5.6 Removal of transferrin -bound iron by DFO . 
DFO was added to FCS or transferrin (30% saturated) to give 
100 ug/ml. The mixture was then spun through an 
ultrafiltration cone to remove ferrioxamine. The serum and 
trarisferrin remaining in the cones were tested for their 
ability to support Con A-stimulation of rat lymph no de cells, 
shown by the uptake of 3 H-thymidine. 
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Table 5.11 Inhibition of lymphoproliferation by removal 
of transferrin-bound iron. 
3 H-Thymidine uptake (cpm x 10 3 ) 
Treatment 
Final concentration of serum used in assay 
10% 5% 2 % 
DFO-FCS 36.7±4.7 7.6±0.7 0.6±0.03 
FCS 74.5+2.5 44.0+1.4 5.4±0.1 
FCS+DFO added 3.4±0.1 7.2+0.9 4.8±0.3 
FCS untreated 78.5±4.7 44.5+0.3 6.1+0.3 
Unstimulated 4.9+0.4 3.8+0.3 1.5±0.03 
The addition of transferrin (30% saturated with iron) 
or FeC1 3 to cultures containing 10% DFO-treated FCS, fully 
restored the lymphoproliferative response at a concentration 
of 500 µg/ml transferrin, or 5 µg/ml FeC1 3 (Fig. 5.7). 
Apo-transferrin, which does not contain iron, was unable to 
reverse the inhibition. 
The normal concentration of transferrin in serum varies, 
but is usually about 2.5 mg/ml (Brock and Mainou -Fowler, 
1983). Levels below this are inhibitory. Using the known 1:1 
binding ratio for DFO and Fe, and known amounts of transferrin 
in this experiment, it would seem reasonable to postulate that 
DFO was reducing the iron saturation of TF to about 20%, and 
that addition of 5µg/ml Fe could restore saturation to 30%, 
thus reversing the inhibition. 
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Figure 5.7 
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+ Restoration of the lymphoprolierative 
response by the addition of transferrin or FeC1 3_. 
800 
Saturated transferrin (a) or FeC13 (b) were added to 
DFO-treated FCS at the concentrations shown, and used 
as a source of FCS in the response of rat LNC to Con A 
(2µg/ml) . 
• Transferrin, D apotransferrin, U untreated FCS. 
Restoration of the proliferative response of LC by 500ug/ml 
transferrin (which by itself does not support proliferation) and 
by 5ug/ml FeC1 3 , indicates that DFO probably acts by removing 
iron from transferrin, however further experiments using 59 Fe are 
needed before any firm conclusions can be drawn. 
5.15 Intracellular iron levels in lymphoid cells. 
Previous experiments showed that T cell proliferation was 
suppressed in the presence of 15uM concentrations of DFO 
(sections 5.3, 5.4); however B cell stimulation in vitro 
(sections 5.3, 5.4) and antibody production in vivo (section 
4.11), was not adversely affected. Macrophage function also 
appeared to be normal (sections 4.7, 4.8, 4.10). In contrast to 
B cells and macrophages , T cells do not synthesize iron-storage 
proteins in response to increased iron levels. Intracellular 
iron was determined by carbon rod analysis in order to determine 
whether intracellular iron stores were greater in B cells and 
macrophages than in T cells, and could thus overcome the 
depletion of extracellular iron by DFO . Two sources of T cells 
were used; CBA thymocytes, and CBA spleen depleted of Ig+ cells 
by rosetting (section 2.16 ) . Both T cell suspensions contained 
the same amount of iron, i.e. 0 . 38 ug/10 8 cells . AB cell-
enriched fraction was obtained by anti - thy 1 . 2 treatment of 
spleen cells. acrophages were obtained from the peritoneal 
cavity; after incubation at 37°c for 5 hr in RP. I - 1640 + 10 % 
HIFCS, non-adherent cells were washed off . All glassware was 
washed in Chelex -tr eated water . Cells were res uspended in 
Chelex-treated distilled water containing 0 . 1% SDS, homogenized, 
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and kept at -20°c until iron determinations were 
made. Iron levels were measured at the Research School of 
Chemistry, ANU, using a Varian carbon rod Atomiser CRA-90. 
Cell size was measured using a calibrated slide and a 
microscope fitted with an eyepiece graticule. The cells were 
placed in medium in a petri dish so that their spherical shape 
was maintained. 
Total iron determinations showed wide differences between 
cell types. However when the cell volume was taken into 
account, the iron content was similar, T cells and adherent 
peritoneal macrophages having the same amount (Table 5.12). 
Table 5.12 Total iron content of lymphoid cells. 
T 
B 
Total iron Cell diameter Cell volume* 
(µg)/10 8 cells (mµ) 
0 . 38 
2.94 
4.60 
6 . 5+0.3 
11.5+0.7 
15.0+l.l 
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796 
1768 
Total Fe content 
(µg/cc3 cell 
volume) 
2.6 
3.69 
2.6 
* Cell volume was calculated by the formula 4/3nr 3 . The cells 
were placed in a petri dish and counted immediately to 
maintain their spherical shape. Ten cells of each type were 
measured. 
145 
5.16 Other antioxidant and iron chelators in vitro. 
Several compounds which are known to have efficient iron-
binding or radical-scavenging properties were tested for their 
ability to inhibit lymphocyte proliferation in vitro. All of 
these had previously been tried in vivo for possible 
therapeutic effects in EAE (section 4.12); although none of the 
iron-chelating compounds appeared to be effective in vivo, the 
antioxidant BHA, Hydergine, and the antineoplastic drug 
Hydroxyurea all reduced the severity of EAE (section 4.12). 
HBED, BHA and Hydroxyurea were also effective at inhibiting 
proliferation in vitro, however they were toxic to cells at the 
concentrations which suppressed proliferation, as indicated by 
the inhibition of H-thymidine uptake of unstimulated cells 
(Table 5.13). BHA, being relatively insoluble in water, formed 
an oily suspension which was detrimental to cell cultures. 
Hydergine, which has been shown to inhibit lipid peroxidation 
in vitro (Koreh, Seligman and Demopoulos, 1982), did not 
inhibit lymphoproliferation. The ribonucleotide reductase-
inhibitor PATS, effectively inhibited proliferation; this could 
be reversed by incorporation of iron in the compound Fe-PATS, 
indicating that the suppression is not due to irreversible 
inactivation of the tyrosyl radical. 
In summary, inhibitors of lipid peroxidation, although 
effective at suppressing EAE in vivo, did not suppress 
lymphoproliferation in vitro. In contrast, the iron chelator 
HBED, while ineffective in vivo, suppressed proliferative 
t in viro. responses to Con A It may be that DFO acts to suppress 
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EAE by inhibiting both iron-catalysed lipid peroxidation and 
lymphoproliferati9n. 
Table 5.13 Effects of various iron-chelators and anti-
oxidants on lymphoproliferation. 
3 H-Thymidine uptake (cpm X 10 3 ) 
Compound Con A concentration (uM) 
1 5 10 50 100 
DFO + 128.5 77.2 13.3 10.0 10.3 
8.0 7.1 6.1 6.5 6.0 
HBED + 79.2 38.8 14.5 4.5 5.5 
9.9 11.5 7.4 3.3 4.8 
PATS + 152.1 150.6 3.5 4.5 4.5 
5.5 6.2 7.3 0.8 0.2 
Fe-PATS + 171.5 192.1 220.5 243.7 16.3 
5.7 8.1 4.6 0.15 0.13 
Hydroxyurea + 130.3 34.4 6.0 2.2 1.0 
8.4 3.1 2.9 3.3 2.4 
Hydergine + 121.6 118.4 116.0 113.9 112.2 
10.0 10.7 10.3 9.9 9.8 
BHA + 154.7 145.3 139.2 2.5 0.6 
8.0 8.3 3.8 0.5 0.4 
DMSO + 171.8 137.9 121.6 1.8 0.4 
8.3 8.0 0.4 0.4 0.35 
Nil + 176.4 
8.4 
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5.17 Suppression of mitogenic effect of the Calcium 
ionophore A23187. 
The calcium ionophore A23187 is a fungal metabolite 
obtained from Streptomyces chartreusensis. It induces 
proliferation in lymphocytes by increasing cell membrane 
permeability to Ca++ ions. Mitogens such as Con A bind to 
the cell surface, and subsequently Ca channels are opened, 
resulting in an increase in cytoplasmic Ca. A23187 acts 
differently in that is a mobile ion carrier, diffusing into the 
lipid bilayer , thereby creating a steep electrochemical 
gradient . As a result, Ca++ ions rush into the cytosol. The 
effect is transient at low concentrations. At mitogenic concen-
trations, however, the Ca++ uptake is sustained (Alberts et al, 
1983) and inability to maintain cytoplasmic Ca levels within 
the normal nanomolar range results in death of the cell. For 
this reason, A23187 is eventually toxic to cells, even at 
mitogenic doses. A23187 has been shown to be a specific 
mitogen for T helper cells (Akerman and Andersson, 1984). It 
appears to act independently of lymphokines, since it is a poor 
IL-2 inducer; blockade of IL-2 receptors by the monoclonal 
antibody anti-TAC does not inhibit proliferation; and addition 
of IL-2 to the medium does not augment the response at sub-
mitogenic responses (Koretzky et al, 1 9 83). In addition, 
macrophage-depleted cultures are able to respond, indicating 
that IL-1 is not necessary for its action. Finally, A23187 can 
induce proliferation in the absence of serum (Brock, 1981). 
Thus, A23187 is able to act by increasing transport of Ca 
across the cell membrane, and independently of transferrin (and 
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Figure 5.9 Suppression of ionophore-induced proliferation 
by DFO. 
Rat lymph node cells were incubated with mitogens and 
various concentrations of DFO as shown, for 48 hr. 
A A Con A (lug/ml) + DFO 
fr--6. A23187 (luM) 
• • A23187 (luM) + DFO 
o--o A23187 (luM) + DFO + equimolar FeC1 3 
unstimulated 
hence iron uptake). Therefore, one might expect an iron 
chelating agent such as desferrioxamine, which has a hi g h 
binding affinity for iron0o 31 ) and low affinity for calcium 
(10 2 ), to be ineffective in blocking ionophore-induced 
proliferation. Figure 5.9 shows that at concentrations of 0.5 
µM, DFO completely inhibited the proliferative response induced 
by A23187. This is 1/30 of that used to suppress all other 
mitogens tested. Suppression of proliferation was reversed by 
saturating DFO with equimolar amounts of FeC1 3 ; at 
concentrations of FeC1 3 -saturated DFO above lOµM, 3 H-thymidine 
uptake was markedly reduced. This was not due to loss of cell 
viability (checked by trypan blue exclusion). The reason for 
this apparent suppression is not clear. 
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5.18 Ultrastructure of A23187-stimulated lymphocytes. 
Incubation of lymphocytes with A23187 at concentrations 
that are mitogenic, or higher concentrations which are toxic 
to cells, results in increased uptake of Ca++ into the 
cytosol. Most of the calcium is concentrated in the 
mitochondria, and as the rate of uptake exceeds that at which 
it can be pumped out into the cytoplasm, the mitochondria 
become swollen and distorted, and eventually disrupt 
(Lichtman, Segal and Lichtman, 1983). Incorporation of 1 uM 
DFO in the culture medium protected mitochondria from such 
damage, as shown in Fig 5.10. It was also interesting to note 
that cells incubated with A23187 and DFO showed dense 
chromatin and prominent Golgi apparatus, indicating that RNA 
and protein synthesis were not inhibited. 
Figure 5.10 (following page) Ultrastructure of A23187-
stimulated lymphocytes. 
Transmission electron micrographs of mouse lymph node cells 
incubated for 1 hr with 1 µM A23187. 
a) Untreated cell, showing intact mitochondria 
b) and c) Cells exposed to A23187, showing swollen, 
distorted mitochondria. 
d) Lysed cell. Even at mitogenic concentrations, A23187 
was toxic to lymph node cells. 
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b ·"' 
d 
Ultrastructure of A23187-stimulated lymphocytes. 
a) Normal lymph node cell, showing intact mitochondria. 
b) Cells were incubated with A23187 for 16 hr, in the 
presence of 10 uM DFO. Note intact mitochondria and 
I 
prominent Golgi apparatus (G). 
a 
5.19 Measurement of cytoplasmic ca++ changes by quin2. 
Since DFO appeared to prevent the damage to mitochondria 
caused by increased calcium uptake it seemed relevant to 
measure Ca++-uptake into the cytosol, to determine whether DFO 
was inhibiting this early mitogenic change. 
One of the earliest, measurable events after binding of 
mitogen to the cell surface is the increased uptake of calcium. 
This can be measured by loading cells with quin2, which 
fluoresces upon binding to calcium. Figure 5.11 shows the 
traces obtained when CBA/H thymocytes were incubated with Con A 
(Fig. 5.lla) or with A23187 (Fig. 5.llc). The intensity of 
fluorescence increased markedly within seconds. Addition of 10 
uM DFO did not significantly affect the increase in cytoplasmic 
Ca++ (Fig. 5.llb). There was some reduction in A23187-
stimulated cells (Fig. 5.lld). This was reproducible and is 
probably a real effect. However, the reduction did not seem to 
be large enough to account for the suppression of 
proliferation, particularly at 10 µM DFO. These results are of 
relevance in the light of a recent report by Halliwell (198 4 ). 
Two patients undergoing DFO therapy for rheumatoid arthritis, 
who received the phenothiazine prochlorperazine concurrently, 
lost consciousness for 48-72 hr. As phenothiazine is a 
calmodulin antagonist (Cheung, Grinstein and Gelfrand, 1 9 8 3 ), 
the combined effects of these two drugs may have unfortunate 
effects, particularly in excitable cells which require Ca++ for 
release of neurotransmitters. 
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Figure 5.11 Measurement of cytoplasmic Ca++ changes by quin2 fluorescence. 
CBA/H thmocytes were incubated with Con A (a,b) or A23187 (c,d), and the 
increase in cytoplasmic Ca++ was measured by quin2 fluorescence in the 
absence (a,c) or presence (b,d) of 10 pM DFO . 
5.20 Discussion. 
T cell proliferation was markedly suppressed by non-to xic 
concentrations of the iron-chelating agent desferrioxamine. 
Thus Con A- or alloantigen-stimulated lymphocytes failed to 
proliferate 1n the presence of 15 µM DFO. This effect could be 
reversed if the drug was saturated with iron, suggesting that 
iron is an important requirement for cell division. Although 
DFO inhibited DNA synthesis, the drug does not seem to 
interfere with the cellular signal for proliferation. Thus, 
lymphocytes exposed to Con A and DFO for 24 hours were still 
committed to proliferate when both Con A and DFO were removed 
(section 5.10). Production of the lymphokines IL-1, IL-2 and 
PCIF was not inhibited by DFO (section 5.12). Flow cytometric 
analysis data suggested that DFO blocked cells in Gl, the stage 
in the cell cycle immediately before DNA synthesis begins 
(section 5.11). Entry into S phase commits the cell to 
subsequent proliferation and, since other cell functions 
requiring RNA or protein synthesis are not inhibited and DFO is 
thought not to enter cells (except for hepatocytes), it would 
appear that the (extracellular) action of the drug 1s able to 
inhibit specifically the (intracellular) synthesis of DNA. 
It is well known that iron is required for DNA synthesis 
(Robbins and Pederson, 1970; Brock, 1981; Novogrodsky et al, 
1982). All cells require some iron and express low levels of 
transferrin receptors, which bind the iron-transporting protein 
transferrin (Morgan, 1971). Stimulated lymphocytes express 
increased numbers of transferrin receptors approximately 6 hr 
after stimulation by mitogen or antigen. The iron-transferrin 
152 
complex is internalised and the iron released from transferrin 
at an intracellular site by a mechanism which is still poorly 
understood. The iron-depleted transferrin is returned to the 
plasma undegraded (Bomford et al, 1983). Uptake of transferrin-
bound iron in all tissues is regulated by the number of 
transferrin receptors, rather than the amount of iron available 
in serum (Huebers and Finch, 1982). The accumulation of 
transferrin receptors on the surface of cells incubated with 
DFO may represent a fruitless attempt to acquire iron. 
Experiments in which iron was removed from transferrin by 
ultrafiltration of ferrioxamine (section 5.14), may have 
rendered it "under-saturated", a process which results in poor 
binding capacity, and, consequently, poor stimulation. 
(Brock,1981). 
The sensitivity of cells to iron depletion is illustrated 
by an interesting report by Hibbs, Taintor and Vavrin (1984). 
The cytotoxic effect of activated macrophages on leukaemia 
cells was shown to be associated with release of iron from the 
targets and uptake of iron by the macrophages, occurring at the 
same time as DNA synthesis in the leukaemia cells ceased, i.e. 
at 4-6 hr. 
It is known that the continual presence of oxygen and 
iron are required for the activity of ribonucleotide reductase 
(Thelander, Graslund and Thelander, 1983), a cytoplasmic enzyme 
which catalyses the first step in DNA synthesis: that of the 
reduction of ribonucleotides to deoxyribonucleotides. Mammalian 
RR is made up of two subunits, Ml (MW 84,000), which has 
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receptors for nucleoside triphosphates, and M2 (MW 58,000) 
containing an iron-tyrosine-free radical structure. The en zyme 
has a short half-life of 10 minutes, and it is thought that 
reconstitution of the tyrosine-radical centre is the primary 
mode of regulation of DNA synthesis (Thelander, Graslund and 
Thelander, 1983). RR is dependent upon iron for regeneration of 
the tyrosine-radical, and inhibition of RR by hydroxyurea and 
thiosemicarbazones, compounds which complex with the iron-
tyrosil radical, can be partially reversed by the addition of 
ferrous ions (Moore, 1969). Mammalian RR differs in two 
respects from~ coli RR which, until recently, was the primary 
aource for such studies. Firstly, mammalian RR is inhibited by 
hydroxyurea, but the effect is fully reversible if the drug 1s 
washed out (Thelander and Reichard, 1979). This 1s 1n contrast 
to RR from E. coli, 1n which the tyrosyl radical is 
irreversibly inactivated. The reversibility of mammalian RR 
indicates a different catalytic process, with the radical 
possibly being formed during catalysis (Thelander and Reichard, 
1979). Secondly, mammalian RR (in calf thymocytes) appears to 
be more sensitive to withdrawal of iron from the medium than 
E. coli RR (Thelander and Reichard, 1979). 
Incubation of PHA-stimulated lymphocytes with DFO (lmM) 
results in a decrease in total ribonucleotide reductase to 11% 
of normal levels within 45 min, and a concomitant fall in dATP 
levels, with a rise in dCTP, dGTP and dTTP (Hoffbrand et al, 
1976; Ganeshaguru et al, 1980; Lederman et al, 1984). This is 
consistent with the inhibition of RR by hydroxyurea. 
Lymphocytes from patients with iron-deficiency anaemia also 
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show reduction in all four ribonucleotides (Hoffbrand et al, 
1976 . 
The ability of desferrioxamine to inhibit a mixed 
lymphocyte culture suggests that the drug may be useful in 
preventing allograft rejection . Experiments are in progress to 
investigate whether DFO prolongs the survival of allogeneic 
pancreatic islet transplants (Lafferty , personal 
communication) . The in vitro proliferation of rat, mouse and 
human lymphocytes is suppressed to the same extent by 
comparable doses of desferrioxamine. These findings, together 
with results presented in the previous chapter, suggest that 
one way in which DFO probably exerts its effects is by 
selectively inhibiting T cell proliferation in vivo; it seems 
likely that this occurs as a result of depletion of iron 
saturation of transferrin , with diminished uptake by 
tra~sferrin receptors, and consequently, inhibition of the 
regeneration of the iron-tyrosyl radical centre of 
ribonucleotide reductase. 
Desferrioxamine seems to be more inhibitory for T cell 
than for B cell responses. Indeed, human B cell proliferation 
in response to LPS in vitro is largely unaffected by 
concentrations of desferrioxamine that totally inhibit T cell 
responses. This may be due to particular properties of LPS, 
since Lederman et al, (1984) obtained complete suppression of 
B cell proliferation by DFO, using the cloned B cell line B8 
from human tonsil and the B cell mitogen STA, which is derived 
from Staph . aureus . 
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Another reason for the apparent lack of effect on B cells 
and macrophages may be that DNA synthesis is not required for 
the secretion of lymphokines, which activate B cells (BAF) 
(Bloom, Gaffney and Jiminez, 1972) and macrophages (MIF, PCF, 
etc.). The same is true for both the production of antibody and 
for phagocytosis. Similarly, the cytotoxic action of 
lymphocytes occurs without DNA synthesis (Mauel et al, 1970, 
Perlmann and Holm, 1969). In addition, Neckers, Yenokida and 
James (1984) have shown that transferrin receptors are not 
required for B cell activity, since antibody secretion occurs 
in PHA-stimulated cells whose proliferation has been blocked by 
the monoclonal antibody 42/6, which binds human transferrin 
receptors. 
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CHAPTER 6. ROLE OF ACUTE PHASE PROTEINS IN EAE. 
6.1 Introduction. 
The injection of CFA into rats produces a chronic, multi-
organ, adjuvant disease which is accompanied by an acute phase 
protein response (Waksman et al, 1960). In view of the report 
by Brosnan et al (1980) describing the inhibition of the 
clinical symptoms of EAE by the injection of a variety of 
proteinase inhibitors, it was relevant to examine the role of 
the endogenous proteinase inhibitor a2-macroglobulin (a 2 M) in 
EAE. a2M irreversibly binds neutral endopeptides of all four 
classes, serine, metallo, thiol and carboxy peptidases 
(Starkey and Barrett, 1977). The Lewis rat is a high responder 
with respect to a~. In response to an intense inflammatory 
challenge, a 2 M levels in plasma rise from microgram levels to 
as high as 15 mg/ml (Baldo et al, 1981) 
In addition to its role in protein capture, a 2 M has 
additional properties which are relevant to a role in EAE. 
a 2 M in either free or proteinase-bound form is reported to 
modulate the secretion of proteinases by macrophages 
(Johnson et al, 1982). At high concentrations, a 2 M inhibits 
the mixed lymphocyte response (Hubbard et al, 1981). Also the 
enzyme-bound form of a 2 M is reported to inhibit the release of 
superoxide anion from stimulated macrophages (Hoffman et al, 
1983). 
The maJor role of Ceruloplasmin (Cp) is the binding and 
transport of copper, however it also acts as a major tissue 
antioxidant, and may be particularly important in the CNS, 
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where levels of catalase are low (Hartz et al, 1983). Cp also 
plays a significant role in the mobilization of iron from 
tissues, by oxidizing Fe++ to the Fe+++ state, making it 
available for uptake and removal by transferrin. Apart from 
the hereditary deficiency of Cp (Wilson's disease), lower than 
normal Cp levels do not occur. Cp levels are raised in acute 
and chronic infections (Markowitz et al, 1955), pregnancy, 
chronic and autoimmune i nflammatory disease, such as systemic 
lupus erythematosis (Denko and Gabriel, rheumatoid arthritis 
(Scudder et al, 1978) and sarcoidosis (Koskelo et al, 1966). 
The acute phase proteins are synthesized by hepatocytes 
1n response to the release of IL-1 from macrophages 
(Kampschmidt, Upchurch and Pulliam, 1982). There is, however, 
additional regulation, particularly 1n the case of a2 M. 
Steroids play an important, but as yet undefined, role in the 
response of this protein to inflammatory stimuli (Thomas and 
Schreiber 1985). 
The purpose of the following experiments was to document 
the acute phase response in EAE, and in particular to relate 
plasma levels ofa 2 M, fibrinogen and Cp to the onset, severity 
of disease, and recovery phases. In addition, the effect, if 
any, of DFO on the acute phase response, was examined. 
Finally, in view of the protective antioxidant role of Cp, 
and previous conflicting reports, levels of Cp in serum of MS 
patients were determined. 
158 
6.2 The acute phase response 1n EAE. 
Serum levels of Cp were consistently elevated over a 60-
day period 1n a group of 5 rats injected with GPSCH-CFA (Table 
6.1). In contrast,a 2 M levels had fallen to normal values by 
day 10, just before the onset of clinical signs on day 12. 
There was a small but significant rise on day 18, when the 
symptoms were subsiding, which again fell to normal levels by 
day 27, and remained at this level. 
Table 6.1 Levels of acute phase proteins 1n rats during EAE. 
Rats 
injected Day Clinical a 2 M Cp Fibrinogen 
with tested score* (mg %) (mg %) (m g% ) 
GPSCH 6 82.5±51.2 74.5±27.0 38.8±4.5 
-CFA 
10 4.5±1 . 5 72.0±4.0 32.0±1.5 
14 2.0(4) 
18 1.2(4) 15.7±5.0 85.2±25.2 26.8± 8.5 
22 
27 8.2±2.5 121.5±19.9 19.2±3.0 
32 25.7±1.6 
46 2.5±0.2 74.7±4.0 
60 3.6±1.6 199.0±24.5 
CFA 10 2.5±1.5 61.0±4.5 
30 
60 
Nil 6.0±2.0 50.5±6.5 20.5±1.4 
* clinical s~ore 1s given as mean for group of 5 rats (no. sick). 
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6.3 Infusion of alpha globulin into rats with EAE. 
The abrupt decline in a 2M levels before disease onset 
(table 6.1), and the increase coinciding with recovery, 
suggested the possibility that the decrease 1n a 2M levels 
might be associated with the development of symptoms. 
In a preliminary study an alpha globulin preparation, 
prepared as described in Hunter et al (1985), containing 
lmg/ml a2M, was given to rats via osmotic pumps at the rate 
of lmg/rat/day for a period of 7 days beginning on day 8 after 
injection of GPSCH-CFA. Rats receiving a 2M were completely 
protected from clinical signs of EAE. Rats receiving buffer 
alone showed symptoms from days 13-23, of similar severity to 
untreated controls (Table 6.2). The plasma levels of 
fibrinogen and a2M in the a2M-infused group are shown 1n Table 
6.2. Fibrinogen levels 1n rats injected with GPSCH-CFA were 
var i ab 1 y e 1 e v a t e d over a 3 2 day per i o d . I n f us i on o f a 2M from 
day ·s-15 resulted 1n a further elevation of fibrinogen levels. 
Si mi 1 a r 1 y , there was a marked 1 n c re as e 1 n a2 M l eve 1 s f o 11 ow i n g 
infusion of alpha globulins. 
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Table 6.2 Infusion of alpha globulin into rats with EAE . 
Rats 
injected 
with 
GP SCH -C F A 
GP SCH-CF A 
CFA 
Nil 
alpha 
globulin day 
infused* tested 
- 4 
8 
12 
16 
20 
25 
28 
32 
+ 8 
21 
25 
- 10 
17 
23 
- -
clinical 
score** 
-
-
-
1.8(4) 
1.4(3) 
-
-
-
*** 
-
-
-
-
-
-
a2 M fibrinogen 
15.4±2.l 38.5±3.6 
3.5±0.6 33.8±5.5 
2.5±0.5 29.5±1.3 
2.8±0.8 31.0±8.4 
2.7±0.3 22.8±2.6 
0 . 6±0.1 24.2±2.5 
2.3±0.5 1 9.2±2.2 
2 .5±0 .3 25.8±1.3 
2.8±0.2 29.7±0.9 
13.7±3.6 39.8±2.5 
7.4±1.9 50.5±2.3 
4.8±1 .6 31.3±3.1 
0.6±0.1 26.1±2.2 
0.6±0.1 24.6±2.5 
4.2±0.8 21.0±1.3 
* given a 2 M days 8-15 after injection of GPSCH-CFA , lmg/rat/day 
** mean clinical score for group of 5 rats (no. sick) 
*** 3 rats showed clinical scores of 1,1,l on day 16 only. 
6.4 Infusion of purified a Minto rats with EAE. 
Following the results with infusion of an alpha 
globulin fraction it was decided to infuse purified a 2 M to 
determine whether this protein protected against EAE. 
Purifieda 2 M was given via osmotic pumps to rats which 
had been injected with GPSCH-CFA 8 days previously, 
infusing 1 mg/rat/day for a period of 7 days. Control groups 
received either PBS or BSA (lmg/rat/day) in osmotic pumps. 
Rats which receiveda 2 M were effectively protected from 
clinical signs, as shown in Table 6.3. Plasmaa 2 M levels rose 
rapidly in all groups, declining on day 8 (Figure 6.1). 
However, thea 2 M-infused animals showed a marked increase in a 2 M 
on days 16 and 20, and overall increases in fibrinogen and 
ceruloplasmin levels suggesting that the infusion of a 2 M had 
re-stimulated the acute phase response. The infusion of 7 mg 
ofa 2 M over a 7-day period from day 8-15 could not account for 
the level of 6 mg/ml of plasma a 2 M on day 20. 
Hand E sections of brain and spinal cord taken from 
rats on day 16 after injection of GPSCH-CFA, showed that 
protected animals had extensive cellular infiltration, 
similar to EAE controls. In addition, the response of 
sensitized lymph node cells, taken on day 20 after injection 
of GPSCH-CFA, to MBP in the MPCA were similar for both 
diseased and protected animals (results not shown). 
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Table 6.3 Clinical scores for rats infused with purified 
alpha 2 macroglobulin. 
Days after BSA-CFA GPSCH-CFA GPSCH-CFA 
sensitisation 0:2M days 8-15 
No. 1n group 8 10 5 
0-12 0 0 0 
13 0 0 1.0(1)* 
14 0 1.0(6) 0 
15 0 1.5(6) 0 
16 0 1.6(5) 1.0(3) 
17 0 2.0(4) 0 
18 0 2.0(4) 0 
20 0 1.6(3) 0 
20+ 0 0 0 
* scores are given as the mean for the group (no . sick) . 
NEXT PAGE: 
Figure 6.1 The acute phase response in rats with EAE. 
Plasma levels of the acute phase proteins a)a 2 macroglobulin, 
b) ceruloplasmin and c) fibrinogen were measured in rats given 
• BSA-CFA on day 0 
0 GPSCH-CFA on day 0 
iNJ GPSCH-CFA on day O and infused with a 2 M from days 8 to 15 . 
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6.5 The effect of DFO on the acute phase response. 
The effect of DFO in EAE appeared to be via the 
suppression of T cell proliferation, without affecting 
macrophage, B cell or interleukin responses. As the acute 
phase response is induced by IL-1, it was relevant to examine 
the effect, if any, of DFO on acute phase proteins. 
Serum and plasma were obtained from rats treated with 
DFO 0-7 days after injection with GPSCH-CFA. DFO did not 
prevent the induction of ceruloplasmin or fibrinogen in EAE 
rats (Table 6.4). Ceruloplasmin levels were enhanced in rats 
given DFO from day 0-7, compared with untreated EAE controls. 
The reason for this is unclear. However stimulation of this 
protective antioxidant, in addition to the reduced T cell 
function in DFO-treated rats, may contribute to the reduction 
of clinical signs in these animals. 
Serum fibrinogen levels were lower in rats given DFO on 
days · 0-7 after injection of GPSCH-CFA, but levels returned to 
that of EAE controls on cessation of treatemnt (Table 6.4). 
The lower levels may reflect a reduction in the amount of 
tissue damage. Since serum fibrinogen is thought to contribute 
to the fibrin deposition in lesions of EAE, a reduction in 
serum levels of fibrinogen during treatment with DFO may be 
responsible for some of the latters' effects, particularly on 
clinical signs. 
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Table 6.4 Ceruloplasmin and fibrinogen levels in rats 
treated with DFO. 
Rats 
injected 
with 
GPSCH-'-CFA 
GPSCH-CFA 
Nil 
DFO 
I day 0-7 
+ 
day 
tested 
3 
7 
10 
14 
3 
7 
10 
14 
ceruloplasmin 
(mg/lOOml) 
NT 
76.5±9.0 
93.0±11.0 
162.0±10.0 
NT 
101.0±11.3 
175.2±23.3 
148.4±13.2 
45.5±9.9 
fibrinogen 
(mg/ml) 
91.2+12.5 
47.0±7.l 
41.5±3.8 
57.5±10.2 
31.1±5.5 
55.2±8.6 
43.5±9.5 
85.0±7.5 
49.7±8.3 
6.6 Ceruloplasmin levels in multiple sclerosis patients. 
A study by Plum and Hansen (1960) showed that in 50 MS 
patients studied, all had low levels of ceruloplasmin. This 
rather unusual finding has not been followed up until 
recentJy. Three small studies have shown that patients with 
recently diagnosed MS (onset less than two years) tend to have 
low levels of ceruloplasmin while older patients, or those 
with chronic disease (onset over five years) have increased 
levels, up to 40% above normal controls. Most, however, fall 
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within the normal range, and the means of such groups are 
similar to controls (Voiculescu et al, 1983; Cendrowski and 
Szajbel, 1966; Becus, Popoviciu and Palade, 1971). 
Ceruloplasmin increases with age, with concomitant infection 
(which is not uncommon in MS) and with ACTH therapy. However, 
the low levels found in recently diagnosed patients are 
interesting. 
Sera from 24 MS patients were kindly provided by Prof. 
A. Basten, Dept. of Immunology, University of Sydney. Control 
sera were obtained from the Blood Bank at Woden Valley 
Hospital, Canberra. Ceruloplasmin levels are shown in Figure 
6 . 2. Control sera were within the normal range of 30 ± 6 
mg/lOOml (Scheinberg and Sternlieb, 1963). The MS sera showed 
greater variation, however. In particular, 3 patients had 
higher than normal values (42.3, 52.7, 75.3 mg %), and two were 
lo~er than normal (12.3,17.5). These patients all had mild 
relapsing MS with a disability of 0-3 on the Kurtzke scale, 
and were not receiving therapy at the time of sampling. 
No conclusion could be reached from this small study, 
although the variation in ceruloplasmin levels found in MS 
patients in this and the reports cited above is worthy of 
further investigation. 
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Figure 6.2 Serum ceruloplasmin levels in MS patients. 
Serum ceruloplasmin levels were detrmined from 24 MS patients 
(MS) and 24 normal controls (N). 
6.7 Discussion. 
The injection of CFA is an effective stimulus of the 
acute phase response. The prolonged elevation of 
ceruloplasmin and fibrinogen levels is in keeping with the 
information relating to chronic adjuvant disease (Pearson et 
al, 1961). a 2 M behaved somewhat differently from ceruloplasmin 
and fibrinogen; levels rose sharply in rats injected with BSA 
emulsified in CFA, declined to normal values by day 12, and 
did not rise again. In contrast, in 3 of 4 experiments where 
animals were challenged with GPSCH-CFA, there was a small but 
significant recovery of a 2 M levels during the clinical 
disease. The exception was aberrant in that a 2 M levels were 
high in the group of rats at the time of the experiment. 
The acute phase reaction is generally thought to be a 
response to IL-1, or a similar hormone released from 
stimulated macrophages (Dinarello, 1984). Keratinocytes also 
produce a mediator of the reaction (Baumann et al, 1984) . 
There is usually a rise in the levels of most of the group of 
acute phase proteins but some seem to have additional 
requirements, for example, the requirement of a 2 M for 
corticosteroids (Thomas and Schreiber, 1985). Also , an 
increase in the plasma concentration of ceruloplasmin in the 
absence of a general acute phase reaction, has been reported 
in rats treated with hyperbaric oxygen (Moak and Greenwald, 
1984) 
Interelukin 1 released from stimulated macrophages is the 
probable inducer of the acute phase response in CFA-challenged 
animals. The functions of the acute phase proteins, although 
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incompletely understood, seem to be essentially anti-
inflammatory and tissue protective (Kushner, 1982). 
In contrast, IL-1 also promotes the immune response directly 
by acting as a co-stimulant for T lymphocytes and a maturation 
factor for B lymphocytes (Dinarello, 1984), and indirectly by 
promoting fever which is reported to augment lymphocyte 
function (Duff and Durum, 1983). By stimulating fibroblast-
like cells to secrete collagenase, IL-1 could also have tissue 
degrading effects. 
One explanation for the data presented here is that 
clinical disease represents a temporary imbalance between 
pro-inflammatory events promoted in part by IL-1 and anti-
inflammatory activities of the acute phase proteins, also 
promoted by IL-1. 
On a molar basis,a 2 M was one hundred thousand to one 
million times more effective in protecting rats from EAE 
than the low molecular weight proteinase inhibitors used by 
Brosnan et al (1980) . This suggests that the proteinase 
binding properties of a 2 M are not the only basis for 
protection. This should be considered, however, in the context 
of the broad spectrum of inhibitory activities of a 2 (Starkey 
and Barrett, 1977 ) compared with other proteinase inhibitors; 
a 2 M may bind a variety of proteinases which could contribute 
to clinical disease . 
The infusion of a 2 contrib uted in only a minor way to 
the increased plasma le ve ls of this protein . The infusion of 
an albumin preparation also restimulated the acute phase 
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response. The injection of a 2 M in the free or proteinase-
bound form into normal animals did not result in an increased 
acute phase response above that produced by injection of 
buffer alone. The reionse of animals with an ongoing 
I\ 
inflammatory process could, however, differ from normal 
animals. 
The maJor difference between the group of rats infused 
with a low dose of a 2 M and albumin was the higher level of 
a 2 M on days 14 and 17 in the a 2 M infused animals. It could be 
that a minimum threshold of a 2 M is necessary for protection. 
This is supported by the drop in level of protection in this 
group . Another possibility is that there is a special 
characteristic of the a2M preparation. In this regard 
Nieuwheizen et al (1979) reported that an a 2 M preparation with 
high levels of esterolytic activity, which may thus be 
in the proteinase-bound form, effectively reduced edema 
induced by carrageenan injection while a preparation shown 
to be predominantly in the nfree" form was ineffective. 
Proteinase bound~2 M was not detected in the preparation used 
in the present study, however. An alternative explanation is 
the possibility of isomeric forms ofu 2 M with differing 
biological properties. Isomers have been reported for human 
~ 2 M (Frenoy and Bourrillon, 1974) and there was an apparent 
heterogeneity in the elution of a 2 M from the Coomassie blue 
affinity gel used in these studies (Hunter et al, 1985). 
There are a number of possible steps where a 2 M could 
intercede in the inflammatory reaction, including suppression 
of the immune response, inhibition of proteinase secretion, 
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inhibition of oxygen radical formation and binding of 
proteinases (Goldstein and Charo, 1983). The data suggest that 
a 2 M does not prevent lymphocyte sensitization or migration into 
the central nervous system. Ifa 2 M is the protective agent then 
it seems that it works by blocking a late stage in the 
effector pathway, perhaps by interfering directly with the DTH 
reaction. 
The rat, like other rodents (but unlike man), has two 
major macroglobulin inhibitors. In this respect the rat 
provides a good model for studying the biological properties 
ofa 2 M, because the protein is a major acute phase protein in 
this species. Further studies are in progress to determine 
if a 2 M is a key protein in the regulation of the disease 
process. 
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CHAPTER 7 GENERAL DISCUSSION 
Rats which were treated during the course of EAE with the 
iron-chelating agent desferrioxamine, showed a marked 
reduction in the severity and duration of symptoms. Some 
groups showed mild symptoms about 1 week after withdrawal of 
the drug, indicating that regulatory mechanisms which prevent 
re-induction of EAE (possibly T suppressor cells) were not 
fully functional. That suppressor mechanisms did eventually 
develop was indicated by the results in sections 4.4 and 4.6. 
Firstly, recovery of lymphocyte res pons iveness after the 
cessation of therapy did not lead to the development of severe 
symptoms, and secondly, 1n a group of rats which had been 
treated on days 8-15 with DFO, and did not show any sym ~ 0 ms, 
the disease could not be induced by challenge on day 35 with 
GPSCH-CFA. Since DFO inhibited the generation of T suppressor 
cells in response to SRBC in mice (se ction 4.16), it may be 
that other protective mechanisms such as antibody or acute 
phase proteins are able to confer resistance to (re)induction 
in EAE. Alternatively, the generation of T suppressor cells 
may be delayed, a possibility which could easily be tested in 
the future. The T suppressor cell of DTH to SRBC 1n mice has 
been shown to be Lyt 1+23- (Ramshaw , Bretscher and Parish, 
1976); T suppressor cells in EAE may be Lyt 1-23+, and it is 
possible that DFO may preferentially suppress the 
proliferation of T cells of the DTH/helper type, allowing the 
development of T suppressor cells. 
170 
The protective effect of DFO in EAE was directly related 
to the level of responsiveness for lymphocytes of the 
DTH/helper subset. The finding that DFO suppressed lymphocyte 
proliferation in vitro, and the fact that this was reversed by 
the addition of FeC1 3 , indicates that the inhibition may 
operate via the removal of iron. There is abundant evidence 
that iron- deficiency anaemia is associated with diminished 
cell-mediated responses, while antibody production is not 
affected (Joynson et al, 1972). Furthermore, Mainou-Fowler and 
Brock (1985) have shown that lymphocytes, incubated in serum 
from iron-deficient animals, respond poorly to mitogens, while 
incubation in normal serum restores the lymphoproliferative 
capacity of lymphocytes from iron-deficient animals. The 
inhibitory effect of iron-deficient serum can be reversed by 
addition of iron, and Mainou-Fowler and Brock (1985) suggested 
that the inhibition is related to the degree of transferrin 
saturation. 
Histological sections taken from DFO-treated rats showed 
an absence of small mononuclear cells from CNS lesions, 
although macrophages could be found. The effect of treatment on 
llS" 
small lymphocytes was confirmed by IUdR labelling (section 
4.13), in which a decrease was found in the numbers of rapidl y 
dividing cells in lesions within 48 hr of starting DFO 
treatment. This could be due to the suppression of 
proliferation. Alternatively, DFO may, by its iron-chelating 
capacity, alter the migration of T lymphocytes. The "homing" 
of lymphocytes to iron deposits in the synovium of rheumatoid 
arthritis patients (Blake et al, 1983), and in the gut and 
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spleen (de Sousa, 1978 and 1981), has been suggested as a 
mechanism of attracting lymphocytes to sites where they obtain 
iron for proliferation. Conversely, iron depletion may result 
in a failure of lymphocytes to migrate to appropriate areas of 
lymphoid tissue, leading to a decrease in the numbers of 
immunologically competent cells (de Sousa, 1981). The 
migration of T cells to T-dependent areas of the spleen was 
altered in mice treated with DFO (section 4.14). Perhaps the 
failure of lymphocytes to migrate to the CNS in EAE rats 
treated with DFO (section 4.5) could similarly be a result of 
a decrease in antigen stimulation within lymphoid tissue. This 
is consistent with the failure of lymph node cells from DFO 
treated rats to respond to MBP (section 4.9) , although such 
cells were capable of responding to Con A in vitro. 
It is well known that primary sensitization to antigen in 
vivo requires the clonal expansion of T effector cells 
(Oppenheim, 1968). Subsequent expression of 0TH is mediated by 
two T lymphocyte populations acting in sequence (van Loveren 
and Askenase, 1984; van Loveren et al, 1984). The first, 
appearing early in the response (12 -2 4 hr), is Ly-1+ and 
radiation-insensitive; the second, appearing 3-4 days later, 
is also Ly-1+, but radiation-sensitive. In these studies, and 
those of Kettman and Matthews (1975) , irradiation of cells 
that transfer the late component of 0TH resulted in defective 
recirculation of these cells into sites of inflammation. 
Injection of the cells with antigen, bypassing the need for 
recirculation, did not affect their ability to mediate a local 
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DTH reaction. 
Proliferation of recipient cells is obligatory for 
expression of DTH, since transfer of sensitized lymphocytes 
into irradiated recipients inhibits the inflammatory 
response (Kettman and Matthews, 1975). 
Thus, treatment of rats with EAE by infusion of DFO, by 
suppressing proliferation, could inhibit the expression of DTH 
at three separate stages: 1) sensitization to MBP in the 
draining lymph node, 2) the homing of specifically sensitized 
T lymphocytes into the CNS, and 3) Infiltration of non-
specific inflammatory cells into CNS lesions. 
The proliferative response of mouse, rat and human 
lymphocytes to T cell mitogens was markedly suppressed by non-
toxic (lSpM) concentrations of DFO in vitro. DFO did not seem 
to interfere with the cellular signal for proliferation, since 
lymphocytes exposed to Con A and DFO for 24 hr were still 
committed to proliferate when both Con A and DFO were 
removed. 
Analysis of the DNA content of lymphoc ytes incubated with 
Con A and DFO showed that cell proliferation was halted in G , 
that is, the stage immediately before DA synthesis begins . 
DFO was ineffective at suppressing antibody production , 
phagocytosis by macrophages, secretion of IL-1, IL-2 and PCIF , 
and cytotoxicity of T lymphocytes, none of which require DA 
synthesis for their action ( Perlmann and Holm, 1969; Mauel et 
al, 1970; Bloom , Gaffney and Jiminez, 1972) . These results 
indicate that DFO may selectively inhibit DA synthesis, a 
view supported by Robbins and Pederson (1970) , who also found 
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that tumour cells cultured 1n the presence of DFO showed a 
selective inhibition of DNA but not of RNA or protein 
synthesis. 
Thus, it appears that DFO selectively suppresses T cell 
proliferation via the inhibition of DNA synthesis. That this 
effect can be reversed with iron, but not with other metal 
salts, suggests that the inhibition is related to the iron-
binding capacity of the drug. Since DFO is thought not to 
enter cells, except for hepatocytes (Morgan 1971; White, 
Bailey-Wood and Jacobs, 1976), and DFO cannot remove 
intracellular iron from lymphocytes (Brock and Rankin, 1981), 
it must exert its effects in the extracellular medium. Nearly 
all of the iron in plasma (and in serum-contain ing culture 
medium) 1s bound to transferrin (Hahn and Ganzoni , 1980). 
Stimulated lymphocytes express transferrin receptors, which 
take .up transferrin-bound iron, internalise the complex, and 
release the apotransferrin. DFO does not interfere with 
binding of transferrin to its receptors (section 5.13). 
There are at least two possible ways DFO could be 
exerting its effects in vitro. Firstly, DFO binds iron present 
in the culture medium, which then cannot be bound by 
transferrin. Transferrin receptors appear about 6 hr after 
stimulation, reaching a peak at 20-24 hr, with a half-life of 
approximately 8 hours (Mattia et al, 1984). Subsequent uptake 
of (30% saturated) transferrin and release of apotransferrin 
results in necessity of further supply of iron for a second 
round of transferrin saturation and uptake. Brock (1981) has 
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shown that 8 ng DFO is sufficient to bind the iron present in 
serum-free medium, preventing its subsequent uptake by 
apotransferrin, and proliferation. DFO may act in this way in 
vitro , however in vivo there would be sufficient saturated 
transferrin in serum to overcome such a deficit. 
Secondly, DFO may compete with transferrin for iron, 
rendering it "undersaturated". Normal serum transferrin is 
approximately 30% saturated with iron; it has been shown that 
saturation of less than 24% results in poor binding of 
transferrin to its receptors, and hence, poor proliferative 
responses (Brock, 1981; Brock and Mainou-Fowler, 1983). 
Keberle (1964) showed that DFO could remove about 14% of 
transferrin-bound iron. It is possible that DFO, at 
concentrations of 15µM, could remove sufficient transferrin-
bound iron to inhibit uptake by lymphocytes. The results in 
section 5.14 suggest that this might be the case. However more 
definitive experiments using radiolabelled iron need to be 
done before any firm conclusion can be drawn. 
Carotenuto et al (1985) have suggested that DFO may 
inhibit the expression of IL-2 receptors on PHA-stimulated 
lymphocytes. However, the appearance of transferrin receptors 
was not diminished by DFO and, since the appearance of the 
latter is dependent upon the prior appearance of Il-2 
receptors (Neckers and Cassman, 1983) this is unlikely. 
However, DFO may interfere with binding of IL-2 to its 
receptors . 
The apparent lack of effect of DFO on B cells could be 
explained by the fact that neither B cell proliferation nor 
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uptake of transferrin-bound iron is essential for antibody 
production (Neckers, Yenokida and James, 1984). In addition, 
irradiated T cells can provide help for antibody production, 
and secretion of B cell-activating factor (BAF) occurs in non-
proliferating T cells (Bloom, Gaffney and Jiminez, 1972) 
The importance of iron in maintaining normal DNA 
synthesis is well recognized (Robbins, Faut and Norton, 1972; 
Hoffbrand et al, 1976). The decrease in DNA synthesis 
resulting from iron-deficiency probably occurs in all cells, 
although the effect is most noticeable in rapidly dividing 
cells such as stimulated lymphocytes. There are several iron-
dependent enzymes which may be affected by iron-deficiency. 
These appear to vary according to the tissue studied. In the 
liver, for example, only succinate-cytochrome c reductase 
activity is affected (Bailey-Wood et al, 1 975) . The 
suppression of DNA synthesis in lymphocytes from patients with 
iron-deficiency anaemia has been linked to a reduction in the 
enzyme ribonucleotide reductase, leading to a reduction in 
deoxyribonucleotide levels, particularly deoxyadeno-
triphosphate (dATP). A similar reduction in dATP has been 
found in vitro by incubation of PHA-stimulated lymphocytes 
with DFO (Hoffbrand et al, 1976 ) . 
The effect of DFO on iron-catalysed lipid peroxidation in 
EAE is less clear. While other antioxidants were able to 
inhibit clinical signs of EAE , none was as effective as DFO or 
hydroxyurea, both of which effectively inhibit 
lymphoproliferation. Attempts to detect products of lipid 
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peroxidation in the CSF of rabbits with severe, chronic EAE 
were unsuccessful (section 4.18). Further experiments are 
intended to establish whether lipid peroxidation occurs within 
CNS lesions of EAE. 
There is evidence to suggest that DFO may prevent 
oxidative damage in vivo. Clark and Hunt (1983) have shown 
that DFO blocks the haemolytic action of several radical-
generating drugs in mice. In humans, DFO has been used 
successfully in the treatment of encephalopathy and 
osteomalacia due to chronic haemodialysis (Ackrill et al, 
1980; Brown et al, 1982), neuronal ceroid lipofuscinos i s 
(Westermarck and Santavuori, 1984) and rheumatoid arthritis 
(Giordano et al, 1984). In all three studies, DFO was thought 
to act via the removal of excess iron, preventing the 
oxidative damage which occurs as a result of iron deposition. 
Some caution needs to be exercised in the use of long-term, 
high-dose DFO therapy in conditions other than iron overload; 
in a preliminary trial of seven rheumatoid arthritis patients 
given DFO (3g daily 5 days/week for 1-3 weeks) three developed 
ocular abnormalities that were reversed on withdrawal of the 
drug (Blake et al, in press). In the same study two patients, 
who also received the anti-emetic drug prochlorperazine, lost 
consciousness for 48-72 hours and then fully recovered. 
DFO may be beneficial in the treatment of MS for two 
reasons: firstly, lesions of S contain cellular infiltrates 
of T lymphocytes in similar proportions to those found in EAE 
(Traugott, Reinherz and Raine, 1983a, 1983b ) . The effects of 
DFO on migration of T cells into the CS and in reducing 
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proliferation of sensitized T cells indicates that it may be 
useful in reducing cellular infiltration into the CNS . 
Secondly, since DFO is able to cross the blood-brain 
barrier, it could act within lesions to remove catalytic iron, 
thus preventing lipid peroxidation. Evidence for oxidative 
processes occurring in MS is conflicting. The occurrence of 
lipid peroxidation is usually accompanied by a rise in 
protective antioxidant mechanisms such as catalase, glutathione 
peroxidase, vitamin E and ceruloplasmin. Studies of MS 
patients have yielded variable results, ranging from decreased 
to increased levels of antioxidant activity (Plum and Hansen, 
1960; Wikstrom et al, 1976; Szeinberg et al, 1981; Mehlert et 
al, 1982; Voiculescu et al, 1983). Recently, Hunter et al 
(1984) have shown that MS patients undergoing hyperbaric 
oxygen therapy exhibit up to six-fold increases in catalase 
levels. These authors have suggested that the beneficial 
effect of hyperbaric oxygen experienced by some MS patients 
( eubauer, 1985) may be due to the increase of antioxidant 
enzymes, particularly catalase, induced by oxidative stress. 
In a group of MS patients used as controls in study by 
Gutteridge et al, (1982) no increase in CSF non-protein-bound 
iron was found, nor was CSF antioxidant activity different 
from normal controls. However, Craelius, Jacobs and Lee-Jones 
(1980) found that iron levels in plaque material from MS 
patients were approximately five times the level found in 
normal white matter. The source of such iron was presumed to 
be red blood cell extravasation and breakdown. In addition, 
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iron deposits in the form of haemosiderin, which can be 
mobilized by DFO, (Shoden and Sturgeon , 1962) have been found 
in multiple sclerosis plaques (Craelius et al, 1982), although 
this finding was not confirmed by Walton and Kaufmann (1984). 
The presence of iron in plaques, apart from contributing 
directly to iron-catalysed lipid peroxidation in myelin-rich 
areas, may attract lymphocytes to sites of inflammation, as 
has been suggested for rheumatoid arthritis (Blake et al, 
1981). Therefore, removal of iron from plaque areas might be 
expected to have a beneficial effect. 
Since DFO does not prevent the production and release of 
lymphokines, nor their action on macrophages and B cells, 
immune surveillance to other antigens, and to cancer cells, 
should be intact. Thus, the prevention of proliferation of 
clones of effector cells, together with an inhibition of 
migration of these cells into the CS , suggests that DFO may 
be of value as a reversible, non-toxic immunosuppressive agent 
to prevent both autoreactive and rejection processes involving 
T lymphocytes. 
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